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1. ABSTRACT 
 
The heat shock response is the most prominent reaction of cells to different stressful 
conditions. As a result, the cells strongly induce the promoters of heat shock proteins to cope 
with the stress. This property is the basis for an application of such promoters in therapeutic 
gene expression. The aim of this work was to establish a system for heat inducible 
expression in encapsulated cells. 
A newly designed artificial heat shock promoter (HSE-promoter) was characterised for its 
application in regulated gene expression in detail. First its inducibility was tested in different 
cell lines and compared to other heat responsible promoters. In order to analyse the 
promoter in more detail a stable cell line was generated. Different established heat shock 
inducers were tested for their ability to activate the artificial HSE-promoter and compared to 
induction of endogenous heat shock promoters. In addition, detailed expression kinetics of 
both the artificial and the endogenous promoter were performed. By this means it was 
demonstrated that the artificial HSE-promoter leads to higher reporter gene expression with 
lower background levels in different cell lines. Furthermore, the artificial promoter responded 
almost exclusively to heat and not to other natural triggers like hypoxia. Cell survival after 
heat induction was analysed and resulted in a non-significant decrease in viability. These 
superior properties make this promoter an ideal tool in gene or cell therapy applications. 
Cell therapy provides a strategy to administer genetically modified cells to patients. When 
incorporated into cellulose sulphate microcapsules, these cells are protected from the host 
immune system and remain localised to the area of implantation. Thus even heterologous 
cells survive in the patient and can produce therapeutic substances over several months in 
the target tissue. In order to externally regulate the expression of the therapeutic gene, the 
heat inducing properties of magnetic nanoparticles were applied. Therefore the cells were 
exposed together with magnetic nanoparticles to an alternating magnetic field. The 
experiments revealed a tight regulation of the HSE-promoter over several orders of 
magnitude by variation of nanoparticle concentration, induction time and magnetic field 
strength. After encapsulation of the cells together with magnetic nanoparticles a first proof-of-
principle in vitro was performed. The magnetic field induced the cells to express high levels 
of the marker gene luciferase. Taken together it was possible to develop an inducible 
expression system for encapsulated cells tightly controlled from the outside. 
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2.  ZUSAMMENFASSUNG 
 
Der Hitzeschock Signalweg ist der wichtigste Abwehrmechanismus von Zellen gegen 
verschiedene Stressfaktoren. Dabei werden hauptsächlich Hitzeschockproteine produziert, 
die ein wichtiger Faktor beim Überleben sind. Die Produktion dieser Proteine wird über hoch-
induzierbare Bereiche in ihren Promotoren gesteuert, den sogenannten Hitzeschock 
Elementen (HSE). Diese Eigenschaft macht den Promoter zu einem hervorragenden 
induzierbaren Expressionssystem für therapeutische Proteine. Ziel dieser Arbeit war es eine 
Methode für Hitze regulierbare Expression in verkapselten Zellen zu etablieren. 
Dafür wurde ein künstlicher Hitzeschock Promotor (HSE-Promotor) verwendet und genau 
charakterisiert. Der Promotor wurde in verschiedenen Zelllinien getestet und auch mit 
anderen Hitze-induzierbaren Systemen verglichen. Zur genaueren Charakterisierung wurde 
eine stabile Zelllinie mit integriertem HSE Promotor hergestellt. Mit dieser Zelllinie wurde 
getestet, ob der Promotor auf verschiedene Stress-Faktoren reagiert und wie diese Reaktion 
mit dem natürlichen Signalweg vergleichbar ist. Es konnte gezeigt werden, dass der HSE 
Promoter sehr hohe Produktionsraten erreichen kann, wobei ohne Aktivierung kaum 
Expression zu sehen war. Zusätzlich reagiert der HSE Promoter zwar stark auf Hitze, nicht 
jedoch auf viele andere natürliche Stressfaktoren, was ihn zu einem idealen Kandidaten für 
eine Anwendung in der Gen- und Zelltherapie macht. Auch das Überleben der Zellen nach 
Stressbehandlung zeigte kaum eine Beeinträchtigung.  
Bei der Zelltherapie können genetisch modifizierte Zellen an Patienten angewendet werden. 
Verkapselung schützt diese Zellen vor dem Immunsystem, daher können die heterologen 
Zellen im Patienten überleben und Wirkstoffe produzieren. Allerdings fehlen bis jetzt 
effiziente Methoden, um diese Wirkstoffproduktion zu regulieren. Wir haben ein 
induzierbares Expressionssystem auf Basis eines artifiziellen Hitzeschock Promotors 
entwickelt. Durch Verkapselung der Zellen zusammen mit magnetischen Nanopartikeln kann 
die notwendige Erwärmung in den Kapseln durch ein alternierendes Magnetfeld erreicht 
werden. Um das System zu etablieren wurde die HSE Zelllinie mit magnetischen 
Nanopartikeln gemischt und durch ein magnetisches Wechselfeld aktiviert. Dabei konnten 
optimale Bedingungen für die Proteinexpression gefunden werden und zusätzlich eine 
Regulation dieser Produktion durch verschiedene Magnetpartikel-Mengen, Induktionszeiten 
und Magnetfeldstärken erreicht werden. Um einen Proof-of-Principle für das System zu 
erbringen, wurden die Zellen gemeinsam mit den Magnetpartikeln verkapselt und im 
Magnetfeld induziert. Dieser Versuch zeigte eine hohe Proteinproduktion durch die Induktion 
im Magnetfeld. Somit konnte der Erfolg dieser neuartigen Methode gezeigt werden. 
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3. INTRODUCTION 
 
3.1. GENE AND CELL THERAPY 
In the last decades, gene and cell therapy manifested as milestone in the treatment of both, 
inherited and acquired disease. With this approach the problems of a wide range of absent, 
misexpressed or deregulated gene products can be compensated by introducing genetic 
material with a therapeutic effect. In principle there are two different ways to manipulate the 
dysfunctional pathways. First, one could deliver genetic material encoding for the absent 
protein directly to the target tissue. This process is called gene therapy as genes or partial 
DNA sequences are used. Cell therapy represents another approach where cells are 
manipulated to produce the therapeutic substance and the cells are then transferred to the 
site of action. In both cases the natural pathways are bypassed by synthetically generated 
proteins or peptides. 
 
3.1.1. GENE THERAPY 
In principle, gene therapy is the delivery of genetic material to cells of the patient. In the 
simplest case, this information codes for a missing or mutated protein like in most of genetic 
diseases. Apart from this, the genetic information can also contain information for artificial 
proteins, peptides or RNA. This kind of therapeutic technique is mainly used in cancer 
treatment, in order to interfere with tumour cell pathways. All current gene therapy 
approaches target somatic cells and do not interfere with inheritance. Gene therapy can be 
classified by the kind of transport to the tissue. DNA can be introduced as plasmids or by 
modified viral vectors (Emery 2004).  
 
3.1.1.1. Nonviral gene delivery 
Naked DNA has to be somehow protected from degradation and guided into the cells. This 
way to the transcription site in the nucleus is paved with barriers such as the cell or nucleus 
membrane. DNA has to overcome certain defence mechanisms like nucleases or immune 
responses and finally has to be capable of expression without silencing by methylation or 
simple dilution in dividing cells. Because of these problems, the efficiency of naked DNA 
transfer is reduced.  
In the last years, several different techniques arose like packaging of the DNA into so called 
liposomes, integration into matrices or carrier particles like nanoparticles (reviewed in (Al-
Dosari et al. 2009). One way to protect and guide DNA is the enclosure with cationic lipids 
(Felgner et al. 1987; Wasan et al. 2000) or polymers like polyethylenimine (PEI) (Boussif et 
al. 1995). The negatively charged DNA is able to form colloidal complexes with the positively 
charged lipids, the so called lipoplexes, or to form polyplexes, when polymers are used. 
Thus, the cellular uptake and the intracellular delivery are enhanced by electrostatic 
interaction with the glycoproteins and proteoglycans in the cell membrane or by endocytosis. 
In addition, the genetic information is protected from enzymatic digests. The transfection 
efficiency of cationic lipids is strongly dependent on the geometric structure of the positively 
charged lipid, the number of charged groups per molecule, the nature of the lipid anchor and 
the linker bondages. Of equal importance is the DNA-lipid ratio (Wasungu et al. 2006) and 
the characteristics of the so-called helper- or co-lipids such as cholesterol or 
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dioleoylphosphatidylethanolamine (DOPE). Employment of the co-lipids results in less 
toxicity but reduced delivery rate. Lipoplexes comprise also the problem of lipid particle 
accumulation in the important routes of transport like the blood stream (Liu et al. 1997) and 
the rapid clearance from circulation. Introduction of neutral polymers such as polyethylene 
glycol (PEG) can slow down clearance (Harvie et al. 2000) but, like DOPE, reduces the 
transfection efficiency. Similar to lipid-based vesicles also polymers are used for gene 
delivery of which PEI is most commonly employed. This polymer shows low to medium 
toxicity at lower molecular weight (<25 000 Da) and in linear form, in opposite to high 
molecular weight or branched appearance (Fischer et al. 1999; Gosselin et al. 2001). PEI 
was first used for DNA delivery in 1995 (Boussif et al. 1995) and leads to release of the 
genetic material into the target cell via endosome disruption by the so-called proton sponge 
effect (Akinc et al. 2005). Nowadays, also other polymers like aminoesters or oligoamines 
which are polymerised by disulfide linkers or polyamino acid derivates are established, which 
present higher biocompatibility (Park et al. 2006).  
Another nonviral delivery approach is the coating of inorganic nanoparticles with DNA. These 
particles range from 10-100 nm and are most of the times compared of metals like iron, gold 
or silver, inorganic salts or ceramics (Sokolova et al. 2008). According to their small size, 
these particles are able to enter the cell via specific membrane receptors and show low 
toxicity and no immune response (Davis et al. 2007; Cai et al. 2008).  
Beside chemically-based vectors also mechanical forces are used to introduce the genetic 
material leading to spatially controlled gene delivery. The first approach is to simply inject the 
DNA close to the cells (Wolff et al. 1990) or to use jet injection (Wendell et al. 2006). This 
transfer mechanism is very simple and lacks problems with tissue and cell barriers or 
targeting as the genetic material is introduced into the cell by physical damage with needle 
injection or generation of pores in the target cells caused by the high-speed ultra thin liquid 
DNA stream of the jet injection. Another transfer method first established in plants is the 
gene gun (Klein et al. 1992), where DNA-coated heavy-metal particles are accelerated by 
highly pressured gas to high velocity and the delivery is based on the impact of the particles 
in the tissue. Because of the direct interaction with the cells, these methods are 
predominantly used for targeting skin as well as for immunizations (Song et al. 2000; Goudy 
et al. 2008). However they also comprise the potential of localized tissue damage like 
edema, pain or bleeding.  
Another mechanism to introduce DNA into cells is the temporal disruption of the cell 
membrane with an electric field, the so called electroporation or the application of ultrasound 
resulting in heating and temporary increase in membrane fluidity. Transport of DNA into the 
cells is guided by electrophoresis in the established electric field, but this technique is limited 
by the accessibility of the target tissue to the electrodes used. Sonoporation could be 
improved by contrast agents (Bekeredjian et al. 2005b) or the use of microbubbles (Endoh et 
al. 2002) which are air-filled bubbles in a range of 1-6 µm with a vesicle membrane of 
polymers or phospholipids. These bubbles enhance the ultrasound action by release of local 
shock waves after ultrasound treatment and a resulting disruption of cell membranes and an 
increase of DNA delivery rate. Ultrasound-mediated delivery in general is safe, non-invasive 
and reaches internal organs without any surgery. Targeted delivery could also be optimised 
by including site-specific ligands (Bekeredjian et al. 2005a). 
Based on the different nonviral techniques used for gene delivery it is possible to target the 
delivery by including tissue or cell specific recognition factors. Constructing nonviral delivery 
systems is less complicated than viral vector design, enables the transfer of large DNA 
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molecules and implies the possibility of repeated administrations. Nevertheless, there are 
certain disadvantages using plasmid DNA for gene therapy. First of all, the efficiency of 
naked DNA transfer is lower than using viral packaging strategies. Second, the gene 
expression is only temporary, as the genetic information is not integrated into the host 
genome.  
 
3.1.1.2. Viral gene delivery 
As viruses are the natural way to introduce foreign genetic information into a cell, this system 
was adopted for gene therapy. The infection of a cell with a virus most of the time leads to a 
massive production of new virus particles and subsequent activation of the immune system 
or to disease. Therefore, the first step was to reduce the potential danger of virus infection by 
creating recombinant versions which harbour the potential to infect cells without replication 
properties and to transport the artificial therapeutic genetic information into the cells. Today, 
four different virus families are used for this approach, the recombinant retrovirus vectors, 
recombinant adenovirus vectors, lentiviral vectors or adenovirus-associated viral (AAV) 
vectors. They can be divided into two major groups, the integrating vectors (retrovirus, 
lentivirus and AAV) and the none integrating (adenovirus, herpesvirus), depending on their 
potential to stably integrate genetic information into the host genome. 
Recombinant retrovirus based vectors are one of the most commonly used delivery systems 
for gene therapy. The natural retroviruses, like the oncoretroviruses (Moloney Murine 
Leukemia virus) or the spumaviruses (human foamy virus) are single stranded RNA viruses 
with a genome of 7-10 kb coding for three essential domains, the structural proteins (gag), 
the coding regions for reverse transcriptase and integrase (pol) and the region coding for 
envelop glycoproteins (env). For their use as gene therapy vectors, the region coding for the 
structural capsid proteins (env) is separated from the regions for replication (pol) and 
structural proteins (gag) and both parts are introduced into cell culture cells to generate so-
called packaging-cell lines (Nolta et al. 1990). In the vector, gag, pol, and env are replaced 
by the therapeutic gene but the packaging signal and remaining sequences like the long 
terminal repeats (LTR) are still present. By introducing the vector into the packaging cell line, 
the primary transcript of the therapeutic gene, is expressed. As this transcript contains the 
packaging signal, it is guided to the cell membrane and new virus particles are produced. 
These recombinant particles consist of the therapeutic transcript and proteins for replication, 
integration or structural proteins provided by the packaging cell line. The recombinant 
retrovirus now has the capacity to infect cells and transfer genetic information into the host 
genome, but without the possibility to replicate and infect other cells. By manipulating the 
envelop proteins, these vectors can be targeted to specific cells or tissues. Retroviral delivery 
systems integrate normally as one unit into the host genome and therefore stable 
transduction is provided also in highly replicating cells without chromosomal rearrangements. 
In addition, gene transfer is efficient and retroviral vectors are considered as safe for clinical 
trials (Kohn et al. 2003). On the other hand, retroviral vectors show differences in gene 
expression levels and sometimes they are also silenced, which might be due to the 
chromosomal region of integration, by the so-called chromosomal position effect (Emery et 
al. 1999; Emery et al. 2000). As for all integrating viruses the problem of insertional 
mutations due to random integration of the genetic information is a main disadvantage. In 
addition, the recombinant vector envelope is built of glycoproteins and is therefore relatively 
fragile compared to other viruses with capsids. Another major disadvantage results from the 
restriction of retrovirus infection to dividing cells like hematopoietic cells, as they need a 
breakdown of the nuclear membrane caused by cell division to deliver the genetic 
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information to the site of transcription and therefore non-dividing cells are excluded from this 
type of gene delivery system. 
Another integrating virus of the retrovirus family, the lentiviruses, are the basis of an 
upcoming generation of gene delivery vectors. In addition to the common retroviral proteins 
gag, pol and env, lentiviruses like the human immunodeficiency virus (HIV) contain in their 
single stranded (ss) RNA genome an additional set of proteins, tat, rev, nef, vif, cpu and vpx 
(Frankel et al. 1998). These proteins enable the virus to form a so-called preintegration 
complex in the cytoplasm of infected cells, followed by active transport into the nucleus. 
Because of this special feature, lentiviruses can also integrate genetic information in non-
dividing cells (Lewis et al. 1992; Bukrinsky et al. 1993). In lentiviral vectors, most of the viral 
genes are removed by the therapeutic gene but sequences responsible for preintegration 
complex formation and nuclear import are still present (Kafri et al. 1997; Zufferey et al. 1997). 
To increase safety and efficiency of the lentivirus based vectors, several improvements like 
insertion of a central polypurine tract (Follenzi et al. 2000; Zennou et al. 2000), the 
woodchuck post-transcriptional regulatory element (WPRE) (Zufferey et al. 1999) or the use 
of SIN (self-inactivating) vectors (Miyoshi et al. 1998; Zufferey et al. 1998) have been 
established. Similar to the other retrovirus based vectors also lentiviral based gene delivery 
systems harbour the problem of non-specific integration into the host genome  
Beside the RNA virus based gene delivery vectors, also DNA based viral vectors are used. 
Among them, the adenovirus based vectors are the most extensively and first used systems 
for gene therapy approaches. Adenoviruses are double-stranded (ds) DNA viruses with a 
large linear genome of ~36 kb coding for several regulatory and structural proteins, including 
the glycoproteins for the viral capsid. The genetic information can be transduced to dividing 
and non-dividing cells by entering via receptor-mediated endocytosis (Bergelson et al. 1997; 
Tomko et al. 1997). However, the DNA is not integrated into the genome but is present as an 
episome, which can be lost, when cells have a high division rate. Recombinant adenoviral 
vectors use only specific viral regulatory elements like the packaging signal or the inverted 
terminal repeats and combine them with the therapeutic gene (Chamberlain et al. 2003). In 
addition, there is an advanced vector available, where all viral genes are deleted, the so-
called gutless vector. Like in retroviral vector production, the recombinant adenoviral vector 
was transfected together with a helper plasmid in a packaging cell line. The helper plasmid 
harvests most of the adenoviral genome information except the information for replication 
(E1, E3). In contrast, the packaging cell line provides the information for the viral protein E1 
and so a replication deficient adenoviral virus particle containing only the therapeutic 
information can be produced. The recombinant adenoviral vectors possess a wide tropism, 
high expression levels and the possibility to transfer large therapeutic genes to the target 
cells. In contrast to the retroviral vectors, adenoviral vectors do not integrate into the host 
genome and therefore lack the problem of insertional mutagenesis (reviewed in (St George 
2003)). The expression of the transgene delivered by recombinant adenoviral vectors is 
observed for a relatively short period (5-20 days) (Dai et al. 1995) and might be linked to the 
strong immune response of the host system to the capsid proteins. Even recombinant 
adenoviral vectors need the viral capsid proteins and therefore host cells react with cytotoxic 
T-cells (Kafri et al. 1998). This major immune response raises problems for a repeated 
administration of adenoviral vectors for gene delivery, which is necessary as the transgene is 
not integrated but it is located on an episome.  
To overcome the problem of the major immune response, other DNA virus vectors were 
established. One of them is the adeno-associated virus (AAV), which is an ssDNA virus of 
the parovirus family. This capsidated virus has a genome of ~ 5 kb coding for two proteins, 
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rep for replication and integration and cap for the structural proteins flanked by two inverted 
terminal repeats. This virus has a wide cell tropism and showed weak immunogenic capacity. 
AAV enters the cell via clathrin coated pits and endosomal disruption via acidification 
(reviewed in (Ziello et al. 2010)) but is not able to replicate and exit the cell, so it needs the 
help of other viruses like adenovirus (Berns et al. 1996). When AAV is used as a gene 
therapy vector, the two genes rep and cap are replaced by the therapeutic gene and this 
vector is then transferred into a packaging cell line where rep and cap and additionally also 
some important adenoviral genes like E1and E2 are expressed (Xiao et al. 1998). In the 
target cells the help of the adenoviral proteins is missing and therefore the virus can no 
longer replicate or exit the cells. Natural AAV has the possibility to integrate on specific sites 
at chromosome 19 through the rep protein, but lacks this site specific integration in 
recombinant vectors lacking the rep gene (Kotin et al. 1990). Beside the site specific 
integration, AAV has also the tendency for homologous recombination (Miller et al. 2002). 
AAV does not always integrate into the host genome as it also exists as an episome, 
dependent on different factors like the cell type. Due to the small size of the virus genome, 
only small therapeutic genes up to 4.5 kb can be delivered. In addition, the rep protein and 
also some of the adenoviral helper proteins are cytotoxic and cytostatic and so the 
production of recombinant AAV viral vector in packaging cell lines is limited. Recombinant 
AAV based delivery systems sometimes bare the risk of insertional mutations and are also 
associated with small chromosomal rearrangements (Miller et al. 2002) which is a 
disadvantage for therapy approaches. 
Recombinant viral gene delivery vectors with a wide range of cell tropism are the first choice 
for gene therapy, but there is also the idea of using viral vectors targeting specific tissues. 
The most prominent virus for tissue or cell type restricted gene delivery is herpes simplex 
virus (HSV). This ds DNA virus has a ~ 150 kb linear genome with approximately 90 genes, 
flanked by inverted repeat sequences. Among the genes there are two subgroups, the 
essential genes for virus growth and the nonessential genes, which are for example required 
for virus-host interactions (Roizman et al. 2007). The HSV genome is surrounded by an 
icosahedral capsid, the tegument, which contains structural and regulatory proteins, and the 
outer envelope, built of 13 glycoproteins. HSV infects cells by binding of the glycoproteins, 
enters the cells via endocytosis (Nicola et al. 2004) or by fusion of the virion at the plasma 
membrane (Satoh et al. 2008). The de-enveloped virus is then transported to the nucleus 
and persists as an episome in the latent phase or can undergo a lytic replication. HSV is a 
neurotrophic virus and can be transported anterograde and retrograde along axons and pass 
synapses by components of the capsid and tegument (Diefenbach et al. 2008). For the use 
as a recombinant gene delivery vector, the essential genes for replication are deleted from 
the viral genome and introduced in a packaging cell line (Todo 2002; Hu et al. 2003). HSV 
based vectors are highly infectious, can easily be produced, show long term transgene 
expression when kept in the latent phase and are specific for neuronal tissue. Therefore, this 
kind of recombinant vector is an ideal tool for gene therapy approaches based on neuronal 
diseases.  
In general viruses are an excellent tool to transfer genetic information into host tissue as they 
have high efficiency in gene delivery, can overcome tissue specific and cellular barriers and 
transfer the therapeutic gene into the nucleus. On the other hand several disadvantages are 
known like inefficient long term expression in adenovirus based systems or insertional 
mutations for retroviruses.  
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3.1.1.3. Clinical gene therapy approaches 
The possibility of generating feasible transport systems for gene delivery around 1990 and 
the growing understanding of genetic diseases resulted in the first clinical gene therapy trial 
by Blaese and Anderson (Blaese et al. 1995) in 1990. Within this approach, a retroviral 
delivery system was used to transfer the gene for adenosine deaminase (ADA) into T-
lymphocytes of two patients with severe combined immunodeficiency (SCID). This first 
clinical trial showed only a temporary response in one of the two patients and a quite weak 
response in the other patient. Nevertheless, this trial could proof the general safety of gene 
transfer to humans. 
In 1997, a clinical trial on the treatment of ornithine transcarbamylase (OTC) deficiency was 
initiated at the University of Pennsylvania. OTC deficiency is an X-linked recessive metabolic 
defect in the urea cycle. A deletion or complex mutation in the OTC gene leads to high levels 
of ammonia in the blood which can result in cerebral edema, coma and death in severe 
cases. The therapeutic approach was to introduce a wild type OTC gene with a recombinant 
adenoviral vector into the liver of the patients by injecting the vector into the hepatic artery 
(Batshaw et al. 1999). One patient, Jessie Gelsinger, who received a high dose of the vector, 
began to experience severe complications within hours after administration and died a few 
days later from multiple organ failure caused by a massive inflammatory response to the 
vector (Raper et al. 2003). Due to this unexpected tragedy, the gene therapy program was 
stopped at the University of Pennsylvania and also other trials at this time were halted to 
review the safety risks.  
One year later, the group of Fisher and Cavazzana-Calvo reported the first success in a 
gene therapy approach by treating X-SCID, an X linked severe combined immune deficiency 
in 10 infants (Cavazzana-Calvo et al. 2000). X-SCID is caused by a deletion in the gamma-
chain of a receptor on maturating immune cells, resulting in severe defects in differentiation 
of T-cells, B- cells and natural killer (NK) cells.  The group of Fisher used a recombinant 
retroviral vector containing the interleukin-2 receptor gamma chain and transduced the 
patient´s bone marrow cells. In nine out of the ten treated infants, a reconstitution of 100 % 
was observed and patients developed a relatively normal T-cell repertoire and good NK- and 
B-cell function (Cavazzana-Calvo et al. 2000). Nevertheless, two patients developed 
leukaemia which was based on an integration of the viral vector in the promoter region of the 
proto-oncogene LMO-2, resulting in overexpression of LMO-2 and other oncogenes. They 
were subsequently treated with a standard therapy for leukaemia and respond well (Hacein-
Bey-Abina et al. 2003). Although the initial trial showed an amazing success in treatment of 
X-SCID, the random integration of the vector with fatal consequences again showed that 
gene therapy approaches lack the overall safety, which is necessary for treatment of 
patients.  
In the following years, gene therapy research was curbed by these two distressing events 
and since then, many improvements on vector safety and trial design were made. Today, 
over 2000 gene therapy approaches are in clinical trials. Most of them are based on viral 
drug delivery using either adenoviral vectors or retroviral vectors (Edelstein et al. 2007). In 
the last years, the primary targets of gene therapy shifted from monogenetic diseases to the 
treatment of more complex disorders like cancer. The first gene therapy is provided by 
SiBiono GeneTech, which achieved approval in China in 2004 for treatment of head and 
neck cancer with an adenoviral vector encoding the tumour suppressor p53, but little 
informations about the therapy are available (Guo et al. 2006). In Europe, Amsterdam 
Molecular Therapeutics filed for approval with the EMA (European Medical Agency) in the 
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beginning of 2010. They use an AAV vector harbouring the human lipoprotein lipase gene to 
cure lipoprotein lipase deficiency (reviewed in (Sheridan 2011)). In June 2012, this approach 
was approved as first gene therapy in Europe or the US by the EMA (and will respond to the 
whole gene therapy community.  
 
3.1.2. CELL THERAPY 
In contrast to gene therapy, where genetic information is introduced into host cells by 
different viral or non-viral delivery systems, cell therapy uses autologous or heterologous 
cells which can be genetically engineered ex vivo, selected for their specifications or just 
expanded and then transferred into the patient. For genetically engineered cells, this method 
has the advantage of an extensive selection for stable cell clones producing the optimal 
amount of the therapeutic substance or the right specifications. Beside this selection another 
advantage compared to gene therapy is the fact that the patient is not exposed to viral or 
non-viral drug delivery systems which might cause severe problems when transferred directly 
into the host. 
 
3.1.2.1. Autologous cell approach 
When naive cells are used for cell therapy, they are placed at the site of action to enhance 
regeneration or correct the function of the tissue. The most prominent therapy using naive 
cells are chondrocytes for cartilage repair (Peterson et al. 2000; Robinson et al. 2000), 
keratinocytes and fibroblasts for burn and wound repair (Navsaria et al. 1995; Carsin et al. 
2000) or Schwann cells for restoring myelin in CNS lesions (Baron-Van Evercooren et al. 
1997).  
All these approaches have the limitation of cell growth, as differentiated adult cells have a 
reduced potential to expand, even if cultivated under enhanced conditions ex vivo. Because 
of this, new approaches working with precursor cells or adult stem cell populations have 
been established. However, embryonic stem cell (ESC) research is limited by ethical issues 
and the possibility of ESC to form teratomas.  
Depending on the initial problem, different precursor or stem cells are used and triggered to 
differentiate into the desire cell type. This differentiation either happens in vivo by the help of 
the surrounding tissue of ex vivo using several differentiation factors. Some of the new 
approaches using progenitor or stem cells try to enhance the generation of the suitable cell 
type by genetically engineering the precursors to express the triggering factors. One of the 
most promising attempts is the transfection of bone morphogenic protein 2 (BMP2) into 
human bone marrow mesenchymal stem cells (BM-MSC) to favour the in vivo differentiation 
into bone tissue. BMP2, which is already clinically approved as a protein therapy, has been 
shown to enhance bone formation by inducing stem cells or progenitor cells (Smoljanovic et 
al. 2009) in a dose dependent manner. Too high concentrations of BMP-2 lead to massive 
bone formation and too low amounts do not show an effect. Therefore genetically engineered 
MSC using transient transfection vectors like adenovirus or inducible expression systems like 
the tetracycline repressor (TetR) system turned out to be more potent than the standard 
treatments in clinical trials.  
A further possible therapeutic use for genetically engineered stem cells or progenitor cells is 
the regeneration in cardiovascular diseases in order to treat or compensate the loss of 
cardiomyocytes (Haider et al. 2008). Mainly BM-MSC or myoblastic progenitor cells 
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expressing myogenic genes like Nox4 (Xiao et al. 2009), angiogenic genes like vascular 
endothelial growth factor (VEGF) (Yang et al. 2010) or factors for engraftment or cell homing 
(Elmadbouh et al. 2007) are used. 
In addition to proliferative or differentiating factors, genetically engineered cells can also 
express artificial gene products or factors normally not expressed in this cell type. For 
example autologous hematopoietic stem cell (HSC) therapy is tested as an effective therapy 
for monogenetic diseases of the hematopoietic system. In clinical trials, HSC´s were 
engineered to express the functional genes for the treatment of storage disorders like the 
gene for interleukin-2 receptor (IL-2R)  chain for the treatment of SCID (reviewed in (Fischer 
et al. 2000)) or the expression of the ATP-binding cassette transporter ABCD1 to cure 
adrenoleukodystrophy (ADA) (Cartier et al. 2009). 
Another cell type used for autologous cell therapy approaches to treat several kinds of 
cancer is the genetically engineered T-cell approach. As these cells are part of the immune 
system, they naturally can act on tumour cells but are normally suppressed because of the 
“self “origin of tumour antigens or the low amount of antigen presented on the tumour cell. 
When artificial T-cell receptors (TCR) recognising specific tumour-antigens are generated 
and expressed in cytotoxic T lymphocytes, this leads to a specific killing of tumour-cells (Dotti 
et al. 2009; Schmitt et al. 2009). One major problem of tumour specific T-cells is the 
expression of tumour antigen in other cells or tissues of the organism which might cause a 
severe self immune reaction (Brentjens et al. 2010; Morgan et al. 2010a), so toxicity and 
safety of this approach still have to be determined. The implementation of virus specific 
cytotoxic T-cells or other cell types of the immune system into the clinic as a tool to treat viral 
infections is already in progress as here the antigen is virus specific and does not naturally 
appear in the host tissue (Hegde et al. 2009). 
Recently it was discovered that also differentiated human adult cells can be reprogrammed 
by expression of four different stem cell transcription factors, Oct4, Sox-2, c-myc and Klf4 
into so-called induced pluripotent stem cells (iPSC) (Takahashi et al. 2006; Yamanaka 2007; 
Yu et al. 2007) . The overexpression of this “stem-cell factors” is either initiated by viral gene 
delivery or non-viral cargo variants into the differentiated cells. The pluripotency of these 
induced stem cells was demonstrated in the last years by differentiation into multiple cell 
types like hematopoetic cells (Schenke-Layland et al. 2008), human hepatocytes (Schenke-
Layland et al. 2008), neurons (Schenke-Layland et al. 2008) or cardiomyocytes (Gai et al. 
2009). Therefore development of patient specific iPSC might overcome the problems of 
limited stem cell isolation efficiency and will probably turn out to be an excellent tool to 
generate genetically modified differentiated cells to treat several kinds of disorders. 
Although precursor or stem cells have a high potential to work as a pool for generation of 
differentiated cells, they always bare the risk of residual pluripotency and the resulting risk of 
tumour formation. As well, the differentiation into specific cell types is still not completely 
understood and often results in only partial differentiation. Beside this also the survival of 
differentiated cells originating from precursor or stem cells is reduced in vivo. 
Using naive or engineered autologous cells for cell therapy is ideal as these cells would not 
initiate an immune response. The major disadvantage of these “self-repair” strategies is the 
limitation of the modified cells to one patient. Treatment of any genetic disorder or disease 
would need an exclusive cell line for each patient, which results in enormous costs and is 
very time consuming. Therefore it is more efficient to use one cell type for different patients 
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and to reduce the immune response to these heterologous cells with well established 
immune suppressors. 
 
3.1.2.2. Heterologous cell approach 
The use of heterologous cells for cell therapy or transplantation has the benefit of a broader 
donor pool but always has to deal with the immune response to the allogenic or xenogenic 
cells. Nevertheless, this approach is routinely used in the clinic due to the optimisation of 
immunosuppressive drugs like rapamycin, cyclosporine or FK506. Most prominent 
heterologous cell therapy approaches are the allogenic bone marrow transplantation or 
transplantation of different organs like heart, kidney or lung, but none of these approaches is 
used for tissue engineering. In addition, also allogenic iPSC are a promising tool to generate 
different genetically modified cell types for many patients. 
The use of most heterologous cells is in a pre-clinical state. Here engineered cell lines are 
used like human cell lines for pancreas regeneration expressing proinsulin with a furin-
cleavable site, whereas expression of furin is regulated by a glucose sensitive promoter 
(Tatake et al. 2007). F3 cells (immortalised human NSC cells) expressing VEGF to repair 
spinal cord injury (Kalamvoki et al. 2007). Some attempts for the use of allogenic cells or cell 
lines to regenerate tissue are already in the clinical phase. The use of allogenic cultured 
retinal pigment epithelial cells from cadaveric sources to treat Parkinson´s diseases 
(Subramanian et al. 2002; Watts et al. 2003) or the use of the human NT2 cell line for the 
treatment of stroke (Kondziolka et al. 2000; Nelson et al. 2002) have shown promising 
results. 
Cell therapy approaches based on cell lines are advantageous because these cell lines can 
be easily expanded, transfected and selected for their specifications ex vivo and have the 
potential to proliferate in vivo. Hence there is the risk of a growth benefit compared to the 
naive cells resulting in excessive amount of modified cells. In general the application and 
modification of heterologous cells shows the clear advantage of availability for different 
patients compared to the limited treatment with autologous cells and therefore reduced costs 
and developing time. However, the immune reaction to the heterologous cells limits their 
application, even if many immunosuppressive drugs are used in the clinic today. Another 
critical issue of cell therapy is the mobility of modified cells within the host organism which 
might lead to interaction with other cell types or tissue than the expected and selected once.  
Taken together, different approaches using autologous or heterologous cells to regenerate 
tissue or to treat disorders, show high potential in pre-clinical experiments and also in clinical 
trials. However, still a better understanding of the underlying mechanisms and a safe and 
detailed manufacturing protocol is needed before they can be transferred into the clinics.  
 
3.1.2.3. Encapsulation 
The use of heterologous cells for cell therapy approaches has the clear benefit of a large 
pool of well characterised cell clones compared to the use of the limited supply of autologous 
cells. When storage diseases or inherited disorders have to be treated, un-modified 
autologous cells are not suitable for therapy. Nevertheless, heterologous approaches always 
have to deal with immune response against the foreign cells. The commonly performed down 
regulation of immune response by immunosuppressive drugs is the only way to overcome 
this problem, although even in these settings resistance or tolerance of the 
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immunosuppressivors can lead to rejection of the implanted cells or tissue. One way to 
protect allogenic or even xenogenic cells and tissues from the immune system is 
microencapsulation. In this technique, cells are separated from the surrounding tissue by an 
artificially generated semipermeable membrane. This membrane prevents large molecules, 
antibodies or immune cells from the contact with the encapsulated cells, but at the same time 
allows diffusion of low molecular weight components like nutrition, substrates or oxygen into 
the capsule. Due to the semipermeability also possible therapeutic products and metabolic 
products of the enclosed cells can be exported to the surrounding tissue. The 
microencapsulation of cells or tissues therefore is an excellent method to introduce 
therapeutic heterologous cells into an organism without activation of the immune response.  
In principle microcapsules are produced by generating stable control-sized droplets of cells 
and polymer, which then interact with a polylinker or compelxation agent to obtain a solid 
microcapsule membrane around the droplet. Today different encapsulation techniques are 
established, the matrix-core/shell microencapsulation, the liquid-core/shell 
microencapsulation and the cell-core/shell microencapsulation (reviewed in (Rabanel et al. 
2009)). Using matrix-core/shell encapsulation, cells are mixed with a hydrogel component as 
alginate and cross linked by divalent cations like calcium (Kierstan et al. 1977) or barium 
(Zekorn et al. 1992). The most commonly produced capsule type here are the Ca2+- or Ba2+-
alginate microcapsules or the coated agarose capsules produced by thermal gelation (Iwata 
et al. 1989; Iwata et al. 1992; Yang et al. 1994). Another way to form matrix-core/shell 
capsules is the complexing of a polyanionic polymer (e.g. alginate) with a polycation (e.g. 
poly-L-lysine (PLL)) (Lim et al. 1980). In this mainly applied approach the core of the capsule 
is gel – like and the cells can arrange in this inner matrix, but growth and cell survival are 
limited by the reduced diffusion rate of nutrition and therapeutic products. In addition matrix – 
core/shell microcapsules are less mechanically stable than capsules of other approaches 
and show limited long term stability (Hoffman 2002). 
To improve cell survival often liquid or semi-liquid inner cores of microcapsules are preferred. 
These types of capsules are generated by extrusion of a cell polymer mixture to produce 
small droplets which interacts with the second polymerisation agent provided in a reaction 
bath. The core of the capsules stays liquid or semi-liquid, while the membrane is formed at 
the interface of the two polymers. The membrane formation occurs either by interfacial 
precipitation or ionic or complex coacervation. The first method uses an aqueous cell-
polymer solution co-extruded with a water insoluble polyacrylate polymer in an organic 
solvent. After solvent removal the polyacrylate precipitates at the interface of the droplet and 
forms a membrane (Sefton et al. 1987; Sugamori et al. 1989). Depending on the polyacrylate 
and the solvent used in this technique, possible limitations are the response of the 
encapsulated cells to the remaining, often toxic solvent and the reduced biocompatibility with 
the membrane. Nevertheless, capsules obtained with hydroxyethyl methaacrylate-
metaacrylic acid (HEMA-MAA) demonstrate high mechanical stability and sufficient 
biocompatibility (Crooks et al. 1990; Lahooti et al. 1999). Microencapsulation by ionic or 
complex coacervation uses the extrusion of a cell – polyelectrolyte suspension in an ionic 
polymer receiving bath. At the interface ionotropic gelation or insoluble polyelectrolyte-
complex formation of the two ionic polymers leads to membrane formation. Examples of this 
approach are the hollow alginate capsules produced by extrusion of CaCl2 and 
carboxymethylcellulose in a sodium alginate bath (Blandino et al. 1999; Chai et al. 2004) or 
capsules built up of cellulose sulphate and poly-diallyl-dimethyl-ammonium chloride 
(pDADMAC) (Merten et al. 1991). The latter capsules display larger pores than other 
capsules but show excellent mechanical stability and long term in vivo survival (Pelegrin et 
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al. 1998; Dautzenberg et al. 1999; Schaffellner et al. 2005). In addition hollow core capsules 
can also be produced by liquefying the hydrogel core of for example Ca2+ - alginate beads 
using a chelator or the exchange by divalent or monovalent cations (Weber et al. 2004; 
Breguet et al. 2007). 
In the last years an additional technique to shield the cells was established. Cells are directly 
coated with polymers resulting in thinner membranes (6 – 50 nm) than those of the traditional 
approaches. Thin membranes can be produced by the different layers of positively and 
negatively charged polymers like pDADMAC and poly styrene sulfonate (PSS) (Germain et 
al. 2006). Other methods for direct coating are the interaction of gaseous siliceous alkaoxide 
precursors with the surface of the cells or tissue, which results in a thin porous silica layer 
(Muraca et al. 2000; Boninsegna et al. 2003) or the interfacial polymerisation coating using 
different polyethylene glycol diacrylate (Cruise et al. 1999; Xie et al. 2005). 
To protect heterologous cells from the environment, the properties of the semipermeable 
membrane are of enormous importance. This barrier has to be biologically inert, 
biocompatible, mechanically stable and permeable for smaller molecules, but excluding high 
molecular components. All these characteristics are dependent on the concentration, 
reaction time, temperature and type of polymers used for encapsulation. Most 
microencapsulations are performed using alginate, a natural polymer existing in brown 
seaweeds and the bacterium Pseudomonas (Govan et al. 1981). Alginates are a family of 
unbranched copolymers of -L-glucuronic acid (G) and -D-mannuronic acid (M) differing in 
mixture and arrangement of M and G depending on their original source (Smidsrod et al. 
1990). Due to the composition of the polymer the biocompatibility differs. It has been 
reported that a high M content in the polymer is associated with increased interleukin-6 (IL-6) 
and tumour necrosis factor (TNF) mediated immune response (Otterlei et al. 1991). In some 
cases also overgrowth of the capsules containing either high amounts of G (Clayton et al. 
1991) or M (Soon-Shiong et al. 1991) was observed. It is not clear if a high content of one of 
the two uronic acids is the basic problem for biocompatibility as contradictory results have 
been published over the years. Another possible reason for evoking an immune response 
might be the tendency of this natural polymer to be contaminated with endotoxine, certain 
proteins and polyphenols (Orive et al. 2002). 
In contrast to alginate, cellulose sulphate is a chemically well defined material with a highly 
reproducible production. Capsules generated of pDADMAC and sodium cellulose sulphate 
(SCS) show high mechanical stability, high long term stability and are well tolerated by the 
donor (Dautzenberg et al. 1999). In addition, cellulose sulphate allows a better pore size 
control and a high survival rate and metabolic activity of encapsulated cells (Karle et al. 
1998; Lohr et al. 1998; Pelegrin et al. 1998). 
The kind of polymer and microencapsulation technique also determines other important 
factors for successful cell survival of the encapsulated cells. One major aspect is the size of 
the generated microcapsule, which should be in the range of 100 – 700 µm, optimally around 
300 – 400 µm (Sakai et al. 2006). Above this size the diffusion of oxygen and nutrition to 
cells located at the centre of the capsule is too low for proper cell survival (Sugiura et al. 
2005). Additionally, larger capsules might activate the immune response easier than small 
capsules and also the rough surface of the capsules will lead to increased immune response 
and overgrowth (Zhang et al. 2008c). The spherical shape of the generated capsules has the 
advantage of an optimal surface-to-volume ratio for protein and nutrition diffusion, which is 
linked to a higher cell survival compared to cell immobilisation on different synthetic 
scaffolds, an alternative approach for cell therapy.  
19 
Another important parameter for cell viability and biocompatibility is the pore size of the 
semipermeable membrane which determines the mass transport properties. The influx of 
molecules necessary for cell viability and metabolism critically depends on the pore size 
(Yuet et al. 1995), but also on the cell type used. On the other hand also the size of the 
largest molecule able to pass the membrane, the molecular weight cut-off (MWCO), has to 
be regulated to block interaction of immune system components with the cells, but enable 
therapeutic and metabolic product diffusion. This parameter is application dependent and 
differs also between allogenic and xenogenic cell encapsulation (Uludag et al. 2000), with 
reduced MWCO for the latter one.  
The idea of protecting foreign cells from the immune system by an immunoprotective 
membrane was introduced around 1930 when tumour cells were covered with a polymer 
membrane and transplanted into an animal (Bisceglie 1933). Later Chang et. al. introduced 
the term “artificial cells” for microencapsulation of cells. Chang used endocrine cells which 
survived after implantation and were able to produce hormone (Chang 1966; Chang et al. 
1966). One of the first approaches of encapsulating naive cells or tissues was the protection 
of allogenic or even xenogenic Langerhans islets for the treatment of diabetes, which 
showed promising results in animal studies (Lim et al. 1980; Altman et al. 1984; Thanos et al. 
2009) and in clinical trials (Calafiore et al. 2006; Elliott et al. 2007). Later also other tissues or 
cells were encapsulated for treating different diseases. Cells of the choroid plexus (CP) 
which express some important neurotrophic factors (Emerich et al. 2005) were used in 
animal models for treatment of neurological disorders as Huntington disease (Borlongan et 
al. 2004) or Parkinson´s disease (Emerich et al. 1992; Ekser et al. 2008; Laguna Goya et al. 
2008). In the 1990th the first human trial using xenogenic bovine chromaffin cells to reduce 
pain was performed (Buchser et al. 1996). 
Despite the use of naive heterologous cells or progenitor cells, in the last decade the 
encapsulation of genetically engineered cells became more popular, as with genetically 
modified cells a defined and even artificial therapeutic protein can be produced independent 
of the cell type. To treat neurological disorders protective neurotrophic factors are expressed 
like cilliary neurotrophic factor (CNTF) in baby hamster kidney cells (BHK) for Huntington´s 
disease (Bachoud-Levi et al. 2000) or amyotrophic lateral sclerosis (ALS) (Aebischer et al. 
1996) treatment in clinical trials. Another attempt is the use of fibroblasts expressing brain-
derived neurotrophic factor (BDNF) for spinal cord injuries or C2C12 cells expressing glia-cell 
line derived neurotrophic factor (GDNF) in Parkinson´s disease treatment (Kishima et al. 
2004; Lindvall et al. 2008). In addition enclosed mesenchymal stem cells (MSC) modified to 
produce glucagon-like peptide 1 were used in clinical trials to treat traumatic brain injuries 
like stroke (Heile et al. 2009).  
Another approach is the reconstitution of dysfunctional or damaged tissues. Bone and 
cartilage defects represent a promising field for encapsulation techniques. Studies have 
shown that encapsulated MSC expressing BMP-2 in vitro lead to cartilage and bone 
formation (Ding et al. 2007) and fibroblasts expressing human transforming growth factor ß1 
(TGF-ß1) result in cartilage regeneration in mice (Paek et al. 2006). The use of 
immunoprotected MSC expressing Sox-9 has also been shown to improve chondrogenesis 
in vitro (Babister et al. 2008). Beside bone formation also regeneration of heart failure was 
under investigation using encapsulated Chinese hamster ovarian cells (CHO) expressing 
vascular endothelial growth factor in a rat model (Springer et al. 2000; Zhang et al. 2008a).  
Microencapsulation offers an optimal tool for expression of therapeutic proteins leading to the 
reconstitution of deregulated or dysfunctional proteins in metabolic and genetic disorders. 
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This approach includes encapsulated epithelial cells expressing ß-glucuronidase I tested for 
mucopolysaccharidosis Type VII treatment (Nakama et al. 2006), myoblastic cells producing 
erythropoietin for ß-thalassemia treatment (Murua et al. 2007; Murua et al. 2009), Factor VIII 
or factor XI expressing mouse C2C12 myoblasts for haemophilia A and B treatment 
(Hortelano et al. 1996; Hortelano et al. 1999; Garcia-Martin et al. 2002), growth hormone 
production in encapsulated myoblasts to treat dwarfism (al-Hendy et al. 1995) or the oral 
administration of encapsulated Escherichia coli transfected with an urease gene to restore 
normal urea levels in renal failure models (Prakash et al. 1996). 
In recent years also the treatment of cancer was in focus of encapsulation approaches. 
Primary tumours seem to be the ideal target for therapeutic proteins produced by capsules 
as tumours are locally delimited and dependent on nutrition and blood supply from the 
surrounding tissue. Hence, inhibition of angiogenesis is one promising approach to stop 
tumour growth. Several attempts to express anti-angiogenic factors by encapsulated cells 
have been published like BHK cells expressing endostatin, a natural inhibitor of angiogenesis 
in mice (Joki et al. 2001) or expressed by human embryonic kidney (HEK) cells in rat models 
(Read et al. 2001). Angiostatin expressed by encapsulated C2C12 myoblasts also showed a 
reduced tumour growth in mice (Cirone et al. 2003). In addition, macrophage stimulated 
killing of tumour cells was initiated by encapsulated human cell lines expressing inducible 
nitric oxygen synthase in a dose dependent manner using inducible expression systems like 
the TetR system in mice (Xu et al. 2002). Stimulating the immune response against cancer 
cells was also the basis of in vivo experiments using encapsulated cells expressing 
interleukin 2 (IL-2) (Cirone et al. 2002). Beside the use of naturally occurring proteins to 
inhibit cancer growth, also artificially introduced therapeutic substances were converted by 
expressed proteins into active anti-cancer drugs (Salmons et al. 2010). Löhr et. al. showed 
that encapsulated HEK 293 cells overexpressing the 2B1 isoform of cytochrome P 450 
(CYP2B1) could significantly reduce pancreatic tumours in mice when the pro-drug 
ifosfamide was converted to its active form (Lohr et al. 1998). The results of this in vivo study 
led to clinical trials where the tumour size was successfully reduced and the median survival 
of the patients could be increased (Lohr et al. 1999; Lohr et al. 2001). This approach was 
also shown to be effective for the treatment of mammary cancer in mice (Kammertoens et al. 
2000) and dogs (Winiarczyk et al. 2002). In addition to the promising results of pro-drug 
conversion by CYP2B1 also other enzyme/pro-drug combinations were published 
(Portsmouth et al. 2007) like the delivery of encapsulated cells expressing cytosine 
deaminase (CD) followed by administration of 5-fluorocytosine in mouse models or a 
combination of two different suicide genes (Kammertoens et al. 2000). If these strategies are 
combined with traditional therapy forms like radiation, the beneficial effect could be increased 
(Ryschich et al. 2005). 
When compared to other administration approaches for the treatment of metabolic or genetic 
disorders, cell encapsulation has the advantage of a controlled de novo synthesis of 
therapeutic proteins in a well defined cell system without the problem of a fast release of high 
or even toxic concentrations of the protein as for example in the case of broken protein 
capsules. In contrast to other cell based techniques, microencapsulation also protects the 
naive or modified cells independently of their origin from the immune system and prevents 
migration of the engineered cells. When combined with regulated gene expression systems, 
encapsulated cells raise a promising field of dose-dependent treatment of several disorders. 
Although many clinical trials based on encapsulation approaches are in progress, the scaling 
up of the encapsulation process is difficult and cells and encapsulation material have to be 
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further investigated for their biocompatibility and safety in patients (Orive et al. 2010; 
Salmons et al. 2010) 
 
3.2. INDUCIBLE SYSTEMS 
Stable and sufficient expression of proteins is one key aspect of most gene expression 
systems. In this case a robust promoter which is resistant to cell dependent up- and down-
regulations is used. Such promoters are often derived from a housekeeping gene like the 
human phosphoglycerate kinase 1-gene (PGK) or the human telomerase reverse 
transcriptase (hTRT) or viral promoter sequences as the cytomegalovirus (CMV) 
intermediate early transcript or Rous sarcoma virus long terminal repeats (RSV). They result 
in constitutive expression of the encoded protein independent of the environment and are 
predominantly used for the production of proteins in many systems like gene therapy 
approaches or cell therapeutical trials. In the last years it turned out, that expression levels of 
therapeutic proteins sometimes need to be tightly regulated as overproduction might result in 
severe complications whereas too low levels of proteins would not show an effect. Therefore, 
regulated gene expression systems were employed to induce the production of a protein in a 
temporal or even spatial manner. For the application of an inducible gene expression system 
in the clinics, it has to accomplish some important issues. First, the system must show high 
inducibility in case of activation, but low basal expression. Second, the system should not 
interfere with endogenous pathways and third, it should show adjustability to intermediate 
levels over a wide range of inducer signals. In addition, the system should not evoke an 
immune response to components used for regulation. Today several inducible gene 
expression systems are known (see Table 1), fulfilling the above mentioned criteria at least in 
part. Some of these systems are already employed in clinical trials, but still there is 
substantial need for improvements. 
 
induction 
system  
components inducer side effects 
of inducer 
kinetics 
in vivo 
reference 
Tet-repressor 
(TetR) 
Tet-repressor fusions 
(TA/rtTA) 
Doxycycline intermediate slow (Gossen et al. 1992; Gossen 
et al. 1995; Urlinger et al. 
2000; Lamartina et al. 2002) 
Progesterone 
receptor 
(GeneSwitch®) 
Truncated 
progesterone 
receptor-GAL4 or p65 
Mifepristone 
(RU486) 
strong slow (Nordstrom 2003; Taylor et al. 
2010) 
ecdysone 
receptor-human 
retinoid X receptor 
(RheoSwitch®) 
EcR/RXR linked to 
GAL4/VP16 
Muristone A 
or RSL1 
weak slow (No et al. 1996; Palli et al. 
2003; Karzenowski et al. 
2005) 
Rapamycin 
dimerisation 
FKBP linked to ZFHD-
1 + FRAP linked to 
p65 
Rapamycin 
derivatives 
intermediate slow (Rivera et al. 1996; Amara et 
al. 1997; Liberles et al. 1997; 
Pollock et al. 2002b) 
hypoxia induction Hypoxia inducible 
elements 
hypoxia intermediate fast (Phillips et al. 2002; Su et al. 
2004) 
heat shock 
induction 
Hsp72-,  Hsp70B- or 
artificial promoters 
heat weak (for 
localized heat) 
fast (Brade et al. 2000; Braiden et 
al. 2000; Huang et al. 2000; 
Vekris et al. 2000; Brade et al. 
2003; Guilhon et al. 2003b) 
TABLE 3-1 DIFFERENT INDUCTION SYSTEMS 
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3.2.1. TWO COMPONENT SYSTEMS  
Most of these inducible systems act via a small molecule, which in turn induces the 
expression of a transactivator followed by expression of the protein of interest. As this 
system needs to be activated in two steps (first the transactivator, then the actual protein) 
they are termed two-step or two component inducible systems. In contrast, the one step or 
one component systems act via direct activation of an inducible promoter. In addition to the 
above mentioned common criteria for the use of inducible gene expression in the clinics, the 
inducer substances should be orally bioavailable, be able to reach the target tissue and have 
a drug metabolism profile compatible with prolonged therapeutic use. The most prominent 
ligand-dependent regulatory gene expression systems are the tetracycline (Tet)-dependent 
induction system, the mammalian steroid receptor based-, the rapamycin based- and the 
insect steroid receptor based systems. 
 
3.2.1.1. TetR System 
The tetracycline (Tet) induced gene expression system originates from the Escherichia coli 
(E. coli) Tn10 tetracycline resistance operon, where the expression of the Tet resistance 
gene is repressed in the absence of Tet. The inhibition of gene transcription is due to the 
binding of the Tet repressor (TetR) to promoter regions upstream of the Tet operon, the so 
called operator sequences or Tet response elements (TetO or TRE). In the presence of Tet, 
the TetR binding to the TRE is blocked and the expression of the Tet resistance gene is 
started. In 1992 Bujard and Gossen established an inducible expression system based on 
the E.coli TetR system (Gossen et al. 1992) by fusing the TetR with the herpes simplex virion 
protein 16 (VP16) transcriptional transactivator domains, generating an artificial tetracycline 
dependent transcriptional activator (tTA). In a second expression cassette, multimerised 
TREs are fused upstream of a CMV minimal promoter to drive expression of the gene of 
interest. When Tet is absent from the system the TetR can bind to the TRE and drive gene 
expression. Due to the repression of gene expression in the presence of Tet the whole 
system is called Tet-Off (Gossen et al. 1992). Although the Tet-Off system allows precise 
control of target gene expression it is limited to approaches where expression should be 
maintained active for long times as continuous exposure to Tet is required to silence the 
system. In addition, the induction kinetics is dependent on the clearance of Tet from the 
system.  
An opposite Tet-system which activates gene expression in the presence of Tet was 
established by Gossen and colleagues a few years later, called Tet-On system. In this 
system the TetR was mutated at four sites, leading to a change in four amino acids. This 
mutated form is termed reverse Tet repressor protein (rtTetR) and leads to a reverse 
behaviour of the protein. When fused to VP16, the repressor (rtTA) binds to the TRE only in 
the presence of Tet and thus activates the transcription of target genes. Compared to the 
Tet-Off system, the activation of the transgene is faster, but higher concentrations of Tet are 
needed to activate expression. To overwhelm this problem, other mutations of the original 
tTA were generated and two new rtTA mutants, the rtTAS-S2 and the rtTAS-M2 mutant, which 
showed improved sensitivity to Tet and reduced background activity compared to the original 
TetOn system (Urlinger et al. 2000; Lamartina et al. 2002) were established.  
An attempt to reduce the potential immune reaction against the system is the combination of 
the TetR with a mammalian transcriptional repressor like Krüppel-associated box (KRAB) of 
the Zink finger protein Kox1 (Deuschle et al. 1995) or the rodent Kid-1(Witzgall et al. 1994a; 
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Witzgall et al. 1994b). This TetR-KRAB (rTS) system is free of the viral VP16 and therefore 
thought to be less immunogenic. In general zinc finger proteins inhibit RNA polymerases via 
their KRAB domain. A combination of the KRAB domain with the TetR gets attached to the 
TRE combined with a normal CMV promoter in the absence of Tet and inhibits gene 
expression. When Tet is present, rTS detaches from the TRE and gene expression starts.  
One problem of the Tet systems discussed above is the background activation in the 
absence of Tet. To minimize basal activation two different approaches were established. On 
the one hand the rtTA and tTS system can be combined to reduce background activation. 
The tTS is cloned into a bicistronic promoter downstream of the transactivator and tTS and 
rtTA are separated by an internal ribosomal entry site (IRES) (Freundlieb et al. 1999). In the 
presence of Tet, the rtTA will bind to the TRE and the rTS is detached and gene expression 
will start. Without Tet the two proteins reverse their activity and the TRE-attached rTS 
reduces the basal expression in the absence of the inducer. This system allows precise 
control of the on/off state, but has the problem that three different foreign proteins have to be 
expressed. This might influence the immune response and also the incorporation into vector 
systems due to size restriction. On the other hand a single cassette Tet system was 
established using a Tet-inducible promoter PCMV-1 driving the expression of both proteins, the 
rtTA and the gene of interest (Haberman et al. 1998). Due to the fact that rtTA is not 
expressed in the absence of Tet it cannot induce background gene expression compared to 
the situation in the Tet-On system, where the expression of rtTA is under control of a 
constitutive promoter. Nevertheless, the expression of the gene of interest is dependent on 
the induction of the Tet-inducible promoter and the following expression of the rtTA. 
Therefore this inducible system shows much slower expression kinetics compared to the 
other systems.  
To optimise induction of Tet response systems and avoid the immunogenic properties of 
tetracycline, also derivatives or analogues of the original antibiotic were tested. One of them, 
doxycycline (Dox), is used in the clinics for more than 30 years and could increase the 
response of the different TetR systems up to hundred fold compared to the original antibiotic 
(Gossen et al. 1995). In summary, the TetR systems provide a feasible tool to regulate gene 
expression in vivo through their inducer substance Tet or Dox. These systems have already 
been used for gene and cell therapy approaches as Tet/Dox are used in the clinics for 
several years and their pharmacokinetics and potential toxicity are well investigated. 
Nevertheless, the TetR system has some disadvantages for regulating therapeutic gene 
expression due to the fact that the inducer substance has to be administered orally, has to 
diffuse to the place of action and can interact with the system as long as it is available in the 
tissue. Hence the regulation of gene expression is in the range of days (Sommer et al. 2002) 
but some approaches might need tighter and faster control of expression levels. In addition, 
Tet and Dox are antibiotics and exhibit this function in the patient including undesired side 
effects.  
 
3.2.1.2. Steroid hormone receptor systems 
Another attempt to regulate gene expression via small inducer substances is the use of 
steroid hormone receptors, which represent one of the largest groups of mammalian 
transcription factors. Wang et. al. introduced in 1994 a system using the human 
progesterone receptor in a C-terminally truncated version (Wang et al. 1994) also known as 
GeneSwitch® (Valentis, Inc) system. This ligand binding site mutated receptor has lost its 
ability to bind progesterone, but still can bind to the agonist mifepristone (MPF or RU486). 
When fused with the yeast GAL4 DNA binding domain and a transactivator domain like 
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VP16, the specificity and inducibility of the system is improved. The chimeric transcription 
factor is under the control of a constitutive promoter, and expressed as an inactive monomer 
which is in a complex with heat shock proteins and other chaperones (Pratt et al. 1997). The 
gene of interest is under the control of an inducible promoter, built of six binding sites for the 
GAL4 DNA-binding domain linked to a TATA box element (Abruzzese et al. 1999). In the 
presence of MPF a conformational change releases the inactive chimeric transcription factor 
from the complex with chaperones and forms a stable homodimer which in turn can bind to 
the GAL4 response elements in the promoter and drive the expression of the therapeutic 
protein. When the inducer is removed, the chimeric transcription factor reverts in its inactive 
monomeric form. To reduce the background activation of the system and to enhance 
inducibility, the VP16 activation domain was exchanged and the p65 activation domain of the 
human NF-B was introduced into the inducible gene expression system (Abruzzese et al. 
1999; Burcin et al. 1999; Abruzzese et al. 2000). The use of p65 also reduces the potential 
immunogenicity of the system in humans, as it now consists of 86 % human sequences. 
MPF, which was originally used in medical termination of pregnancy, has antiprogestin and 
antiglucocorticoid activity. In humans most of the substance is bound to -1-glycoprotein 
hence only a small fraction is available for inducing gene expression (Heikinheimo et al. 
1989; Sarkar 2002). For these reasons MPF has to be administered in higher concentrations 
and due to its progesterone agonistic activity might also be involved in endogenous 
pathways.  
To overwhelm the problem of interaction with endogenous pathways, non-mammalian or 
even artificial systems can be employed. In 1992 the Drosophila melanogaster steroid 
receptor system, regulating metamorphosis by responding to the hormone 20-OH ecdysone, 
was established as an inducible gene expression system (Christopherson et al. 1992). In the 
presence of ecdysone, the ecdysone receptor (EcR) dimerises with the Ultraspiracle gene 
product, a Drosophila homologue of the human retinoid X receptor (RXR). This active 
heterodimer than can bind to ecdysone response elements in the promoter region to activate 
gene expression (Horodyski et al. 1993). To optimise the system, the transactivation domain 
of EcR was replaced by a transactivation domain of VP16 and co-expression of the RXR 
instead of the Ultraspiracle gene. In addition, the EcR was modified in the P box of the DNA 
binding domain, which allows the specific binding to artificial response elements, a hybrid of 
the naturally occurring glucocorticoid response elements and the response elements of RXR 
or EcR (No et al. 1996). When Muristone A, a synthetic analog of ecdysone, is orally 
administered, the two constitutively expressed receptors form active heterodimers and 
activate the expression of the gene of interest by binding to the artificial hybrid binding 
elements. In the absence of Muristone A, the dimer is no longer stable, dissociates and gene 
expression is stopped. A further improvement of the system was commercialised by New 
England Biolabs, called RheoSwitch® Mammalian Inducible Expression system. This system 
is based on the improvements made by Palli et al. (Palli et al. 2003) and Karzenowski et al. 
(Karzenowski et al. 2005), using a fusion protein of a highly modified EcR ligand-binding 
domain with the DNA binding domain of GAL4 and an activator fusion protein of RXR ligand 
binding and the VP16- activator. In the presence of a synthetic ligand, the RSL1, which 
showed no side activity in humans, the active dimer induces gene expression at high levels 
and without the ligand almost no background activation (Palli et al. 2003; Karzenowski et al. 
2005). One advantage of these systems is that the active dimer has no natural binding sites 
present in the host and therefore the basal expression is lower than in other systems like the 
Tet system. In addition, substances as the hydrophobic Muristone A or small molecule 
analogs (Saez et al. 2000) can easily diffuse through the tissue and even cross the blood-
brain barrier, making this system an ideal tool for gene expression in the brain. Although this 
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inducible gene expression system shows high inducibility and low background activation it 
has to overexpress two transgenic receptors simultaneously, which might lead to problems in 
the efficiency of the system. Like in the Progesterone receptor system, also this induction 
model harbours a receptor potentially involved in metabolic pathways, the RXR (Subbarayan 
et al. 2000) and therefore might result in complications when used for longer periods.  
 
3.2.1.3. Dimerisation systems 
A different way to regulate gene expression by small inducer molecules is the dimerisation 
approach (reviewed in (Pollock et al. 2002a)). Here the capability of rapamycin to 
heterodimerise two proteins is used to bring two parts of a transcriptional activator in close 
proximity and therefore induce gene expression through special binding elements of the 
activator. The original heterodimer consists of FK506-binding protein (FKBP) and FKBP-
rapamycin-associated protein (FRAP), also known as mammalian target of rapamycin (mTor) 
and dimerisation is established via the FKBP rapamycin binding (FRB) domain of FRAP. For 
the use as an inducible expression system, an activation domain (AD) can be attached to 
FRB domains and a DNA binding domain (DBD) can be linked to FKBP domains to induce 
expression of certain proteins in the presence of rapamycin (Ho et al. 1996; Pollock et al. 
1999). One of the most prominent combinations for clinical settings is the use of zinc finger 
homeodomain 1 (ZFHD-1) as a DBD linked to three copies of the human FKBP. NF-B 
subunit p65 is used as an activation domain and fused to a single FRB domain. Both 
chimeric proteins are expressed from one cassette by a bicistronic promoter and separated 
by IRES. In the absence of the dimeriser, both proteins show no binding affinity to the 
inducible promoter, consisting of 12 modified ZFHD-1 binding sites followed by a TATA box. 
In the presence of rapamycin, the two chimeric proteins dimerise and can bind tightly to the 
response elements to induce expression of the gene of interest (Rivera et al. 1996). As 
rapamycin was introduced into the clinics as an immunosuppressive agent, other analogues, 
known as Rapalogs were established, which showed no or less immunosuppressive activity 
in combination with mutations in the FRAP domain of the AD fusion protein (Amara et al. 
1997; Liberles et al. 1997; Pollock et al. 2002b). When compared to the TetR or ecdysone 
regulation system, the dimerisation system showed no background activation but less 
maximal inducibility (Senner et al. 2001; Go et al. 2002). Although this system provides 
robust expression over long periods, it lacks the possibility of fine tuning the expression of 
therapeutic proteins like most other inducible gene expression systems. 
In general, two component expression systems show high target gene expression in 
response to an orally administered inducer. This inducer is typically well characterised for 
clinical applications and is used in moderate doses. Nevertheless, these systems might 
evoke an immune response or the inducer leads to some kind of resistance in clinical use. In 
addition, for all of these systems an activator or transcription factor has to be produced in the 
host constitutively, which might also interfere with endogenous pathways or evoke an 
immune response. Another general disadvantage is the fact that the inducer has to be taken 
up orally and has to be transported or to diffuse to the site of action, which limits the fine 
tuning possibilities of all the two component induction system approaches. 
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3.2.2. ONE COMPONENT SYSTEMS 
In contrast to the two component inducible gene expression systems described above, also 
inducible promoters can be used, which are activated by external stimuli and therefore are 
referred to as one component systems. In principle these one component systems have the 
advantage that no activator or artificial transcription factor has to be expressed in the system 
and that the inducer is not a small molecule, which has to reach the expression system, but 
an external environmental signal or patho-physiological signal that stimulates the expression 
of the therapeutic protein by employing the endogenous machinery. The most prominent 
systems use hypoxia or hyperthermia for induction. 
 
3.2.2.1.  Hypoxia inducible promoters 
If cells are exposed to hypoxic conditions, they activate a signaling pathway, mediated by 
hypoxia inducible factor-1 (HIF-1), which then activates gene expression of certain protective 
proteins by binding to special response elements (reviewed in (Rocha 2007)), the so-called 
hypoxia response elements (HRE) (Binley et al. 1999). If these HRE in combination with a 
TATA box or minimal promoter are placed in front of a therapeutic gene, the expression of 
the protein will be induced if hypoxia is established in the tissue or cells harbouring the 
artificial system. As in tumours hypoxia can result from poor vascularisation, the employment 
of this inducible system may be a proper way to induce gene expression linked to tumours. 
With this approach, mainly suicide genes are expressed in tumours, sometimes also 
combined with tissue- or tumour specific promoters like the integration of HRE in an -
fetoprotein promoter, driving the suicide gene for the HSV-1 thymidine kinase (HSV-tk) to 
treat hepatocarcinoma (Ido et al. 2001). Another application of the hypoxia inducible 
expression system is myocardial ischemia, as here severe hypoxic events can cause 
myocardial fibrosis and lead to death. Using a combination of heart specific promoters 
enhanced with several HREs, protective and angiogenic factors can be expressed 
specifically in the ischemic tissue to improve cardiac function (Phillips et al. 2002; Su et al. 
2004). In general, this inducible system turns out to be an ideal tool for gene and cell therapy 
of hypoxic tissues, but is limited to this special patho-physiological condition. Regulation of 
the hypoxia inducible system is only possible by reversing the hypoxic conditions and 
therefore is very slow and ineffective. Taken together, this system can only be used for long 
term expression in special situations. 
 
3.2.2.2. Heat shock promoters 
Another system triggered by external signals is the heat shock pathway (see also 3.5). This 
ancient stress response mediates the induction of target genes like chaperones in response 
to several kinds of stress. This is achieved through heat shock factor 1 (HSF1) binding to 
special recognition sites in the promoters, the heat shock elements (HSE) (reviewed in 
(Shamovsky et al. 2008). The most prominent proteins driven by these promoters are the 
heat shock proteins (HSPs) and within this group mainly the HSP70 proteins, HSP70-1, 
Hsp70-2, and in humans also HSP70B and HSP70B´. Promoters of these genes show high 
inducibility in response to heat, but also to other stressors like, heavy metals, irradiation, 
nutrition depletion or infections. As they are involved in normal cellular processes like the 
correct folding of proteins, they show moderate basal levels which are tightly regulated and 
also integrated in other cellular signaling pathways. Nevertheless, their inducibility through 
externally applied heat and the fast down regulation when the external heat is removed 
makes them an interesting tool for induced gene expression. Early attempts used natural 
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heat shock promoters, but due to their high basal activity and complex regulation, most of 
them showed proper inducibility, but high background (Dreano et al. 1986; Brade et al. 2000; 
O'Connell-Rodwell et al. 2004). The most employed natural promoter for therapeutic 
approaches is the highly heat-inducible HSP70B promoter, driving expression of mainly 
suicide genes in tumours in response to heat (Braiden et al. 2000; Huang et al. 2000; Brade 
et al. 2003; Guilhon et al. 2003b). Several attempts to improve the natural promoters were 
performed like reducing the natural promoter to minimal sequences consisting of the HSEs 
and a TATA box, called minimal HSP70 promoter (Vekris et al. 2000; Smith et al. 2002) or 
the introduction of additional HSE into a HSP70 promoter (Brade et al. 2000). All these 
improvements lead to high inducibility of the expression systems in response to heat and low 
background activation. In addition, these systems show a better defined reaction to different 
heat durations and temperatures, making regulation of the system more precise. One big 
advantage of heat induced gene expression is the accurate spatial control of heat 
generation, established in recent years by focused ultrasound (FU), or magnetic nanoparticle 
mediated heat generation by an alternating magnetic field (AMF) (for details see 3.4) 
(reviewed in (Rome et al. 2005)). These heat generation techniques are already in clinical 
use for hyperthermia treatment of solid tumours (Thiesen et al. 2008) and can efficiently be 
combined with heat-responsive gene expression systems. As natural heat shock promoters 
respond to different kinds of stress, the employment of heat shock promoters for regulated 
gene expression might be activated under certain cellular conditions even without heat 
treatment. This broad responsiveness is reduced in the artificially generated heat shock 
promoter variants almost exclusively to heat induction. Nevertheless, a possible activation by 
oxidative stress, cytokines or lack of nutrition, which is most prominent in tumours, might 
cause severe problems. Applying heat to a specific tissue might also result in problems as 
additionally to the inducible gene expression system also the natural heat shock response 
will be activated. Therefore, an exact spatial control of heat generation with well defined 
temperatures has to be used for this system.  
 
3.3. NANOPARTICLES 
Nanoparticles have a size of a few nanometres up to tens of nanometres and have a broad 
range of application, from electro-technics up to biomedicine. Although they consist of 
different materials like polymers or silica, mostly magnetic nanoparticles are employed in 
bioscience (reviewed in (Pankhurst 2003)). For most applications, iron oxide particles in a 
range of 5-60 nm were used, consisting of either magnetite (Fe3O4), maghemite (-Fe2O3) 
or hematite (Fe2O3). Beyond these iron oxides also cobalt, nickel, manganese or zinc 
ferrites as well as gold or platinum were applied in biomedicine. Magnets can be produced 
either by sintering or casting, but for magnetic nanoparticles typically the wet chemical routes 
are performed due to efficiency and the possibility to control size, composition and even 
shape of the resulting particles, which have a high influence on their magnetic properties. For 
example, magnetic iron oxide particles are synthesised by co-precipitation of an aqueous 
solution of Fe2+ and Fe3+ salts (e.g. chloride) in the presence of a base. Depending on the 
molecular ratio and the established pH a complete precipitation of the salts like Fe3O4 at a pH 
between 9-14 and a molecular ratio of Fe2+ to Fe3+ of 1:2 will occur in a non-oxidising oxygen 
free environment (reviewed in (Babincova et al. 2009)). Beside the efficient and cheap 
generation of magnetic nanoparticles, they can also be coated with organic or inorganic 
materials. On the one hand, this coating prevents agglomeration of nanoparticles and on the 
other hand, certain different macromolecules can be fixed to the nanoparticle surface. This 
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shielding with biological molecules improves the application of the particles in biomedicine. 
Another synthesis route is the decomposition of organic precursors in the presence of a 
surfactant, as this approach results in small and narrow size distributed nanoparticles.  
Magnetic nanoparticles are defined as particles which can be manipulated by a magnetic 
field based on Coulomb´s law. Magnetic fields can penetrate human tissue and therefore 
magnetic nanoparticles can be influenced inside the tissue by an externally applied magnetic 
field. This potential of manipulation from the outside makes magnetic particles a promising 
tool for biomedical problems. Their application cover a broad range from separation, drug 
targeting, contrast agents for magnetic resonance imaging (MRI) or transfection reagents to 
the use as “nanoheaters” in hyperthermia approaches.  
 
3.3.1. MAGNETIC SEPARATION 
Magnetic particles are attracted by an established magnetic field, which is the basis for 
magnetic separation. In this application, magnetic nanoparticles are coated with polymers 
like dextran, phospholipids or polyvinylalcohol (PVA) (reviewed in (Molday et al. 1982; 
Chanana et al. 2009)). For separation the targets have to be tagged or labelled with the 
magnetic particles, mostly performed by antibodies which recognise special epitopes on the 
surface of the targets. When a magnetic field is established, the nanoparticles start to 
agglomerate at a high magnetic field strength and therefore, the target, which could be a 
virus, bacterium or protein, is separated from other components. Applications for magnetic 
separation range from the detection of malaria parasites in blood samples (Paul et al. 1981), 
enrichment of rare tumour cells like breast cancer cells (Schindlbeck et al. 2008) or the 
detoxification of blood from certain poisons (Chen et al. 2007).  
 
3.3.2. CARRIER PARTICLES 
Similar to the approach of separating macromolecules by coupling to magnetic nanoparticles 
these particles can be used as carriers for DNA or drugs. By applying a magnetic field, they 
will be transported to a selected area within a cell or a tissue. This concentration at the site of 
action bears a great benefit for different applications including cancer treatment with 
cytotoxic agents. Magnetic carriers therefore reduce the systemic distribution of a potentially 
harmful therapeutic substance and the necessary total amount. To act as carriers, the 
particles have to be covered or coated with a biocompatible material like dextran, biotin, 
avidin, carbodiimine, polyethylenimine or inorganic materials like silica (Plank et al. 1998; 
Arias et al. 2001; Gomez-Lopera et al. 2001; Santra et al. 2001; Reimer et al. 2003; 
Mykhaylyk 2007; Mykhaylyk et al. 2010). When the coated nanoparticles reach their target 
tissue, the attached substance is released from the carrier. Different approaches were 
established to release the therapeutical substance like the cleavage from a pH-sensitive 
linker through pH changes, enzymatic cleavage or temperature dependent release. In 
contrast, nanoparticles can also remain covalently linked to their therapeutic substance, as 
for example to radioactive substances (Hafeli et al. 1995; Hafeli et al. 2003). They can be 
applied in hydrogels or liposomes to trace the embedded drug to a designated area. The 
release from the hydrogel or liposome can either be triggered by rupture of the carrier vesicle 
or by thermal regulation (reviewed in (Brazel 2009)). The use of magnetic nanoparticles in 
drug release and targeted drug delivery increased dramatically during the last years (Dobson 
2006; Yang et al. 2006). Most of the research focused on the treatment of cancer using 
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cytotoxic drugs linked to nanoparticles, for which an efficient drug delivery and tumour 
remission could be demonstrated in different animals (Pulfer et al. 1998; Alexiou et al. 2000; 
Goodwin et al. 2001). In recent years also some clinical trials using magnetic nanoparticle 
mediated drug targeting dealing with cancer treatment were performed (Lubbe et al. 1996b; 
Alexiou et al. 2000; Lanza et al. 2002). Most of the time, the transported drug is a cytotoxic 
drug for cancer treatment, but also siRNA, viral vectors or DNA are used (reviewed in (Plank 
et al. 2011)). Nevertheless, the use of nanoparticles always bears the risk of accumulation in 
smaller blood vessels which is one typical application route and might result in embolisation 
(Lubbe et al. 1996a; Lee et al. 2007; Hafeli et al. 2009). In addition, nanoparticles loaded with 
drugs have the problem of a small payload of each particle resulting in low doses of 
therapeutic substance at the point of application. Although some problems have to be solved, 
magnetic nanoparticle mediated drug delivery is a promising tool for the treatment of several 
diseases in the near future. 
 
3.3.3. MAGNETIC RESONANCE IMAGING 
Another application of magnetic nanoparticles is diagnostic imaging using magnetic 
resonance imaging (MRI). This non-invasive technique visualises soft tissue and metabolic 
processes by application of a strong magnetic field and radiofrequency (RF) radiation. Due to 
the magnetic field, the nuclear magnetisation of hydrogen atoms is aligned resulting in a 
detectable signal which differs between the tissues. Therefore, a spatial determination of the 
signal is possible. The resulting image strongly depends on the contrast between 
background and tissue specific factors. Contrast agents are used to enhance the signal 
difference of a specific tissue to the background signals. The most popular contrast agents of 
the last years are based on gadolinium chelates and iron oxide nanoparticles. Gadolinium 
has a short half-life of around 12 min. Another problem with gadolinium based agents is the 
fact that they do not cross the blood brain barrier (BBB) and can lead to nephrogenic 
disorders (Marckmann et al. 2006). Iron oxide nanoparticles can enhance the MRI by 
distorting the local magnetic properties of a region because of their large magnetic moment 
leading to a stronger signal change. In addition, iron oxide particles are biocompatible and 
due to coating can increase long term circulation of the contrast agent. Magnetic 
nanoparticles smaller than 40 nm are able to cross the blood brain barrier to some extent, 
offering for the first time a contrast agent suitable for brain specific imaging without direct 
injection into this area. Although normal magnetic nanoparticles have several advantages in 
MRI their great potential is their ability to target specific areas depending on their 
biofunctional coating. Most prominent in this field is the coupling of antibodies to specifically 
target tumour cells expressing special proteins on their surface, like the detection of rectal 
cancer (Toma et al. 2005) or breast cancer (Funovics et al. 2004). Beside the use of 
antibodies also small peptides or other small ligands can be linked to the particles (Sun et al. 
2008, Weitman et al. 1992; Ross et al. 1994) Today there are some magnetic nanoparticles 
already in clinical use for imaging of abdominal viscera, like Feridex I.V. or Combidex 
(Advanced Magnetics, Inc., Cambridge MA) but till now none of the targeted particles have 
been approved 
 
3.3.4. HEAT GENERATION 
The ability of heat generation in an alternating magnetic field is another important feature of 
magnetic nanoparticles. Depending on the kind of magnetic nanoparticle, the magnetic field 
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strength and the frequency, the nanoparticles absorb the applied energy and convert it into 
heat. Heat generation is due to the established magnetic moment of the nanoparticle in a 
magnetic field. If this field changes its direction at a certain frequency, the established 
magnetic moments of the individual particles also change cyclically. At high frequencies, the 
net movement of the magnetic dipole is zero and the applied energy is directly turned into 
heat by Brownian and Néel relaxation processes (reviewed in (Pankhurst 2003; Fortin et al. 
2008; Jordan et al. 2009)). Larger particles of more than 100 nm convert the applied energy 
of the alternating magnetic field (AMF) into heat by eddy current heating, particles of an 
average size between 100 nm and 40 nm generate heat due to hysteresis heating (reviewed 
in (Pankhurst 2003; Jordan et al. 2009)). Beside their size also the composition and physical 
properties of the magnetic nanoparticles is important for heating characteristics. One 
important characteristic is the Curie point (Tc), which is defined as the temperature where the 
particles switch to a paramagnetic state and stop absorbing the energy from the AMF and 
therefore stop heating. Below the Curie point, the particles return to magnetic behaviour and 
convert the applied energy again into heat. The Tc of a magnetic nanoparticle depends on its 
chemical composition as for example Fe2O3 has a Tc of around 600°C and Mn-Zn-ferrite 
nanoparticles have a Tc of around 44°C (Meijer et al. 1995; Kotte et al. 1998). Therefore, the 
choice of the material and the corresponding Tc is important for the different applications as 
potential overheating of a tissue or a material can be avoided by the use of a low Curie point 
material (Gazeau et al. 2008). In addition, also the settings for the AMF are important for 
heat generation. Generally the frequencies used for the AMF generation are in the range of 
50 kHz up to 10 MHz and magnetic field strength up to 55 kA/m are tolerated by organisms 
(Ivkov et al. 2005) although they normally have been in the range of 10-20 kA/m in clinical 
trials (Thiesen et al. 2008). 
The main application of the nanoheaters is in hyperthermia treatment (see also 3.4.) of 
cancer but in the last years also thermally induced release of therapeutic substances from 
nanoparticles or thermo-responsive carrier materials as well as heat induced gene 
expression were established.  
In hyperthermia treatment, where a tissue or normally a tumour is heated to temperatures 
above 42°C to induce specific cancer cell killing, mostly iron oxide nanoparticles were used. 
These particles are either injected directly into the tissue or applied within a suspension 
(magnetic fluid) or embedded in a carrier (Wust et al. 2002; Lao et al. 2004; Thiesen et al. 
2008; Latorre et al. 2009). Like for other therapeutic applications the high biocompatibility of 
the coated nanoparticles is a big advantage and also the targeting to specific areas 
represents a further benefit for the treatment. Using magnetic nanoparticles to induce heat is 
important for hyperthermia treatment at a local area compared to more widespread heating 
techniques used before. Localised thermotherapy reduces the potential harmful side effects 
of heating up a tissue from the outside and is therefore the preferred treatment.  
Similar to their use as nanoheaters for hyperthermia treatment, the heat generated by 
application of an AMF can be used to disrupt or open carrier systems in drug delivery. The 
development of thermoresponsible polymers as vehicles for therapeutic substances leads to 
the involvement of nanoparticles within this area. First of all the magnetic nanoparticles can 
be used to guide the carriers or to enable real time imaging of the transport and in a second 
step they can induce the drug release. For the use as thermoresponsive drug carriers, 
nanoparticles with a Curie temperature slightly above the physiological temperature are 
preferred and polymers have to change their properties or shape in response to small 
temperature changes. In general, the drug is embedded in the polymer hydrogel and is 
somehow released through temperature increase. Drug release could either be triggered by 
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squeezing, where the hydrated gel starts to shrink at a higher temperature and so the drug is 
exuded (Bikram et al. 2007) or the drug is released from a thermosensitive polymer in the 
hydrogel. The latter type of drug release is still under basic investigation, but both systems 
still have to be improved for the use in clinics. 
Another approach combines heat responsive gene expression with magnetic nanoparticles 
producing heat in response to an AMF. On the one hand, a heat inducible promoter driving 
the expression of a protein can be linked to magnetic nanoparticles and expression starts 
when the AMF is applied to the particles. Using this system and Mn-Zn-ferrite magnetic 
nanoparticles coupled to an Hsp70 promoter driven expression construct, a highly regulated 
and efficient gene expression system could be established in mice (Tang et al. 2008). 
Another attempt is to include the magnetic nanoparticles in so called magnetic cationic 
liposomes (MCL) and transfect target tissue with a heat inducible expression construct. In 
one approach, TNF- was expressed in response to heat generation after AMF treatment in 
mice (Ito et al. 2001) in another one MCL were used for heating of glioma tumour tissue in 
rats (Yanase et al. 1998). Although both approaches show promising results in animal 
studies, further research has to be done to transfer this application into clinical trials. 
 
3.4.  HYPERTHERMIA 
If cells or tissues are exposed to temperatures above 40°C they induce several defence 
mechanisms to survive. In normal tissue, increased perfusion helps to deal with the higher 
temperatures and stress dependent protein denaturation is reversed by activating the heat 
shock response. At temperatures above 44°C, the resulting damage is too severe and the 
cells start to die. In contrast to normal tissue, regions affected by cancer react more sensitive 
to increased temperatures. On the one hand the mutated cells need more energy and 
oxygen supply because of their deregulated growth. Therefore, tumours often stimulate 
angiogenesis resulting in new blood vessel formation. Most of these blood vessels derive 
from already tumourigenic cells or regions near the tumour and are therefore not regularly 
shaped, have chaotic structures and do not sufficiently supply the tumour with nutrition and 
oxygen resulting in hypoxic regions. In addition to the low oxygen levels, also waste products 
are not sufficiently removed from areas with deregulated vascularisation leading to an acidic 
environment (Vaupel et al. 1989; Vaupel 2004). In response to higher temperatures, cells in 
this area induce apoptosis through intra-nucleosomal DNA-cleavage (Sellins et al. 1991). On 
the other hand the primary defence against stress, the heat shock response is also 
deregulated in most tumours. The key player of this response, heat shock factor 1 (HSF1), 
was already identified to promote tumour growth (Dai et al. 2007) and members of the heat 
shock protein 90 (Hsp90) family localise to the mitochondrion of cancer cells to inhibit stress 
initiated membrane rupture and therefore prevent tumour cell apoptosis (Kang et al. 2007). 
By initiating the heat shock response with increased temperatures, cancer cells start to 
express Hsp on their surface, which is noticed by the natural killer cells (Multhoff et al. 
1995a; Multhoff et al. 1995b). Despite the activation of the innate immune response also the 
adaptive immune response is stimulated by the increased release of tumour-associated 
antigens or self-antigens (Zhang et al. 2008b).  
This tumour-specific reaction to heat is used in clinical applications to specifically kill 
cancerous regions in the body. Dependent on the temperature two different types of 
treatment are distinguished. Above 46°C, cells are directly killed by temperature dependent 
protein denaturation. This treatment is called thermoablation. On the other hand, 
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hyperthermia is performed at lower temperatures (40-44°C) leading to a tumour-specific 
destruction of the cells, while normal tissue is unaffected. To reach these higher 
temperatures, energy has to be introduced, described as power-density specific adsorption 
rate (SAR), measured in W/kg. To establish hyperthermia conditions above 42°C in a target 
region, at least 20-40 W/kg have to be applied (Tilly et al. 2001). Depending on the method 
and material used, different SAR is reached within the tumour or even within the whole 
patient. 
 
3.4.1. TYPES OF HYPERTHERMIA 
Hyperthermia treatment can be classified into three different types, depending on the 
affected area. If the temperature is increased only in the tumour region, this method is called 
local hyperthermia. Treatment of larger regions like organs or limbs by heated fluids is called 
regional hyperthermia and heating the whole patient is called whole body hyperthermia 
(reviewed in (van der Zee 2002)).  
 
3.4.1.1 Local hyperthermia 
For heating of tumour tissue in local hyperthermia, several different methods are used today 
like radio wave (RFA), laser (Vogl et al. 2001), microwave (Fan et al. 1996) or ultrasound 
wave based systems. RFA uses a needle-like probe, directly injected into the tumour which 
releases high frequent current to heat the tissue (Goldberg 2001) or an applicator consisting 
of four dipole antenna arranged in a ring (Seebass et al. 2001). Another attempt to increase 
the temperature locally is the use of a transducer generating high-frequency ultrasound 
waves which are focused to a single point within the tumour (ter Haar 2001). Compared to 
other heating techniques, this high-intensity focused ultrasound (HIFU) can be adjusted 
better and reach deeper regions within the body. Although HIFU and also infrared are able to 
precisely heat a certain area, their therapeutic depth is limited to a few centimetres and 
therefore, these treatments are limited to tumours near the body surface. The use of HIFU to 
treat prostate cancer was tested in a different clinical trials (reviewed in (Rewcastle 2006)) 
resulting in clinical application. Regional hyperthermia using radio waves to treat several 
kinds of cancer entered clinical trials up to phase III, either combined with chemotherapy 
(Issels et al. 2010), radiation (van der Zee et al. 2000) or without additional treatment (Wust 
et al. 1998). To treat deep-seated tumours different heating sources have to be positioned 
next to the area of interest. Examples for such heating sources are microwave antennas, 
ultrasound transducers or radiofrequency arrays. As these antennas or arrays have to be 
positioned near the tumour to ensure a therapeutic temperature increase, these methods are 
highly invasive. In addition, the positioning of the heating elements in case of microwave or 
radiofrequency antennas is important in respect to interference and focus.  
Another type of intestinal heating is the application of nanoparticles in combination with an 
electromagnetic field. In this situation, the nanoparticles are injected into the tumour and the 
energy is applied from the outside. The first therapeutical concepts for the use of magnetic 
nanoparticles in combination with an alternating magnetic field to treat cancer was introduced 
in the 1950s (Gilchrist et al. 1957) and was further improved by several groups in the last 
years (reviewed in (Thiesen et al. 2008)). For this application mainly ferromagnetic 
nanoparticles are used because of their excellent biocompatibility, their known metabolic 
pathways and the heating potential (see also 3.3.4.) but also other metal nanoparticles 
consisting of manganese (Mn) or zinc (Zn) ferrites are in focus. Ferromagnetic nanoparticles 
are normally coated to prevent agglomeration and injected directly into the tumour (Jordan et 
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al. 1997), or into blood vessels supplying the tumour (Archer et al. 1989; Archer et al. 1990). 
Treatment of malignant diseases using magnetic nanoparticles either dispersed (magnetic 
fluid hyperthermia) or as integrated magnetic material have entered clinical phase and 
showed promising results treating prostate carcinoma (Johannsen et al. 2005), bone 
metastases (Matsumine et al. 2011) or glioblastoma (Jordan et al. 2001). In 2010 the 
German company MagForce Nanotechnologies received the first clinical approval for the 
treatment of brain tumours using magnetic nanoparticles (Gneveckow et al. 2004), which will 
promote the development of other nanoparticle based therapies for clinical use. 
Beside the use of a magnetic field combined with ferromagnetic nanoparticles also other 
nanoparticles are used to locally produce heat within the tumour. Gold (Au) nanoparticles 
increase temperature in the tissue when this area is exposed to radio waves, which are low-
frequency electromagnetic waves with good tissue penetration and low tissue specific 
adsorption rates. The nanoparticles, either tagged with antibodies or alone, are injected into 
or near to the tumour and exposed to a radiofrequency field produced by an external field 
generator (Kanzius RF generator) (Curley et al. 2000; Glazer et al. 2010). Beside radio 
waves also near-infrared can be used to heat Au nanoparticles for hyperthermia applications 
(Gobin et al. 2010). In comparison to the direct implantation of arrays or antenna into the 
tumour the entire nanoparticle based approaches are less invasive and can be regulated 
from the outside of the patient. As the nanoparticles can be modified on their surface, also 
tumour targeting strategies like antibody coupling to the particles directed against tumour 
surface markers (Gazeau et al. 2008; Cherukuri et al. 2010) can be utilised. In addition, the 
applied electromagnetic energy has a high tissue penetration with low energy-dependent 
specific adsorption rate (SAR). This kind of treatment is more convenient and less invasive, 
but the heat production is always dependent on the power of the applied field and the 
amount of nanoparticles in the tumour. Nanoparticle distribution in the tissue is not entirely 
regulated and therefore, the local heat production cannot perfectly be controlled. To avoid 
overheating and the resulting damage of healthy tissue, the temperature in the hyperthermia 
region has to be controlled properly, but standard methods like MRI cannot be used as they 
will interfere with the magnetic field. Therefore new and precise temperature sensoring 
systems have to be developed for magnetic field induced hyperthermia, like fibre optic-
probes injected into the tumour (Gneveckow et al. 2004) or addition of NMR active 
substances (Klingeler et al. 2008). Another limitation is the generation of the magnetic field 
for heat induction with ferromagnetic nanoparticles. The electromagnetic field strength has to 
be at least 5-18 kA/m, depending on the particles used, and therefore efficient magnetic field 
generators forming strong magnetic fields have to be employed, which is challenging for the 
constructors. Nevertheless, local hyperthermia is now in clinical trials or even approved for 
clinics and demonstrates the great power of this new cancer treatment. 
 
3.4.1.2. Regional hyperthermia 
When not only a distinct tumour area but a whole organ or region is heated, this is called 
regional hyperthermia. The classic example is the temperature increase within the limb by 
heated fluids (Coit 1992; Ceelen et al. 2000) and is based on bypassing a large supplying 
artery and a limb-draining vein. This treatment is well tolerated by the patient up to 43°C 
(Eggermont et al. 1996) and can be combined with other treatments like chemotherapy. 
Another example is the positioning of antenna into hollow organs combined with counter 
electrodes positioned on the body surface. Temperature increase in hollow organs like 
urethra, cervix or oesophagus can also be generated by hot water tubes but here the risk of 
overheating is very high and the technique has to be further improved for clinical trials. 
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3.4.1.3. Whole body hyperthermia 
The application of local or regional hyperthermia is designed for the destruction of primary 
tumours or a defined area, but not for the treatment of metastasis. To affect areas all over 
the patient whole body hyperthermia is applied. For all the different methods the whole body 
temperature has to be increased up to 41.8-42°C for at least 1 hour. Consequently, energy 
has to be applied to the body and at the same time, the natural energy loss through the body 
surface has to be minimised. With perfect thermal isolation the body would heat up to 42°C 
within 3 hours without any additional energy. This perfect isolation cannot be established and 
the duration of the heating would be too long. The first attempts to heat up the patient were 
extracorporeal heating or contact heating but these methods showed several side effects like 
burn or systemic reactions and low efficiency. Hence, other heating techniques with 
acceptable adverse effects were developed like radiant systems. This heating technique 
applied water-steam and long-wavelength infrared in an isolated chamber to increase the 
total body temperature to 42°C within 60-90 min (Robins et al. 1985; Wehner et al. 2001). 
Although the new developed methods showed less severe side effects, all whole body 
hyperthermia treatments can cause overheating of the skin resulting in thermal lesions and 
together with the applied deep anaesthesia or sedation also systemic toxicity can arise (Bull 
et al. 1982; Wust et al. 2000).  
 
3.4.2. INTERACTION WITH OTHER TREATMENTS 
For the treatment of cancer it is state of the art to not only use a single strategy but a 
combination of different treatments like radiotherapy and chemotherapy. When hyperthermia 
is combined with other treatments this enhances the therapeutic effect. Combined with 
radiotherapy, hyperthermia is one of the most potent radiosensitisers known. Radiotherapy 
destroys the tumour cells by the formation of oxygen radicals due to ionising radiation, but 
most of the cancerous tissues have a reduced perfusion rate and are therefore more 
resistant to this therapy. Hyperthermia increases the perfusion rate in the tumour resulting in 
a higher supply with oxygen radicals resulting in a higher radiosensitivity (Song et al. 1997). 
These radicals can now induce DNA damage which is further potentiated by the fact that 
hyperthermia in tumour cells interferes with cellular DNA-repair mechanism which is linked to 
the deregulated heat shock response (Kampinga et al. 2001). In addition, cells that are in the 
S-phase are highly resistant to radiotherapy, but are sensitive to hyperthermia. The high 
complementary action of hyperthermia and radiotherapy enhances the therapeutic outcome 
up to a factor of 5 and at the same time the radiation dose can be reduced to minimise 
radiation induced toxicity. Several clinical trials combining hyperthermia with radiation have 
been performed in the last years focusing on cervical cancer (reviewed in (Lutgens et al. 
2010)), breast cancer (reviewed in (Zagar et al. 2010)) or soft tissue sarcoma (Prosnitz et al. 
1999). 
The combination of hyperthermia with chemotherapy also showed therapy synergistic effect. 
In general the temperature dependent enhancement of perfusion and the change in 
cytoskeleton architecture, which leads to enlarged pores, promotes the uptake of 
chemotherapeutic drugs by the tumour (Dahl 1995). Like for thermoradiotherapy, also the 
combination of chemotherapy with hyperthermia allows reduction of drug concentrations and 
is was shown that mild heat treatment can potentiate the therapeutic outcome (Urano et al. 
1999). Different drugs show diverse effects when combined with higher temperatures. The 
cell-specific toxicity of platinum based drugs and alkylating agents like ifosfamide was shown 
to enhance linearly depending on the temperature increase (Istomin et al. 2008). For other 
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drugs, like anthracyclines only weak or even no additional effect was detected, but in some 
cases, like for doxorubicin, a counteraction was observed when hyperthermia treatment was 
performed. This reduction is due to the thermal instability of some chemotherapeutics (Ng et 
al. 1996). The combination of heat with chemotherapeutic agents was tested for different 
drugs in clinical trials, like in soft tissue sarcoma, where whole body hyperthermia was 
combined with ifosfamide, carboplatin and etoposide (ICE chemotherapy) resulting in 
response rates between 24 and 33 % (Westermann et al. 2003). 
In general, hyperthermia has emerged to be an efficient method for cancer treatment 
although the different heating techniques still have to be improved. The approach for deep-
seated tumours using nanoparticles is a novel non-invasive strategy for tumours mostly 
resistant to the commercial chemo- and radiotherapies and will boost the development of 
other nanoparticle based treatments. Beside the efficient tumour killing ability, hyperthermia 
is also the most potent enhancer of radiotherapy and most chemotherapeutic agents.  
 
3.5. HEAT SHOCK RESPONSE 
The heat shock response is a highly conserved stress response of all cells from bacteria to 
humans but with differences in the involved proteins or the regulation. Therefore, in this work 
mainly the human situation will be discussed. The heat shock response was first discovered 
by Ritossa in 1962 (Ritossa 1962) after the treatment of Drosophila busckii and Drosophila 
melanogaster larvae with higher temperatures. In response to this treatment, chromosome 
puffs in the polytene chromosomes of salivary glands were observed in regions encoding 
stress response proteins, the so called heat shock proteins. From this time on, a lot of effort 
was put into the analysis of this fast and robust reaction to heat. Although the heat shock 
pathway was initially discovered as a reaction to higher temperatures, soon afterwards it was 
shown that cells used this response when exposed to several kinds of stress, environmental 
and internal. The reaction to such conditions is an ancient mechanism of cells to survive 
stress like heat, radiation, increased or decreased pH and oxygen levels, exposure to heavy 
metals, but also bacterial or viral infections. In addition, the heat shock response is also 
initiated by inflammation, certain protein disorders or aging. When cells are exposed to 
severe stress, like heat, several problems arise in the cells. Firstly, the naive proteins in the 
cells start to partially unfold and also the cytoskeleton is affected. At mild stress actin is 
converted into stress fibres and in severe situations the whole cytoskeleton collapses 
including actin, tubulin and intermediary structures. Secondly, the different cell organelles 
lose their correct position within the cell, start to degrade and also the intracellular transport 
is disrupted (Welch et al. 1985). Thirdly, the whole transcriptional machinery is hit by stress 
resulting in inhibited RNA splicing (Vogel et al. 1995) and downregulation of protein synthesis 
(Storti et al. 1980; Dinh et al. 2001). Beside the intracellular effects, stress also acts on the 
cell membrane initialising hyperfluidisation, changes in lipid composition and rearrangement 
of microdomains (Nagy et al. 2007; Vigh et al. 2007). To prevent cells from this undesired 
effects the heat shock pathway is induced.  
In principle, the pathway is turned on by an external or internal trigger, leading to the 
activation of key mediators, which then turn on expression of stress responsive genes. 
Although several stimuli are known today, they all result in protein denaturation (Figure 3-1 B 
1) followed by activation of the heat shock factor (HSF), the major player in the heat shock 
response. HSF is activated by trimerisation (Figure 3-1 B 2) and modifications like 
phosphorylation (Figure 3-1 B 3) leading to an enhanced DNA binding capacity at special 
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recognition sites, the heat shock elements (HSE) (Figure 3-1 B 4). Due to induction via 
stress, active HSF trimers turn on the expression of several “survival proteins”, most of them 
preventing cell death and enhancing survival like the heat shock proteins (HSPs). They act 
as molecular chaperones preventing incorrect protein folding or refolding of partially unfolded 
proteins. Beside the role in survival, the heat shock proteins are also involved in de novo 
protein synthesis (Figure 3-1 A), several other cellular response mechanisms and certain 
diseases. Therefore, this pathway is relevant in most cellular reactions but still, its regulation 
and activation are not completely understood.  
 
A 
B 
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FIGURE 3-1 THE HUMAN HEAT SHOCK RESPONSE. In unstressed cells HSF1, the key mediator of the heat shock 
response, is engaged in an inactive complex with Hsp90 and Hsp70/40. HSF is localised in the nucleus or the cytoplasm and 
the RNA polymerase is locked at the promoter of Hsp genes. In response to several different stress factors, like heat, 
radiation, heavy metal exposure or hypoxia, proteins in the cell start to denature and the Hsp´s of the inactivation complex are 
recruited to the misfolded proteins. As a result, HSF monomer is released, starts to trimerise, is modified at several positions 
and binds to the HSE in the promoter of target genes (mainly Hsp) and also to the stress granula. In addition, the membrane 
gets hyperfluid which also triggers HSF activation. As an additional activator, a heat responsible RNA, heat shock RNA 1 
(HSR1) together with the elongation factor 1a (eEF1A) promote HSF1 activation. After binding of the HSF1 trimer to the HSE 
the RNA polymerase II is unlocked and transcription starts. 
3.5.1. HEAT SHOCK PROTEINS 
One of the most dominant groups of proteins regulated during the heat shock response are 
the so called heat shock proteins. These proteins primarily assist the refolding of cellular 
proteins after stress dependent denaturation and therefore belong to the family of 
chaperones. As the Hsps constitute 1-2 % of total protein in unstressed cells, it is clear that 
they also have important functions in normal cells. In principle, heat shock proteins all act as 
cytoprotective agents, both in normal and stressed cells. Some of the family members are 
involved in de novo protein synthesis, others are important for cytoskeleton maintenance 
(Hsp27) or act as enzymes (Hsp32). Heat shock proteins are divided into five classes 
according to their molecular weight, the small Hsps (15-30 kDa), Hsp60s, Hsp70s, Hsp90s 
and the sub-group of Hsp110s. 
 
3.5.1.1. Small heat shock proteins 
The small heat shock proteins are a group of conserved ATP independent chaperones with a 
molecular mass ranging from 15-30 kDa. They all share a conserved C-terminal domain of 
eight beta strands forming an intermolecular beta sheet, the so called alpha-crystallin domain 
(Hayes et al. 2009) and some subunit interaction or stabilisation domains. The members of 
this family display their role in mainly preventing protein aggregation by the formation of large 
hetero- or homo-oligomers out of monomeric or dimeric modules (Benesch et al. 2008). In 
humans 10 different small heat shock proteins (HSPB 1-10) are known, some of them are 
ubiquitously expressed like Hsp27 (HSPB1), Hsp20 (HSPB6) or Hsp22 (HSPB8) while others 
are only expressed in special tissues like heart and muscle (HspL27 (HSPB3), cvHsp 
(HSPB7) or Mkbp (HSPB2)), testis (CT51 (HSPB9) and ODF1 (HSPB10)) or eye lens (alpha-
crystallin A chain (HSPB4)) (Kampinga et al. 2009). Beside their role in protein aggregation 
prevention, some small Hsps also interact with components of the cytoskeleton. Hsp27 for 
example is bound to the barbed ends of F-actin (Lavoie et al. 1993), Hsp20 is important for 
actin cross linking (Tessier et al. 2003) and -crystallin interacts with intermediate filaments 
as vimentin or desmin (Nicholl et al. 1994; Perng et al. 1999). The overall potential of the 
small Hsps to form large oligomers up to 100 kDa is dependent on different post-translational 
modifications, mainly phosphorylation of serin residues. The phosphorylation status of the 
proteins determines their accumulation to larger aggregates as de-phosphorylation results in 
larger oligomers whereas higher levels of this post-translational modification lead to smaller 
oligomers (Parcellier et al. 2005). In addition to the oligomerisation status also the cellular 
localisation is influenced by the phosphorylation status of the proteins. Hsp27 for example is 
bound to F-actin as a dimer or tetramer and after stress treatment, Hsp27 is phosphorylated 
and translocates to the nucleus where it forms larger multimers and actin polymerisation in 
response to stress is initiated (Guay et al. 1997; Garrido et al. 1998; Brunet Simioni et al. 
2009). In response to several kinds of stress, the small Hsps are rapidly modified and as a 
result change their oligomerisation form and their binding properties (Lee et al. 1997). They 
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can work together with Hsp70 in protein re-folding, the degradation machinery of the 
proteasome (Lanneau et al. 2007) or interact with key apoptotic proteins to prevent stress 
induced cell death (Bruey et al. 2000; Charette et al. 2001). Mutations in the small Hsps lead 
to neuro-myopathies (Irobi et al. 2004) or cataract (Koteiche et al. 2006). 
 
3.5.1.2. Heat shock protein 60 
Heat shock proteins 60 (Hsp60) belong to the family of chaperonins, which are oligomeric 
ring-shaped structures and together with a second protein, Hsp10 perform correct folding of 
proteins in an ATP dependent manner. The structure of this chaperonin was extensively 
studied in the Escherichia coli (E.coli) analog of Hsp60, the GroEL chaperonin (Ranson et al. 
2001). In principle, the protein is built of three domains, the apical domain which is 
responsible for substrate binding and interaction with the co-chaperone, the equatorial ATP-
binding domain and the intermediate domain, which acts as a linker between the other two 
domains. The Hsp60 chaperonin machinery consists of two heptameric rings, connected via 
the intermediate domain of each Hsp60. These ring structures are flanked by the heptameric 
ring-shaped co-chaperone Hsp10/GroES (E.coli) at the top and the bottom of the cavity. The 
chaperonin oligomer can engage unfolded proteins up to 60 kDa and convert it to the correct 
folded proteins in the presence of ATP. Two transitional states are defined for the Hsp60 
cavity, the peptide-accepting state, where the non-native peptide is captured by a flexible 
hydrophobic part in the so-called “open” state of the chaperonin (Weissman et al. 1995; 
Sigler et al. 1998). After internalisation of the naive peptide, the lid and bottom heptamers of 
Hsp10 close the cavity and ATP-dependent protein folding is performed, termed peptide-
folding state (Farr et al. 2000). The Hsp60, as other Hsps, is highly conserved from bacteria 
to humans and shares ~95 % sequence and structural homology in different bacteria and up 
to 70 % homology in certain protein domains when compared to humans. Nevertheless, the 
human Hsp60 exhibits special oligomeric states and can be present as a mono-, hepta- and 
tetradecamer which is in contrast to the oligomeric state of other chaperonins (Levy-Rimler et 
al. 2002). Human Hsp60 (HSPD1) is translated into a preprotein and targeted to 
mitochondria via an N-terminal mitochondrial targeting sequence (MTS). During the uptake 
into the mitochondria the preprotein is cleaved and assembles to its functional oligomeric 
chaperonin structure (Singh et al. 1990; Venner et al. 1990). Hence, the primary location for 
Hsp60 is the mitochondrium, although recently it was also shown to be localised in the 
cytoplasm or the cell membrane in stressful conditions (Pfister et al. 2005) or during diseases 
like cancer (Ghosh et al. 2008) or atherosclerosis (Wick 2000). As Hsp60 displays a high 
homology with bacterial Hsps the innate and adaptive immunity of humans somehow can 
cross-react with the human Hsp60 when expressed on the cell surface (Young et al. 1989; 
Derbinski et al. 2010). Although Hsp60 is constitutively expressed it is up-regulated to some 
extent in response to heat (Naylor et al. 1996; Vargas-Parada et al. 2001) and plays also a 
bifunctional role in apoptosis. On the one hand, Hsp60 located in the cytoplasm was shown 
to release active caspase-3 in an ATP-dependent manner (Samali et al. 1999; Xanthoudakis 
et al. 1999) and therefore exhibits a pro-apoptotic role. On the other hand, cytosolic Hsp60 
also prevents apoptosis by forming complexes with Bax and Bak (Kirchhoff et al. 2002) and 
is associated with the survival of tumour cells (Ghosh et al. 2008). 
 
3.5.1.3. Heat shock protein 70/100 family 
The proteins of the Hsp70 (HSPA) family are a highly conserved group of ATP-dependent 
chaperones ranging from 66 to 78 kDa. All members of the family share two conserved 
domains, the N-terminal adenine nucleotide-binding domain of ~ 44 kDa (ATPase domain or 
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NBD) and the ~ 27 kDa C-terminally located peptide binding domain (PBD) or substrate 
binding domain (SBD). The SBD consists of two motifs, one substrate binding ß-sandwich 
motif built of two ß-sheets and an -helical domain responsible for substrate binding affinity 
(Mayer et al. 2001). The linker domain between NBD and SBD is important for the 
conformational changes in chaperone function and is therefore highly conserved. As Hsp70 
is a ATP-dependent foldase, the substrate is bound to the SBD in the presence of ATP and a 
co-chaperon (Hsp40) with low affinity, after hydrolysis to ADP the substrate binds with high 
affinity and ADP is released using nucleotide exchange factors (NEF) like heat shock protein 
binding protein 1 (HspBP1) (Shomura et al. 2005) or Bag (Sondermann et al. 2001). This 
switch between the two conformations is repeated till the protein has its correct folding. In 
normal cellular environment the Hsp70s are involved in de novo protein synthesis, protein 
transport across membranes and assist the generation of protein complexes using different 
co-chaperones as Hsp40, Bag, Hsp-organising protein (HOP) (Chen et al. 1998), HSC70-
interacting protein (HIP) (Hohfeld et al. 1995) or carboxyl terminus of Hsp70-interacting 
protein (CHIP) (Ballinger et al. 1999). These co-chaperones modulate the chaperone activity 
of members of the Hsp70 family by binding to the two conserved domains. When cells are 
exposed to several kinds of stress, some members of the Hsp70 family (Hsp72, Hsp70B´) 
are transcriptionally up-regulated and prevent protein aggregation or unfolding and refold 
partially denatured proteins. The group of Hsp70s is highly conserved except in some 
hyperthermophilic archaea (Gribaldo et al. 1999) and shares about 60 % sequence 
homology even with the major bacterial Hsp70, the DnaK. In humans today 13 members are 
known in the family of the HSPA (former known as Hsp70s) (Kampinga et al. 2009) with 
different localisation in the cell and different expression levels or inducibility in response to 
stress. Some HSPA genes do not contain introns (HSPA1A/B, HSPA1L, HSPA2, HSPA6 and 
HSPA7) while all other members have different numbers of introns. 
Three of this proteins are encoded in the major histocompatibility (MHC) locus on 
chromosome 6, the HSPA1A (Hsp72), the HSPA1B (Hsp70-2) and the HSPA1L (Hsp70-Hom 
or Hsp70t). HSPA1A and HSPA1B are two highly homologous proteins differing in only two 
amino acids and seem to be interchangeable. Both HSPA1A and HSPA1B are intronless 
genes differing in their 3´untranslated region (3´ÚTR) (Walter et al. 1994) and both proteins 
are stress inducible, the HSPA1A at higher levels upon prolonged activation in severe stress 
and HSPA1B as a stronger inducible Hsp activated even at mild stress (Akcetin et al. 1999). 
HSPA1A is the best studied of the inducible chaperones and is long known to be sensitive to 
several kinds of stress like heat (Wu et al. 1985), hyperoxia (Chambellan et al. 2006) or 
hypoxia (Benjamin et al. 1990), depletion of nutrition (Nissim et al. 1992; Bergeron et al. 
1996), heavy metals (Murata et al. 1999) or radiation (Nogami et al. 1993; Trautinger et al. 
1999) and works as a cytoprotective agent to prevent and repair protein denaturation 
(reviewed in (Morimoto 1991; Mathew et al. 1998; Morimoto 1998; Mathew et al. 2000; Soti 
et al. 2005; Voellmy et al. 2007; Shamovsky et al. 2008; Akerfelt et al. 2010; Morimoto 2012). 
HSPA1A and HSPA1B are located in the cytoplasm in unstressed cells and translocate to 
the nucleus in stressful conditions. In addition to their prominent role in the heat shock 
response by preventing protein degradation, HSPA1A plays also an important role in 
apoptosis, as the protein inhibits the activation of caspase (Mosser et al. 2000), the 
apoptosis signal-regulating kinase 1 (Ask-1) (Park et al. 2002) or the activation of c-Jun N-
terminal kinase (JNK) (Park et al. 2001a) after stress. It also stabilises the protein kinase B 
(PKB)/Akt and primes the protein kinase C (PKC) for phosphorylation (Gao et al. 2002), 
blocks NF-B activation by inhibition of I-B kinase activation (Shanley et al. 2000) or the 
release of cytochrome c by preventing Bax translocation (Stankiewicz et al. 2005). Another 
important feature of the inducible HSPA1A is the suppression of the immune response via 
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inhibiting the transcription (Cahill et al. 1996; Cahill et al. 1997; Housby et al. 1999) or the 
negative regulation of inflammatory cytokines (Ianaro et al. 2001). On the other hand, 
HSPA1A can also be found extracellularly or associated with the membrane in response to 
stress, which in fact stimulates the immune response. The release of HSPA1A from the cell 
is either the result of necrotic cell death (Basu et al. 2000) but also intact cells like B-cells 
(Clayton et al. 2005), glia cells (Guzhova et al. 2001) or peripheral blood mononuclear cells 
(PBMC) transport HSPA1A to the extracellular space using exosomes (Lancaster et al. 
2005). When expressed at the cell surface in response to stress or diseases, the heat shock 
protein can interact with cytotoxic T-cells and natural killer cells (Multhoff 2002; Lehner et al. 
2004) without the involvement of MHC. Extracellular HSPA1A is also associated to the stress 
response and can stimulate inflammatory cytokine production (Multhoff et al. 1999), inducible 
nitrogen oxide synthase (iNOS) (Panjwani et al. 2002), tumour necrosis factor TNF-), 
interleukin production (Asea et al. 2000) or activation of the complement cascade (Prohaszka 
et al. 2002). Beside its role in stress response, HSPA1A is also involved in normal cellular 
functions as cell-cycle control, development and differentiation or cell growth. HSPA1A is 
regulated mainly by HSF in the heat shock response, but is also affected by other cellular 
signaling pathways like, transforming growth factor beta (TGF) signaling (Takenaka et al. 
1992), JAK-STAT signaling (Stephanou et al. 1999) and the mitogen-activated protein 
kinase/ extracellular signal-regulated kinase (MAPK/ERK) pathway (Song et al. 2001). The 
third protein encoded in the MHC locus, HSPA1L is localised in the cytoplasm (Milner et al. 
1990) and the gene is induced after heat stress to some extent without tremendous increase 
in protein levels (Hageman et al. 2011), but high constitutive expression levels in testis (Ito et 
al. 1998).  
HSPA2 (Hsp70.2) another member of the family is also highly expressed in testis but also to 
some extent in other tissues. This protein was shown to play an important role in 
spermatogenesis (Dix et al. 1996; Govin et al. 2006), but is as well expressed in other 
tissues (Scieglinska et al. 2011). Beside other members of the family the HSPA2 gene 
contains HSE which are not functional and the gene is not expressed in response to stress 
(Wisniewski et al. 1990). It is located in the cytoplasm and is predicted to play a role in 
tumour cell growth (Rohde et al. 2005).  
Most of the HSPA family members are localised in the cytoplasm, but there are also some 
chaperones which are specific for certain organelles. The constitutively expressed HSPA5 
(GRP75 or BiP) is localised in the lumen of the endoplasmic reticulum (ER) and responsible 
for the import and folding of secretory proteins and other ER specific proteins (Munro et al. 
1986). HSPA5, like HSPA1A, is involved in the apoptotic pathway by interaction with p53 
(Wadhwa et al. 2002). The mitochondrial chaperone HSPA9 (mortalin, mtHsp75 or GRP75) 
is also constitutively expressed and like HSPA5 is not up-regulated in response to stress 
(Bhattacharyya et al. 1995). This chaperone is necessary for the import of proteins into the 
lumen of mitochondria where the proteins are correctly assembled by Hsp60. Another 
compartment specific HSPA is HSPA13 (Stch), which is associated with microsomes 
(Otterson et al. 1994). Like the other more distantly related family members HSPA12A and 
HSPA12B (Han et al. 2003), this gene is not induced in response to heat stress. Another 
distant member, the HSPA14 (Wan et al. 2004) shows some inducibility in response to stress 
and seems to play a role in immune response. 
In normal cells, the most abundant HSPA is the housekeeping chaperone HSPA8 (Hsc70 or 
Hsp73). This constitutively expressed protein maintains polypeptides in an unfolded stage to 
transport them across membranes. HSPA8 also targets denatured proteins to degradation 
via lysosomes. 
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In large mammalians but not in mice, there is another inducible member of the Hsp70 family 
expressed, the HSPA6 (Hsp70B´) (Leung et al. 1990; Noonan et al. 2008) and the highly 
homologous HSPA7 (Hsp70B), which is also highly inducible, but does not encode a 
functional protein (Parsian et al. 2000). HSPA6 shows ~ 80 % overall sequence homology 
and even 100 % homology in the peptide binding domain when compared to HSPA1A, but is 
exclusively expressed under severe stress (Noonan et al. 2007a). In addition, the inducibility 
even increases, when cells are kept at low cell density (Noonan et al. 2007b). HSPA6 unlike 
all other HSPA family members was not shown to be able to refold proteins, maybe because 
this chaperone has an abnormal N-terminal ATPase domain. However, it is able to rescue 
p53 activity even without the normally necessary co-chaperone DNAJ (Hsp40) (Hageman et 
al. 2011). The HSPA6 promoter contains 4 HSE (Schiller et al. 1988; Noonan et al. 2007b) 
and is strongly induced in response to severe proteotoxic stress, but regulated more tightly 
compared to HSPA1A as it persists just for some hours, whereas HSPA1A expression can 
continue for several days (Noonan et al. 2007a).  
Closely related to the HSPA family are the four known HSPH proteins, HSPH1 (Hsp105), 
HSPH2 (Hsp70RY, HSPA4, APG-2, Hsp110), HSPH3 (HSPA4L, APG-1) and HSPH4 
(Grp170, ORP150, HSP12A). These proteins were previously classified as member of 
Hsp70s as they consist of the same ABD and SBD but an extended linker domain and a 
longer C-terminal end (Liu et al. 2007; Shaner et al. 2007). Due to these structural 
differences these proteins were recently classified into a new sub-family of heat shock 
proteins (Lee-Yoon et al. 1995; Kampinga et al. 2009). Except HSPH4 (Grp170), which is an 
ER-specific protein (Chen et al. 1996), all other HSPHs are located in the cytoplasm. The 
proteins of this family act as NEF for HSPA (Dragovic et al. 2006) and in addition have 
chaperone activity on their own. Nevertheless, they are not able to fold proteins, but bind 
immediately to aromatic stretches in unfolded peptides, compared to the aliphatic residues 
preferred by the HSPA chaperones (Xu et al. 2012a). Associated to HSPA proteins the 
HSPHs are involved in different cellular processes like de novo folding of proteins (Yam et al. 
2005), translocation of proteins into the ER (Shaner et al. 2005), protein degradation or 
refolding under stress conditions (Albanese et al. 2006). Two members of the family were 
shown to be induced in response to stress, HSPH1 (Hsp105) (Subjeck et al. 1983) and 
HSPH3 (APG-1) (Kojima et al. 1996; Kaneko et al. 1997) while HSPH2 (Hsp70RY) was 
shown  not to be induced by heat stress (Fathallah et al. 1993; Santos et al. 1998). 
In conclusion the proteins of the HSPA and HSPH family are located in several 
compartments in the cell and are involved in the protein life cycle from de novo synthesis up 
to the refolding of stress denatured proteins and assist transport across membranes and 
degradation. Therefore, these groups of chaperones play an important role in normal cell 
processes, but some of the members are also key players in stress response.  
 
3.5.1.4. Heat shock protein 90 family 
In normal cellular environment, the group of Hsp90 proteins (HSPC family) are among the 
most strongly expressed cytoplasmic components (Borkovich et al. 1989). They regulate 
many processes in cellular compartments and their expression can be further induced in 
response to stress (Jakob et al. 1995; Yonehara et al. 1996). In bacteria, only a single 
Hsp90, called high-temperature protein G (HtpG), is known whereas the group of archaea 
lacks this family of heat shock proteins (Stechmann et al. 2004). In humans, five different 
HSPC proteins are known today, HSPC1 (Hsp90, Hsp87, Hsp90AA1), HSPC2 (Hsp90AA2), 
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HSPC3 (Hsp90AB1, Hsp90), HSPC4 (GRP94, endoplasmin, HSP90B1) and HSPC5 
(Hsp75, Hsp90L, TRAP1) (Chen et al. 2005; Kampinga et al. 2009).  
Hsp90 proteins share three highly conserved regions, a 25 kDa N-terminal ATP-binding 
domain (ABD), a middle domain and a 50 kDa C-terminal dimerisation domain. In general, 
Hsp90 acts as a homodimer, in which the dimerisation is mediated via the C-terminal region. 
This region consists of - helices and -sheets and two of these -helices per monomer form 
the tetra-helical dimer structure (Minami et al. 1994; Harris et al. 2004). In addition to 
dimerisation, the C terminus of cytosolic HSPC members also harbours a motif to recognise 
the tetratricopeptide repeat (TPR) domain, the Met-Glu-Glu-Val-Asp or MEEVD motif (Young 
et al. 1998) which is similar to the Hsp70 TPR binding motif. The C-terminal domain is linked 
to the N-terminus by a middle domain, containing two  motifs linked to  helices. This 
middle domain contains many recognition sites important for client protein interactions 
(Meyer et al. 2003). The ABD at the N-terminus is highly conserved and is build of a  and -
sandwich motif (Prodromou et al. 1997a; Prodromou et al. 1997b) which is also the binding 
site for the major Hsp90 inhibitors like geldanamycin (Stebbins et al. 1997). Other conserved 
amino acids form a lid like structure, which closes the ATP-bound pocket and together with 
loops of the middle domains are required for efficient ATP hydrolysis (Meyer et al. 2003). In 
the ATP bound state, the N-terminal domain also stabilises the Hsp90 dimer and enhanced 
activity (Cunningham et al. 2008). For the compartment specific HSPC members tumour 
necrosis factor receptor-associated protein 1 (TRAP1, HSPC5) which is located in the 
mitochondria and the ER specific Grp94 (HSPC4, HSP90B1) a leader sequence is also 
located at the N-terminus. In addition, the Grp94 has a highly conserved KDEL sequence in 
the C-terminal region which locates this chaperone to the ER (Chang et al. 1989). Cytosolic 
HSPC members like HSPC1 (HSP90AA1), HSPC2 (HSP90AA2) or HSPC3 (HSP90AB1) 
harbour an additional flexible and charged linker sequence, which is located between the N-
terminus and the middle domain. This linker is essential for ATP hydrolysis dependent 
conformational changes in the cytosolic Hsp90 (Hainzl et al. 2009).  
In contrast to other chaperones, the conformational states of the Hsp90 chaperone cycle are 
less conserved. Hsp90 itself has weak ATPase activity which is enhanced by interaction with 
co-chaperones (Nadeau et al. 1993). Without ATP, the Hsp90 dimer is attached to each 
other just at the C-terminal part also called the opened state of the cycle. After binding of 
ATP to the N-terminal binding site, the lid closes and due to conformational changes, an 
additional dimerisation site at the N-terminus is formed. This conformation is termed closed 
state. The hydrolysis of ATP triggers the conversion to an intermediate form which is not 
understood till now. The release of ADP then converts the Hsp90 back into the opened state. 
Within this cycle, the conformational changes in the chaperone are rate limiting steps (Graf et 
al. 2009; Hessling et al. 2009) and some co-chaperones are involved in the Hsp90 client 
maturation like p23 (Freeman et al. 2000; Young et al. 2000). 
Proteins of the HSPC family play an important role in several cellular processes but they 
have only limited influence on de novo protein synthesis (Nathan et al. 1997). The 
chaperones bind together with co-chaperones to partially folded intermediate conformations 
of their target proteins, the Hsp90 clients, and stabilise these conformations or enhance 
maturation (Pearl et al. 2006). Recognition of Hsp90 clients does not involve a special motif, 
as shown for other chaperones, but seems to be linked to the different co-chaperones and 
client binding found for all three conserved regions of Hsp90. These attached proteins, 
around 20 for cytosolic eukaryotic Hsp90, influence Hsp90 in different ways. A subgroup of 
co-chaperones enhances (AHA1, Cpr6) (McLaughlin et al. 2002; Panaretou et al. 2002) or 
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inhibits Hsp90 ATPase activity (like HOP, Cdc37 or p23) (Prodromou et al. 1999; Siligardi et 
al. 2002). Others recruit special clients as for example Cdc37, which recruits protein kinases 
or Cpr6, FKBP51 and FKBP52 which recruit progesterone and glucocorticoid receptors 
(Riggs et al. 2004; Caplan et al. 2007). In addition, co-chaperones also influence the Hsp90 
chaperone cycle.  
The cytosolic Hsp90s (HSPC1-3) are responsible for most processes associated with this 
family and are, except for one co-chaperone known for Grp94 (Liu et al. 2010), the only ones 
that need these associated proteins. In combination with the different co-chaperones, Hsp90 
proteins are involved in the regulation of many different clients like steroid hormone receptors 
(Bresnick et al. 1989; Nathan et al. 1995), protein kinase (Xu et al. 2001), but also eNOS 
(Garcia-Cardena et al. 1998), myosin (Rayment et al. 1993; Liu et al. 2008) and transcription 
factors like STAT3 (Sato et al. 2003). HSPC family members are also involved in antigen 
processing (Li et al. 2002; Kunisawa et al. 2006), protein trafficking and secretion (Chen et 
al. 2006; Lotz et al. 2008), RNA processing (Boulon et al. 2008; Zhao et al. 2008), telomere 
stability (Holt et al. 1999) but also protein degradation (McClellan et al. 2005). In addition, 
Hsp90 proteins combined with the TPR domain containing co-chaperones such as HOP 
interact with chaperones of the HSPA family (Hsp70) and their co-chaperones Hsp40 to 
facilitate client maturation. These clients include progesterone receptor (Cintron et al. 2006) 
or HSF1, thus priming its activation (Nadeau et al. 1993).  
Although Hsp90 is highly expressed in normal cells, the expression can be further increased 
by environmental stress via HSF1 (Sorger et al. 1987) or immune response via STAT1 or 
STAT3 (Stephanou et al. 1997; Ripley et al. 1999; Ammirante et al. 2008) leading to a kind of 
self-regulation of the chaperone. Hsp90 and many of its co-chaperones were also shown to 
be up-regulated in certain diseases including cancer (McDowell et al. 2009; Whitesell et al. 
2012) or neurodegenerative disorders (Salminen et al. 2011) reflecting their important role in 
cellular processes.  
The proteins of the HSPC family are in general essential for many cellular processes in 
unstressed environment and in addition play an important role in stress response. They are 
located in several compartments and, except for the cytosolic proteins, act on the 
stabilisation of immature clients without additional help. In case of cytosolic Hsp90, the co-
chaperones trigger the protein specific activity and enhance the action of the chaperone. 
 
3.5.1.5. Other heat shock proteins 
The above mentioned groups of heat shock proteins play several key functions in cells, either 
in regulating normal cellular processes or in enhancing survival after the exposure to different 
kinds of stress. In addition to these chaperone families, there exist also other heat shock 
proteins involved in cellular functions. One of these protein groups are the Hsp40 (DnaJ) 
proteins, which act as major co-chaperones for Hsp70 proteins. They are characterised by a 
highly conserved J-domain and are further subdivided in humans into DnaJA and B 
depending on the position of the J-domain and the presence of an additional cysteine-rich 
region (Cheetham et al. 1998). DnaJ proteins are localised in the cytoplasm or the nucleus 
(Hageman et al. 2009) and a subset of these proteins is induced in response to stress 
(Hageman et al. 2011).  
Most heat shock proteins are involved in the folding or stabilising of protein structures. 
Beside these members, also special heat shock proteins exist, which do not affect protein 
synthesis or maintenance, but have other roles. Hsp32, for example, is not a chaperone but 
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shows enzymatic activity as haemoxygenase-1 (HO-1) catalysing the conversion of pro-
oxidant haem into biliverdin (reviewed in (Chan et al. 2011)). Hsp32 is increased in response 
to stress (Stocker 1990) and thereby activates nitric oxide synthase (Weiss et al. 1994). 
Another example for a specialised heat shock protein is Hsp47, a collagen specific protein. 
Hsp47 is responsible for the appropriate three-dimensional arrangement of procollagen 
chains and prevents accumulation of these chains. The protein is localised in the ER and is 
further induced in response to stress (Nagata 1998).  
In general, heat shock proteins of all different families mediate important cellular functions, 
but are even more important for cells exposed to any kind of harmful conditions. Heat shock 
proteins are involved in protein homeostasis, signaling transduction cascades, cellular 
architecture and survival.  
 
3.5.2. HEAT SHOCK FACTORS 
Heat shock factors (HSF) are key mediators of the cellular stress response. These proteins 
act as transcription factors which are constitutively expressed (Fiorenza et al. 1995) but exist 
in a repressed state in normal cells. Upon activation via stress the repressed HSF monomers 
are released from the inactivating chaperone complex and trimerise to generate a high 
affinity DNA binding domain recognising special elements, the so called heat shock 
elements, in the promoter of target genes (reviewed in (Anckar et al. 2011)). HSF are highly 
conserved throughout all organisms, but they differ in the number of family members. In 
invertebrates like yeast, only one HSF is known whereas in mammals four different HSFs are 
found, (HSF1-4 in mouse, HSF1, HSF2 and HSF4 in humans) and plants contain even more 
family members (Nover et al. 2001; Akerfelt et al. 2010).  
The structure of the HSF members is highly conserved and contains an N-terminal DNA 
binding domain (DBD), a region responsible for trimerisation, a central regulatory domain 
(RD) and a C-terminally located transactivation domain (TAD) (Figure 3-2).  
The DBD is the highest conserved domain in the HSF and is built of a winged helix-turn-helix 
motif, where the wing stabilises DNA binding by protein-protein interaction (Littlefield et al. 
1999). In its trimerised form, the HSF DBD recognizes the HSE in the promoter of target 
genes (Figure 3-3). HSE are inverted repeats of at least three pentamers with a consensus 
sequence of nGAAn (Amin et al. 1988) and are located at the major groove of the DNA helix 
 
FIGURE 3-2 STRUCTURE OF HUMAN HSF1. The human HSF1 is composed of an N-terminally located DNA binding 
domain (DBD) which recognises the heat shock elements (HSE) in the promoter of target genes. Next to it there is a 
trimerisation domain built of two -helices with hydrophobic hepta repeats (HR-A and HR-B). In the middle, a regulatory 
domain (RD) is located which is responsible for most post-translational modifications either inhibiting or enhancing HSF1 
function. Between the RD and the two transactivation domains (TAD1 and TAD2) there is another hepta repeat located 
(HR-C) which interacts with HR-A and HR-B in the inactive monomeric form of the HSF. The TAD is located at the C-
terminus and facilitates transcriptional activation of target genes. Important repressing and activating post-translational 
modifications are shown at the distinct positions. Ac: acetylation (blue), p: phosphorylation (red), Su: sumoylation 
(green); PMT: post-translational modification. 
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(Wu 1995). In addition to DNA binding, the DBD also mediates interaction with other proteins 
to influence transactivation of the HSF (Bulman et al. 2001). Next to the DBD a domain 
responsible for trimerisation is located (Figure 3-2). This region is composed of two sub-
domains, which each contain an amphiphilic helix with an array of hydrophobic heptad 
repeats (HR-A and HR-B) like in leucine zipper motifs (Sorger et al. 1989; Peteranderl et al. 
1992). In the trimeric form of the HSF, the two leucine zipper motifs HR-A and HR-B form a 
triple-stranded coiled-coil structure (Peteranderl et al. 1999), which is further stabilised by 
intermolecular disulfide bonding (Ahn et al. 2003). Trimerisation is inhibited in the inactive 
state of HSF1 by the interaction of HR-A and HR-B with an additional HR located between 
the regulatory domain and the transactivation domain, the HR-C. This domain is thought to 
interact with the other two HR domains in the inactive monomer by conformational proximity 
(Figure 3-3) (Rabindran et al. 1993). In between the HR-A/B and HR-C domains, a central 
regulatory domain (RD) is located (Figure 3-2) (Green et al. 1995). Within this area most 
post-translational modifications (PTMs) (reviewed in (Xu et al. 2012b)) are found and this 
region inhibits the transactivation domain. The RD also harbours the intrinsic function to 
assay heat stress even without other parts of the HSF (Newton et al. 1996). At the C-
terminus HSF1 has a transactivation domain (TAD), divided into two sub-domains, the TAD1 
and the TAD2. Both domains are rich in hydrophobic and acidic residues and seem to be 
largely unfolded (Pattaramanon et al. 2007) although TAD1 seems to harbour a -helical 
short hydrophobic linear motif, which interacts with the basal transcription factor TATA box 
binding protein (TBP)-associated factor,TAF-9 (Choi et al. 2000). In contrast, TAD2 is rich in 
proline residues and therefore seems to be nonhelical (Newton et al. 1996). The acidic parts 
of the TADs are necessary for initiation of target gene transcription, whereas the hydrophobic 
residues are responsible for elongation by interaction with chromatin remodelling complexes 
(Brown et al. 1998; Sullivan et al. 2001). In addition, HSF also contain a bipartite nuclear 
localisation signal (NLS) next to the HR-A and HR-B (Sheldon et al. 1993; Vujanac et al. 
2005) which is responsible for location of the transcription factor in the nucleus (Mercier et al. 
1999). 
HSF is activated by a multi-step process converting the inactive monomer into a 
transcriptionally active trimeric version. In the monomeric state, HSF is attached to a 
chaperone complex which prevents formation of trimers. Hsp90 is bound to the RD but also 
the DBD and inhibits the binding of HSF to the target DNA (Ali et al. 1998; Bharadwaj et al. 
1999). On the other hand trimerisation of the monomers is inhibited at least in hHSF1 and 2 
by the interaction of HR-C with the oligomerisation domain of HR-A and HR-B (Rabindran et 
al. 1993). Human HSF4 lacks the additional C-terminal HR-C, and therefore was shown to be 
in a constitutive trimeric state, highlighting the importance of HR-C as a trimerisation inhibitor 
region (Chen et al. 1993; Nakai et al. 1997). In addition to the block of DNA binding and 
trimerisation, also the transactivational capacity of HSF is inhibited by binding of the 
chaperone Hsp70 together with its co-chaperone Hsp40 to the TAD (Abravaya et al. 1992; 
Shi et al. 1998) (Figure 3-3). In response to stress stimuli, Hsp90 and Hsp70/40 are released 
from the complex with HSF monomer (reviewed in (Morimoto 2002)) and the HSF monomers 
trimerise either as homotrimers or as heterotrimers containing HSF1 and HSF2 (Ostling et al. 
2007; Sandqvist et al. 2009). Within this trimerisation process, HSF becomes localised in the 
nucleus by shuttling the trimers into the nucleus and blocking nuclear export of the nuclear 
transcription factor (Mercier et al. 1999; Vujanac et al. 2005). Another step of regulation 
contains several posttranslational modifications like phosphorylation, sumoylation and 
acetylation. These post-translational modifications either inhibit or promote transcriptional 
activation of HSF (Figure 3-2 and Figure 3-3). In the inactive monomeric form, HSF is 
phosphorylated at least at 5 sites, in the DBD at serine residue 121 by MAPK- activating 
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protein kinase 2 (MK2) (Wang et al. 2006), three times in the RD at serine (Ser) 303, 307 by 
glycogen synthase kinase 3beta or(GSK3) (Chu et al. 1998) and MAPK (Chu et al. 1996; 
Kline et al. 1997) and 320 by protein kinase A (Murshid et al. 2010) and once at residue 363 
between HR-C and the TAD1 by c-Jun NH2-terminal kinase (JNK) (Dai et al. 2000), but only 
inhibition of phosphorylation at Ser303 and Ser307 resulted in activation of target gene 
transcription (Batista-Nascimento et al. 2011). In addition to phosphorylation, also 
sumoylation at lysine298 using SUMO E2 conjugating enzyme (Ubc9) (Anckar et al. 2006) 
was shown to repress transactivational activity of HSF. This sumoylation was shown to be 
dependent on the previous phosphorylation of Ser303, which together with Lys298 form the 
so called phosphorylation dependent sumoylation motif (PDSM) (Hong et al. 2001; 
Hietakangas et al. 2003). Another level of HSF repression is the acetylation of numerous 
lysine residues after stress-dependent activation to reduce HSF DNA recognition property, 
trimerisation and sub cellular localisation (Westerheide et al. 2009). Acetylation of lysine 80 
mediated by histone acetyltransferase p300 and CREB for example, leads to reduced 
binding affinity of HSF as this residue was shown to directly interact with the DNA backbone 
(Littlefield et al. 1999). The inhibitory effect of acetylation can be diminished in stressful 
conditions by the deacetylase sirtuin 1 (SIRT1) resulting in a prolonged binding of HSF to the 
DNA (Westerheide et al. 2009). In contrast to the numerous PTM repressing HSF activity 
only three phosphorylation events have been linked to activation, the phosphorylation of 
serine residue 230 by calcium/calmodulin-dependent kinase CaMKII (Holmberg et al. 2001), 
the Polo-like kinase 1 (PLK1) (Kim et al. 2005) mediated modification at serine 419 and the 
phosphorylation of serine residue 326 by an unknown kinase, which triggers interaction of 
HSF with the co-activator Daxx1 (Boellmann et al. 2004). 
In mammals four different HSFs are known, of which HSF1 is the key mediator of stress 
responsive target gene activation. In addition, HSF1 also regulates expression of several 
genes in normal cellular environment (Murray et al. 2004; Trinklein et al. 2004) without 
increase in response to stress. These genes are involved in the regulation of cell cycle, lipid 
metabolism or cell proliferation (Page et al. 2006). In parallel to the translocation to the 
promoters of stress inducible genes, HSF1 in human cells also localises to distinct sub-
nuclear structures, the so-called nuclear stress bodies (NSB) in response to stress (Biamonti 
2004). NSBs are only found in human cells and are transiently formed within minutes after 
stress in the nucleus where they are located close to the nucleoli (Cotto et al. 1997; Chiodi et 
al. 2000). The HSF within the NSB binds to a region at chromosome 9q12 and regulates the 
transcription of a subclass of satellite III repeats. This results in the generation of large non-
 
FIGURE 3-3 HSF1 TRIMERISATION. Human 
HSF1 is initially present as a monomer in 
unstressed cells. This monomer is kept in an 
inactive state by post-translational 
modifications (phosphorylation, acetylation 
and sumoylation) at several sites. The TAD is 
inhibited by binding to a complex of Hsp70 
and its co-chaperone Hsp40. Hsp90 is bound 
to the RD, the HRs and the DBD. In response 
to stress, the inhibitory chaperones are 
released from the complex. HSF trimerises 
and is phosphorylated at two sites in the RD 
and one residue in between HR-C and TAD1. 
The HSF1 trimer now binds to the HSE in the 
promoter of target genes and activates 
transcription. 
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coding RNA transcripts with unknown properties (Jolly et al. 2004; Rizzi et al. 2004). The 
knockout of the Hsf1 gene in mice results in diminished Hsp induction, a reduced cellular 
integrity in response to stress and abolished thermotolerance (McMillan et al. 1998) but also 
several developmental defects like female infertility, placenta abnormalities, as well as 
growth retardation and deregulated cytokine production (Xiao et al. 1999; Inouye et al. 2004; 
Takii et al. 2010). 
HSF2 has the same structural organisation as HSF1 but is active in non-stressed cells and 
binds to HSE without stress trigger. As HSF2 is constitutively active on the promoter of target 
genes, it seems to regulate their expression in normal environment and especially during 
development (Mezger et al. 1994). HSF2 also binds to the Hsp promoter in response to 
stress, but only in combination with HSF1 (Ostling et al. 2007). In addition, HSF2 also 
localises to the nSB in heterotrimers together with HSF1 in response to stress (Alastalo et al. 
2003). Heterotrimers of HSF1 and HSF2 seem to modulate the stress-inducible transcription 
of target genes as they are formed during the acute phase of the heat shock response. 
However, during the elongation phase HSF2 is no longer present and HSF1 homotrimers 
regulate transcription (Sandqvist et al. 2009). Mice lacking the Hsf2 gene showed 
developmental defects like altered brain morphology, reduced ovulation and defective 
meiosis (Kallio et al. 2002) as well as increased apoptosis in testis and reduced sperm 
quality (Wang et al. 2003). Cells lacking Hsf2 do not show a complete inhibition of stress 
triggered Hsp expression like in Hsf1 knockout cells rather than a repression of some Hsps 
(Hsp40, Hsp25). Therefore it seems that HSF2 has a modulatory effect on some but not all 
Hsp promoters (Ostling et al. 2007). 
HSF4 is the only member of the family which is not involved in stress response. Due to the 
lack of HR-C, HSF4 is constitutively trimerised. The transcription factor is expressed in 
human lens cells where it regulates the transcription of non-stress inducible target genes 
(Fujimoto et al. 2004). In addition, HSF4 is involved in the regulation of DNA damage repair 
(Cui et al. 2012). Although all HSF bind to HSE, the consensus sequence for HSF4 differs 
significantly from that of HSF1 as here only the G nucleotide is conserved leading to a 
nGnnn pentameric sequence (Hayashida et al. 2011). When HSF4 is absent in mice, they 
start do develop cataracts in early postnatal periods (Bu et al. 2002) caused by increased 
activation of transcription factors and a decrease of chaperones in lens cells (Fujimoto et al. 
2004). 
HSF3, the last member of the mammalian HSFs, is not found in humans and was originally 
thought to be an avian specific HSF where it is activated in response to severe stress 
(Tanabe et al. 1997). In the last years, HSF3 was also identified in mice, but in this case 
HSF3 was shown to activate non-classical heat shock target genes like PDZK3 in response 
to stress (Fujimoto et al. 2010). 
 
3.5.3. HEAT SHOCK REGULATION 
The heat shock response is known for more than 50 years but still the regulation and the 
initial events triggering this universal defence mechanism are only partially understood. Early 
in the research of the heat shock response it was shown, that not only heat triggers the 
activation. Up to now, several different stress factors have been shown to induce the heat 
shock response like radiation, hypoxia, hyperoxia, low or high pH, depletion of nutrition, 
exposure to heavy metals, reactive oxygen species (ROS), bacterial or viral infections, DNA 
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damage and many others (reviewed in (Voellmy 1994; Morimoto et al. 1996; Morimoto 1998; 
Shamovsky et al. 2008)).  
Today at least four different mechanisms for the conversion of an external stimulus to the 
activation of target gene expression are proposed which might all together be part of a 
complex regulatory network. The best analysed mechanism of heat shock response 
activation is based on stress dependent protein denaturation. Exposure of cells to different 
kinds of stress most of the time results in an increased number of denatured or partially 
unfolded proteins in the cell leading to increased need of molecular chaperones, which 
stabilise folding intermediates, refold proteins or trigger degradation (see also 3.5.1.). Among 
these chaperones, Hsp90 and Hsp70 are prominent chaperones necessary for proteostasis, 
which are recruited to the stress induced non-native proteins. As Hsp90 and Hsp70 are also 
the major components of the HSF inactivation complex, chaperones are released from the 
monomer and HSF is able to trimerise and is further modified and starts transcription of 
target genes (Bharadwaj et al. 1999; Morimoto 2002). Among the activated target genes, the 
heat shock proteins represent a large sub-group. Therefore, the necessary chaperones are 
up regulated and prevent protein unfolding. In response to the accumulation of Hsps in the 
cell, their expression is reduced, suggesting a self-regulatory mechanism in heat shock 
protein expression. In agreement with this model, the introduction of non-native protein into a 
cell results in up-regulation of Hsp expression (Ananthan et al. 1986). In addition, blocking of 
Hsp90 binding to the HSF by pharmacological inhibitors like geldanamycin also results in 
HSF trimerisation and binding to the HSE (Zou et al. 1998; Kim et al. 1999; Guo et al. 2001). 
Hsp90 is also bound to the RD of trimeric HSF in a complex with FKBP52 and p23 resulting 
in attenuation of HSF DNA-binding (Ali et al. 1998; Bharadwaj et al. 1999). In contrast, 
Hsp70 and its co-chaperone Hsp40 do not influence DNA binding of HSF trimer, but inhibit 
the transactivation capacity of HSF in dose dependent manner (Abravaya et al. 1992; Baler 
et al. 1996; Shi et al. 1998). The reduced activity of HSF seems to involve the Hsp70-
interacting transcriptional co-repressor CoREST (Gomez et al. 2008). Another evidence for 
the role of Hsp70 in heat shock regulation is based on experiments where overexpression of 
Hsp70 was shown to inhibit heat activation of HSF (Baler et al. 1996) and that Hsp70 is able 
to bind its own mRNA and reduce its expression (Balakrishnan et al. 2006). Although protein 
denaturation is definitely a key event in heat shock response activation, additional sensoring 
mechanisms must be involved because the recruitment of HSF to the promoter and 
transcription of target genes was shown to take place within seconds up to a few minutes 
after heat shock initiation (Boehm et al. 2003; Zobeck et al. 2010), which is too fast for the 
protein denaturation based activation model.  
Another sensory mechanism for heat shock response is directly linked to temperature. It was 
shown that a ribonucleoprotein complex is able to facilitate HSF1 activation. The complex 
contains the translational elongation factor eEF1A and a non-coding, constitutively 
expressed RNA, the heat shock RNA-1 (HSR-1) (Shamovsky et al. 2006). Mechanistically, 
this RNA might be related to the thermosensoric bacterial 32 RNA (Kugel et al. 2006), which 
is involved in the transcriptional activation of heat shock genes by temperature-dependent 
conformational changes (Morita et al. 1999). Another thermosensor mechanism is linked to 
the RD of HSF which has been determined as heat responsive (Newton et al. 1996) and 
additional cysteine disulfide bounds in the DBD which act as sensors (Ahn et al. 2003; Lu et 
al. 2009). The activation of the heat shock response via heat induced conformational 
changes is a fast response. As it was previously shown that the threshold temperature for 
heat shock response can be down regulated when cells were cultivated at lower 
temperatures (Abravaya et al. 1991), it is not likely that the thermosensors are the initial 
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activation event. In addition, expression of human HSF1 in Drosophila results in a decrease 
of heat shock temperature of around 10°C down to the normal heat shock temperature of 
fruit flies (Clos et al. 1993). 
In cells exposed to stress not only intracellular proteins are affected but also membrane 
composition and fluidity differs from unstressed cells (Carratu et al. 1996; Horvath et al. 
1998). The cell membrane starts to get hyperfluid and to rearrange sub-domains in response 
to mild stress (Curran et al. 2000; Shigapova et al. 2005), resulting in activation of membrane 
associated enzymes like phospholipase A2, which in turn activates protein kinase C and 
therefore promotes phosphorylation of HSF (Jurivich et al. 1994; Holmberg et al. 1997). In 
addition, the rearrangement of microdomains also results in the activation of membrane 
associated signalling cascades like the Ras/Rac1 pathway (Han et al. 2001) or growth factor 
receptors (Park et al. 2005), but also increase in intracellular Ca2+ concentration (Kultz 2005) 
and cholesterol glycoside (Kunimoto et al. 2002), which all result in increased Hsp 
expression (reviewed in (Vigh et al. 2007)). Experiments using membrane fluidiser resulted in 
a decrease of the heat shock threshold temperature (Balogh et al. 2005) indicating the 
important role of cellular membranes as sensors for mild temperature increase, but not the 
initial trigger for heat shock response. 
The sensor mechanisms described above all act at the cellular level but the in vivo situation 
seems to be even more complex. Experiments in Caenorhabditis elegans (C. elegans) could 
show that the heat shock response was not controlled by single cells but some kind of tissue 
spanning response could be observed. The initiation of the overall heat shock response 
could further be narrowed down to specific neuronal structures, thermosensory neurones and 
their post-synaptic cells (Prahlad et al. 2008). Although the research on whole organism heat 
shock regulation is still at the beginning, the results will be quite important to understand heat 
shock regulation and the associated diseases. 
To convert an external stimulus into a signal able to activate heat shock response is one 
level of regulation. Another level of regulation is focused on HSF1 activation, as this is the 
key event for target gene expression. This activation involves not only the heat shock 
pathway but is also induced by other cellular signaling cascades. Regulating the HSF1 
activation targets either post-translational modification, HSF1 localisation or trimerisation 
(reviewed in (Akerfelt et al. 2010; Anckar et al. 2011), see also 3.5.3.). The next level of heat 
shock regulation concentrates on transcriptional activation of target genes. At this level, the 
active HSF1 trimer binds to the HSE in the promoter of target genes as for example Hsp72, 
the major inducible heat shock protein. The promoter of Hsp72 contains at least 3 HSE ((Wu 
et al. 1986; Tsutsumi-Ishii et al. 1995) and is free of nucleosomes, leading to a fast binding of 
HSF1 upon stress activation. In the promoter of unstressed cells, RNA polymerase II is 
engaged, but kept in a paused state (Rougvie et al. 1988; Core et al. 2008) in Drosophila but 
also mammals (Brown et al. 1996; Meininghaus et al. 2000) by binding to negative 
elongation factor (Narita et al. 2003; Wu et al. 2003). In addition, nucleosomal packaging of 
the gene enhances RNA polymerase pausing (Brown et al. 1996; Lis 1998).  
Upon activation, HSF1 trimer binds to the HSE in the promoter of target genes and RNA 
polymerase II is released from its paused form. This release is due to the binding of positive 
transcription elongation factor b (P-TEFb) (Bres et al. 2008) and the interaction of HSF1 with 
BRG1, the ATPase subunit of SWIF/SNF chromatin remodelling complex (Sullivan et al. 
2001). Nucleosome displacement occurs across the whole gene and is triggered by 
poly(ADP)-ribose polymerase 1 (PARP-1) (Tulin et al. 2003; Ouararhni et al. 2006). The 
recruitment of HSF to the promoter and the start of RNA polymerase II driven transcription in 
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response to nucleosome disruption all occur within seconds after heat shock activation 
(Zobeck et al. 2010). Beside the chromatin remodelling interaction, HSF1 also interacts with 
TATA-binding protein (TBP) or basal transcription factors (TFIIB), which are part of the 
preinitiation complex (Mason et al. 1997; Yuan et al. 2000) and recruits and co-activates the 
so-called mediator complex to the promoter. This complex transmits the activation signal to 
the basal transcription machinery (Park et al. 2001b). In addition, Stress-responsive activator 
of p300 (Strap) is necessary at the promoter bound to HSF1 for acetylation of histones via 
the HAT domain of the co-recruited p300 (Xu et al. 2008). After expression, when target 
genes like heat shock proteins reach a certain level, the heat shock response starts to 
attenuate. This is caused by binding of Hsp70 to the HSF1 trimer in a self-regulatory manner 
(Abravaya et al. 1991; Abravaya et al. 1992; Baler et al. 1992) and the additional binding of 
heat shock factor binding protein 1 (HSBP1) resulting in a decreased expression of target 
genes (Satyal et al. 1998). 
 
3.5.4. HEAT SHOCK RESPONSE IN DISEASES 
The heat shock response represents a highly conserved mechanism of cells to handle 
different harmful conditions. In case of a deregulation of this pathway, several disorders like 
cancer or protein degradation associated diseases arise. HSF1 has been shown to be 
involved in cancer development as Hsf1 -/- mice are highly resistant to tumourigenesis (Dai 
et al. 2007) and HSF1 levels are higher in tumourigenic cells. In addition, levels of HSP are 
also up regulated in tumour cells (Jaattela 1999; Tang et al. 2005). The up-regulation of HSP 
results in anti-apoptotic signaling activation and the deregulation of important transcription 
factors and signaling molecules like NF-B or Raf1, which therefore promotes survival of 
cancer cells (Mosser et al. 2004). Due to the important role of the heat shock response in 
tumour formation the modulation of the response was established as a new therapeutical 
approach to treat several types of cancer (reviewed in (Westerheide et al. 2005; Murshid et 
al. 2011)). 
The heat shock response and the involved heat shock proteins primarily are responsible for 
the correct folding of proteins and the prevention of protein aggregation. Consequently, 
problems in the heat shock pathway are associated with diseases depending on misfolded 
proteins. Neurodegenerative diseases like Huntington disease, Parkinson disease or 
Alzheimer disease were all shown to be linked to the heat shock response (Kakizuka 1998; 
Neef et al. 2011). Hsp70 was shown to interact with huntingtin aggregates in cell culture 
experiments (Kim et al. 2002). Tau proteins, which are the cause of Alzheimer´s disease, 
when they are deposited into neurofibrillary tangles, are client proteins of Hsp90 (Salminen et 
al. 2011) and the mitochondrial Hsp70 member mortalin is associated with Parkinson 
disease (Jin et al. 2006). A common feature of all of these neurodegenerative diseases is 
their increased incidence with age. This increase might be linked to a lower activation of the 
heat shock response in aged cells (Soti et al. 2003; Shamovsky et al. 2004) due to reduced 
DNA binding capacity of HSF (Jurivich et al. 1997; Gutsmann-Conrad et al. 1998). 
Supporting this theory, HSF1 was shown to be required for long life in C. elegans (Morley et 
al. 2004), where it is involved in the highly conserved insulin/insulin-like signaling pathway, 
which is important for life span determination (Kenyon et al. 1993; Cohen et al. 2008). 
In summary, the heat shock response is a highly regulated cellular mechanism of cells 
dealing with harmful environmental conditions. Although it was discovered as a stress 
activated response, the components of the heat shock pathway also play important roles in 
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normal cellular situations and deregulation of the response results in severe 
neurodegenerative diseases as well as in cancer. 
 
3.6. AIM OF THE PROJECT 
The aim of this thesis was to establish a new approach for regulated gene expression in 
encapsulated cells and to perform first proof-of-principle experiments. For this, different 
already established methods like cell therapy, encapsulation technology, hyperthermia and 
heat inducible gene expression had to be combined.  
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4. MATERIALS AND METHODS 
 
4.1. DNA/RNA METHODS 
 
4.1.1. CLONING 
4.1.1.1. General procedure 
For the generation of new plasmids the backbone vector (=vector) and the plasmid 
containing the insert sequence (=insert) were digested over night with restriction enzymes 
(Thermo) generating corresponding types of overhang or blunt ends (see Tab.4-1). 
Afterwards the backbone vector was purified using a DNA purification kit MSB® Spin 
PCRapace Kit (INVITEK) according to the manufacturer´s protocol and optionally treated 
with alkaline phosphatase (FastAP, Thermo) according to the manufacturer´s. The digested 
plasmid containing the insert was loaded on a 1 % agarose gel, the DNA fragment of the 
expected size was cut out of the gel and purified with Invisorb® Spin DNA Extraction Kit 
(INVITEK) as described by the manufacturer. After purification both, the vector and insert 
were controlled for their amount and proper length using agarose gel electrophoresis. For 
ligation a T4 DNA ligase (Thermo) was used according to the manufacturer´s protocol and a 
ratio of insert : vector of 3 :1 was used. Next day the ligation mix was transformed into E.coli 
Top 10F´ and incubated at 37°C for 24 hrs on LB-Agar plates (LB-medium + 1.5 % agar). For 
the selection of the colony producing the correct plasmid, 10-20 colonies were picked, 
inoculated over night at 37°C in LB- medium (1 % bacto trypton, 0.5 % yeast extract, 0.5 % 
NaCl, 1 ml 5M NaOH) + 100 µg/ml Ampicillin (LB-Amp) and DNA was isolated by a rapid 
alkaline extraction method (see also Miniprep). Isolated DNA was digested with specific 
restriction enzymes to verify the correct sequence of the produced plasmid. One colony 
containing the expected plasmid was inoculated in 75 ml LB- Amp and incubated over night 
in the shaker at 37°C. Next day DNA was isolated (see also Midiprep) and again controlled 
by restriction enzyme digest. Purified DNA was now used for transfection of cells. 
 
TABLE 4-1 RESTRICTION ENDONUCLEASES 
Restriction enzyme Restriction site 
Cla I 
5'...A T↓C G A T...3' 
3'...T A G C↑T A...5' 
Bgl II 
5'...A↓G A T C T...3' 
3'...T C T A G↑A...5' 
Nco I 
5'...C↓C A T G G...3' 
3'...G G T A C↑C...5' 
I-SceI 
5'...T A G G G A T A A↓C A G G G T A A T...3' 
3'...A T C C C↑T A T T G T C C C A T T A...5' 
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4.1.1.2. Agarose gel electrophoresis 
To control the correct size of the digested plasmids up to 100 ng were analysed by agarose 
gel electrophoresis. Fragments between 200-3000 bp were separated on 1 % agarose gels, 
for smaller fragments a higher concentration of 2 % agarose (BIOZYM) in SB-buffer (2 M 
NaOH, 7.3 M Boric acid) was used. To determine fragment size a mixed DNA ladder (100 bp 
ladder +  BstEII (Thermo)) was employed. Electrophoresis standard settings were 120 V for 
20 min. DNA was visualised by intercalating etidiumbromide (10 µg/ml) by UV light using an 
Alphamager(R) Mini (Cell Biosciences). 
 
4.1.1.3. Miniprep 
Selected colonies were inoculated in 2 ml LB-Amp medium over night at 37°C on a shaker. 
Next day bacteria were harvested by centrifugation resuspended in cell suspension buffer P1 
(50 mM Tris, 10 mM EDTA, 100 µg/ml RNase A,), cells were lysed using buffer P2 (0.2 M 
NaOH, 1 % SDS), and reaction was stopped by the addition of neutralisation buffer P3 (3 M 
KAc, 11.5 % Glacial acetic acid). Cellular components and denaturated proteins as well as 
chromosomal DNA was removed by centrifugation (20 min 14 000 rpm) and extracted DNA 
was precipitated with PEG (12 %), washed with 70 % ethanol and DNA pellet was resolved 
in 20 µl dH2O. 1 µl of DNA was used for restriction analysis. 
 
4.1.1.4. Midiprep 
One colony selected after control restriction analysis was inoculated in 75 ml LB-Amp 
medium over night on a shaker at 37°C. Next day cells were harvested by centrifugation and 
DNA was extracted using JETSTAR 2.0 Midi Kit (Genomed) according to the manufactures’ 
protocol with one modification. For cell lysis and washing steps, only half of the 
recommended volume was used. DNA yield was determined by OD260 measurement and the 
isolated plasmid was verified by restriction analysis.  
 
4.1.2. PLASMIDS: 
4.1.2.1. Constructed plasmids 
hHsp70B´ part promoter driven firefly luciferase expression construct: 
A 400 bp fragment of the human Hsp70B´promoter containing 300 bp of the promoter 
harbouring the HSE an additional 100 bp leader sequence was amplified by PCR from 
genomic DNA and the resulting PCR fragment was ligated into pGemT Easy (Promega), 
transformed into E.coli, cell clones were selected (Miniprep) and plasmid DNA was isolated 
(Midiprep). The pGemT vector containing the Hsp70B´part promoter was digested using Bgl 
II and Nco I and the promoter was inserted into pMlucF (Figure 4-1 A) (Bgl II, Nco I). The 
resulting expression construct harbours the human Hsp70B´part promoter driving the 
expression of firefly luciferase in response to the heat shock pathway activation (Figure 4-1 
B). 
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A 
B 
FIGURE 4-1 PLASMIDS FOR GENERATION OF phHSP70Bluc. A) Backbone vector pMlucF. B) Newly generated plasmid 
phHsp70B´luc expressing firefly luciferase in response to Hsp70B´ partial promoter activation. For selection within the cloning 
procedure the plasmid contains an ampicillin resistance gene. 
 
Constitutive Gaussia luciferase expression construct: 
The coding sequence of the secreted form of Gaussia luciferase was amplified by PCR from 
a Gaussia luciferase encoding plasmid (pGLuc Basisvector) and the resulting PCR fragment 
was ligated with pGemT Easy (Promega), transformed into E.coli, cell clones were selected 
(Miniprep) and plasmid DNA was isolated (Midiprep). The pGemT vector containing the 
Gaussia luciferase was digested using Bgl II and ClaI and the promoter was inserted into the 
pMC backbone (Figure 4-2 A) (Bgl II, ClaI). The resulting expression construct harbours a 
constitutive active CMV promoter driving the expression of the secreted form of Gaussia 
luciferase (Figure 4-2 B). 
 
A  
B 
FIGURE 4-2 PLASMIDS FOR GENERATION OF pMCGluc S. A) Backbone vector pMC. B) newly generated plasmid pMC 
GlucS constitutively expressing the secreted version of Gaussia luciferase. For selection within the cloning procedure the 
plasmid contains an ampicillin resistance gene. 
 
4.1.2.1. Other plasmids 
Artificial HSE promoter luciferase construct: 
An HSE promoter construct containing a core of eight idealised HSE flanked by two CMV 
minimal promoters was used (Bajoghli, 2004) driving the bidirectional expression of firefly 
luciferase and GFP. For the generation of a stable cell line, a puromycin resistance was 
introduced into the HSE promoter (Figure 4-3). 
4990 bp 
Gaussia luciferase 
Secreted version 
SV40 late pA 
simian CMV (IE1) 
 promoter 
Bgl II (1171) 
ClaI (1751) 
Ampicillin 
Ressistance 
pMC GlucS 
pMC 
4417 bp 
SV40 late pA 
simian CMV (IE1)  
promoter 
Bgl II (1171) 
ClaI (1178) 
Ampicillin 
Ressistance 
phHSP70B´luc 
5290 bp firefly luciferase 
Ampicillin 
Resistance 
SV40 late pA 
hHsp70B´part promoter 
Bgl II (17) 
Nco I (430) 
pMlucF 
5114 bp 
firefly luciferase 
Ampicillin 
Resistance 
SV40 late pA 
Fos-promoter 
Bgl II (17) 
Nco I (254) 
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pzfHsp70-luc 
5326 bp 
firefly luciferase 
Ampicillin 
Ressistance 
SV40 early pA 
zfHsp70 promoter 
pKC2luc2a
6416 bp firefly 
luciferase 
Ampicillin 
Resistance 
SV40 early pA 
human CMV (IE1) promoter 
7520 bp 
gfp 
firefly 
luciferase 
Ampicillin 
Resistance 
Puromycin Resistance 
8xHSE 
pA BGH 
SV40 late pA 
CMV minimal promoter 
actin part promoter 
CMV minimal promoter 
Sce-I 
Sce-I 
 
FIGURE 4-3 pSGH2luc puro. The artificial HSE promoter contains a core of 8 idealised HSE flanked by two minimal CMV 
promoters driving the expression of the two reporter genes gfp and firefly luciferase in a bidirectional manner. For selection of 
stable cell clones a puromycin resistance gene was introduced. Two Sce-I sites are located in the plasmid to allow 
linearization. For selection within the cloning procedure the plasmid contains an ampicillin resistance gene. 
 
Constitutive firefly luciferase expression construct: 
This plasmid contains a CMV promoter driving the expression of firefly luciferase in a 
constitutive manner (Figure 4-4). 
 
FIGURE 4-4 pKC2luc2a. This expression construct encodes the sequence of firefly luciferase and a constitutively active CMV 
promoter. For selection within the cloning procedure the plasmid contains an ampicillin resistance gene. 
 
Zebrafish Hsp70 promoter luciferase construct: 
The expression construct harbours a truncated zebrafish (zf) Hsp70 promoter (Grabher et al. 
2004) driving the expression of firefly luciferase in response to heat shock pathway 
activation. 
 
FIGURE 4-5 pzfHSP70-luc. The plasmid encodes the truncated version of zf Hsp70 promoter driving the expression of firefly 
luciferase. For selection within the cloning procedure the plasmid contains an ampicillin resistance gene. 
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4.1.3. ISOLATION OF GENOMIC DNA 
Cells were seeded on 10 cm cell culture dishes (PAA) and grown to ~80 % confluence. 
Afterwards medium was removed, cells were washed with PBS and harvested in 7.5 ml PBS. 
Cells were centrifuged and pellet was resuspended in Bmod buffer (400 mM Tris, 5 mM 
EDTA, 150 mM NaCl, 0.1% SDS, pH 8.0) + Proteinase K (10 mg/ml) and incubated for 1 hr 
at 60°C on a shaker. To remove cell debris the suspension was centrifuged for 10 min at 
maximum speed and DNA was isolated using a DNA purification kit MSB® Spin PCRapace 
Kit (INVITEK) according to the manufacturer´s protocol with slight modifications (the elution 
was performed using 2x 25 µl dH2O). 
 
4.1.4. RNA ISOLATION 
Cells were incubated for different durations at 43°C or incubated with different inducers and 
lysed directly or up to 48 h after recovery at 37°C. Total RNA was isolated according to the 
manufactures protocol using Invisorb® Spin Tissue RNA Mini Kit (INVITEK) and RNA was 
eluted using 20 µl nuclease free water (from Kit). 
 
4.1.5. CDNA SYNTHESIS 
RNA lysate were used for cDNA. Residual DNA was removed with DNAse I (Thermo) 
according to the manufacturer’s instructions and RNA was transcribed into cDNA (total 
volume 20 µl) using random hexamer primers (100 µM, Thermo) using RevertAidTM H Minus 
M-MuLV Reverse Transcriptase (Thermo)according to the manufacturer’s protocol for 
RevertAidTM H Minus First strand cDNA synthesis kit (Thermo). 
 
4.1.6. PCR 
For the amplification of promoter regions or coding sequence of Gaussia luciferase a PCR 
using Phusion polymerase (Thermo) was performed. 
Per reaction: 
10 ng plasmid DNA /100 ng genomic DNA 
25 pmol primer forward 
25 pmol primer reverse 
1 µl 10mM dNTPs (Thermo) 
1 U Phusion polymerase (Thermo) 
10 ml 5x HF-buffer (Thermo) 
H2O to 50 µl 
 
Temperature protocol: 
98°C 30 sec 
98°C 10 sec 
55°C 30 sec  40 cycles 
72°C 15 sec 
72°C 5 min 
 
After PCR amplification product was controlled with electrophoresis and purified using DNA 
purification kit MSB® Spin PCRapace Kit (INVITEK) according to the manufacturer´s protocol 
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and A-tailing was performed for 20 min at 72°C afterwards and 3 µl A-tailing product was 
ligated with 1 µl pGemT Easy (Promega) according to the manufacturer´s protocol.. 
 
A-tailing – per reaction: 
6 µl PCR product 
1 µl 10x PCR-buffer (Thermo) 
0.5 µl 25 mM MgSO4 
0.5 µl Taq Polymerase (AGROBIOGEN) 
2 µl 0.1 µM dATP 
 
TABLE 4-2 PRIMER FOR CLONING PCR 
Primer Sequence 
Gaussia luciferase forward 5´-AGA TCT GCT AGC ACC ATG GGA GTC AAA GTT-3´ 
Gaussia luciferase reverse 5´-TCT AGA TTA ATC GAT TCC ACC TCC GTC ACC ACC GGC CCC CT-3´ 
hHsp70B promoter forward 5´-GAG ATC TCC AGC CCG GAG GAG CTA GAA-3´ 
hHsp70B promoter reverse 5´- GCC ATG GCT GAA GCT TCT TGT CGG-3´ 
 
4.1.7. QPCR 
For qPCR, Taqman hydrolysis probes were designed using Primer Express V2 and cDNA 
was analysed in an Mx3000P (Strategene) qPCR cycler. As an endogen control hGAPDH 
was used.  
Per reaction: 
1.5 µl cDNA 
2 µM primer forward 
2 µM primer reverse 
2 µM Taqman hydrolysis probe 
1x buffer B (80 mM Tris, 20 mM (NH4)2SO4, 0.02% Tween 20)  
or 1x buffer ABI (10 mM Tris, 50 mM KCl) 
3-3.5 mM MgCl2 
0.2 mM dNTP mix (Thermo) 
0.025U Taq polymerase (AGROBIOGEN) 
water to 25 µl 
Temperature protocol: 
5 min 95 °C 
30 sec 95°C  
60 sec 60°C 
All cDNA tested in qPCR were performed in triplicates and to determine concentration a 
standard curve (based on 1:4 dilution series of standards Table 4-3) was added on each 
plate. cDNA were normalised to the hGAPDH levels. Standard dilution series were 
performed in duplicates. 
TABLE 4-3 qPCR SETTINGS 
Gene buffer MgCl2  mean eff.% Standard 
hGAPDH (NM_001256799.1) buffer B 3.5 mM 97-99% GAPDH PCR product 
Luc buffer B 3.5 mM 96-98% Firefly luciferase plasmid 
mHsp72 (HSPA1A, NM_005346.4) buffer ABI 3 mM 92-95% mHsp72 plasmid 
hHsp70RY (HSPA4 NM 002154) buffer B 3 mM 93-95% cDNA C5 cells 1hr 43°C+ 2 hrs 37°C 
eGFP buffer B 3 mM 97-99% eGFP plasmid 
 
40 cycles 
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TABLE 4-4 PRIMERS FOR qPCR: 
Gene sequence Tm 
hGAPDH forward 5´-GGA AGG TGA AGG TCG GAG TCA A-3´ 64°C 
hGAPDH reverse 5´- ACC AGA GTT AAA AGC AGC CCT G-3´ 62°C 
Firefly luciferase forward 5´- TGG ATT ACG TCG CCA GTC AAG-3´ 61°C 
Firefly luciferase reverse 5´-TTC GGT ACT TCG TCC ACA AAC A-3´ 60°C 
hHsp72 (HSPA1A) forward 5´-AAC CAG GTG GCG CTG AAC-3´, 58°C 
hHsp72 (HSPA1A) reverse 5´-TGG AAA GGC CAG TGC TTC AT-3´ 58°C 
hHsp70RY (HSPA4) forward 5´-GTG GGC ATA GAC CTG GGC TTC CA-3´ 62°C 
hHsp70RY (HSPA4) reverse 5´-TCC AAT TGA ACG ATT CTT AGG ACC A-3´ 63°C 
GFP forward (Paar et al. 2007) 5´-GCA GTG CTT CAG CCG CTA C-3´ 62°C 
GFP reverse (Paar et al. 2007) 5´- AAG AAG ATG GTG CGC TCC TG-3´ 60°C 
 
TABLE 4-5 PROBES FOR QPCR 
Gene Sequence Tm 
hGAPDH 5´-HEX-ATT TGG TCG TAT TGG GCG CCT GGT C-BHQ1-3´ 69°C 
Firefly luciferase 5´-FAM-CGC GAA AAG TTG CGC GGA GG-BHQ1-3´ 65°C 
hHsp72 (HSPA1A) 5´-FAM-AAC ACC GTG TTT GAC GCG AAG CG-BHQ1-3´ 66°C 
hHsp70RY (HSPA4) 5´-FAM-CTA CGT CGC TGT GGC CCG CG-BHQ1-3´ 69°C 
GFP modified  
(Paar et al. 2007) 
5´-FAM-CCG ACC ACA TGA AGC AGC ACG ACT T-BHQ1-3´ 69°C 
 
4.2. CELL CULTURE 
 
4.2.1. CELL LINES 
HEK 293 (ATCC: CRL-1573) 
Human embryonic kidney cells (fetus). Cells were grown at 37°C in a humidified environment 
of 5 % CO2 in DMEM high glucose (PAA), supplemented with 10 % FCS, 100 U/ml penicillin, 
and 100 U/ml streptomycin sulphate (1x Penicillin/Streptomycin, PAA). Propagation was 
performed using 1xtrypsin (PAA) and a sub-culturing rate of 1:10-1:15 was used. 
 
U2Os (ATCC: HTB-96) 
Human osteosarcoma epithelial cells (female origin). Cells were grown at 37°C in a 
humidified environment of 5 % CO2 in DMEM high glucose (PAA), supplemented with 10 % 
FCS, 100 U/ml penicillin, and 100 U/ml streptomycin sulphate (1x Penicillin/Streptomycin, 
PAA). Propagation of the cells was performed using 1xtrypsin EDTA (Gibco, 0.25 %trypsin, 
0.03 % EDTA) and a sub-culturing rate of 1:10 was used. 
 
HeLa (ATCC: CCL-2) 
Human epithelial cervix Adenocarcinoma cell line (female). Cells were grown at 37°C in a 
humidified environment of 5 % CO2 in DMEM high glucose (PAA), supplemented with 10 % 
FCS, 100 U/ml penicillin, and 100 U/ml streptomycin sulphate (1x Penicillin/Streptomycin, 
PAA). Propagation was performed using 1xtrypsin (PAA) and a sub-culturing rate of 1:10-
1:15 was used. 
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MCF-7 (ATCC: HTB-22) 
Human epithelial mammary gland Adenocarcinoma cell line (female). Cells were grown at 
37°C in a humidified environment of 5 % CO2 in DMEM high glucose (PAA), supplemented 
with 10 % FCS, 100 U/ml penicillin, and 100 U/ml streptomycin sulphate (1x 
Penicillin/Streptomycin, PAA). Propagation of the cells was performed using 1xtrypsin EDTA 
(Gibco, 0.25 %trypsin, 0.03 % EDTA) and a sub-culturing rate of 1:10 was used. 
 
PANC-1 (ATCC: CRL-1469) 
Human pancreas epitheloid carcinoma cell line (male). Cells were grown at 37°C in a 
humidified environment of 5 % CO2 in DMEM high glucose (PAA), supplemented with 10 % 
FCS, 100 U/ml penicillin, and 100 U/ml streptomycin sulphate (1x Penicillin/Streptomycin, 
PAA). Propagation of the cells was performed using 1xtrypsin EDTA (Gibco, 0.25 %trypsin, 
0.03 % EDTA) and a sub-culturing rate of 1:10 was used. 
 
SW480 (ATCC: CCl-228) 
Human epithelial colorectal adenocarcinoma cell line (male, Tumour stage Dukes´type B). 
Cells were grown at 37°C in a humidified environment of 5 % CO2 in DMEM high glucose 
(PAA), supplemented with 10 % FCS, 100 U/ml penicillin, and 100 U/ml streptomycin 
sulphate (1x Penicillin/Streptomycin, PAA). Propagation of the cells was performed using 
1xtrypsin EDTA (Gibco, 0.25 %trypsin, 0.03 % EDTA) and a sub-culturing rate of 1-5 up to 
1:10 was used. 
 
Stable HSE promoter cell line: 
HEK 293 cells were transfected with the HSE promoter construct (pSGH2luc puro) using PEI 
as a transfection reagent. Cells were cultivated for 2-3 days and then stably transfected cells 
were selected with puromycin (1 µg/ml) as a selection marker. After one to two weeks, single 
clone colonies were picked using single cloning discs (Invitrogen) and cultivated with 
puromycin. First tests were performed using 1h HS 43°C with ensuing GFP detection and 
luciferase reporter gene assay.  
 
Stable cell line C5: 
The stable cell line C5 showed robust GFP expression and highest luciferase inducibility and 
therefore was used for further experiments.  
Stable cell cline D4: 
The stable cell line D4 showed no GFP expression but high luciferase inducibility and 
therefore was used for the comparison of promoter activation in different HSE promoter cell 
lines. In contrast to the missing GFP expression, sequencing of the promoter showed full 
length integration of the promoter region.  
Stable cell line A6: 
The stable cell line A6 showed robust GFP expression but constitutively high luciferase 
expression and therefore was used for the establishment of the luciferase assay in 
encapsulated cells. In contrast to the constitutive activation, sequencing of the promoter 
showed full length integration of the promoter region.  
All stable cell lines were grown at 37°C in a humidified environment of 5 % CO2 in DMEM, 
supplemented with 10 % FCS, 100 U/ml penicillin, and 100 U/ml streptomycin sulphate.  
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4.2.2. TRANSFECTION 
For transient transfection experiments 0.3x 105 cell/ well of a 24 well plate (PAA) were 
seeded and incubated for 24 hrs at 37°C. In total 400 ng DNA (tested plasmids + backbone 
vector pBluescript to fill up to 400 ng total DNA amount) in 100 µl DMEM without serum was 
mixed with 100 µl serum-free DMEM containing the transfection reagent (depending on the 
used cell line, see Table 4-6) and incubated at room temperature for 30 min. Afterwards, 
medium was removed from the cells and 200 µl transfection mix was added and incubated 
for 2-4 hrs at 37°C (depending on the transfection reagent). Transfection was stopped by the 
addition of 1 ml DMEM containing serum and cells were incubated additional 48 hrs before 
lysis. 
TABLE 4-6 TRANSFECTION CONDITIONS 
Transfection reagent per well Cell line Incubation time 
0.8 µlTurbofect (Thermo) HeLa, SW480, U2Os 2 hrs 
1.6 µl PEI (0.0435% PEI 25000) HEK 293, PANC-1, MCF-7 4 hrs 
 
4.2.3. STABLE CELL LINE GENERATION 
To generate a stable HSE promoter cell line, 2x106 HEK 293 cells per 10 cm dish were 
seeded and transfected with 1 µg of the HSE promoter construct pSGH2luc puro (Figure 
4-3), which was previously linearised with I-SceI + 9 µg herring sperm DNA (GIBCO) to reach 
a total DNA amount of 10 µg and 8 µl PEI. Two days after transfection puromycin (100 µg/ml) 
was added for selection of stable construct integration and medium was changed frequently 
the next two weeks. Single cell clones were picked using single cloning discs (SIGMA) and 
the cell clones were tested for their inducibility after heat treatment. 
 
4.2.4. STRESS INDUCTION 
Heat treatment:  
A defined number of cells were seeded into cell culture dishes (0.3x105 cells for 24 well 
plates, 2x105 cells /well for 6 well plates) and cultivated for 3 days at 37°C. For heat 
treatment, cells were placed on an iron plate in a cell culture incubator at a temperature of 
43°C for a distinct time. To recover from the heat stress, cells were returned to 37°C or 
directly used for the experiments. 
Induction with chemical inducers: 
For the induction with heavy metals or pharmacological substances, cells were seeded as 
described above and after 3 days at 37°C medium was removed. Different concentrations of 
inducer in DMEM containing 10 % FBS were added to the cells for 1 hr and afterwards 
medium was changed. To recover, cells were returned to 37°C or directly used for the 
experiments. 
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4.2.5. VIABILITY ASSAY 
Trypan blue assay:  
To analyse the survival after heat treatment, medium was removed, cells were trypsinised, 
washed with PBS and all washing fractions were combined with the removed medium and 
the detached cells. Cells were collected by centrifugation for 5 min at 900 rpm, resuspended 
in 1 ml PBS and an aliquot of 50 µl was mixed with the same amount of a 0.5 % Trypan blue 
solution and incubated for 2 min. The number of dead cells was determined in a bright field 
microscope by counting the blue cells and the total cells in a Neubauer chamber. 
 
4.2.6. HYPOXIA TREATMENT 
Cells were prepared as for induction with heat treatment and after 3 days transferred to a 
hypoxic chamber (STEMCELL Technologies Inc.) floated with a mixture of 10 % CO2 and 90 
% N2. Cells were incubated in the chamber for 6 – 20 hrs at 37°C and afterward recovered 
under normal oxygen levels at 37°C.  
To mimic hypoxic conditions cells were incubated with 1 – 100 mM CoCl2 like described for 
induction with chemical inducers. 
 
4.2.7. DEGRADATION ASSAY 
HeLa cells were transfected with plasmids encoding constitutively expressed firefly luciferase 
(10 ng pKC2luc2a Figure 4-4) or Gaussia luciferase (1 ng pMC GlucS Figure 4-2) and 
pBluescript backbone vector (389 ng) to reach the optimal amount of 400 ng total DNA for 
transfection with 0.8 µl Turbofect. 48 hrs after transfection cells were incubated for 1 hr with 
different inducers and lysed directly afterwards in 50 µl luciferase lysis buffer. Firefly 
luciferase as well as Gaussia luciferase activity were determined using the dual luciferase 
assay. 
 
4.3. PROTEIN METHODS 
 
4.3.1. LUCIFERASE ASSAY 
Cells or capsules were lysed in luciferase lysis buffer (0.1 M Tris pH 7.5, 1 % Triton X and 
1mM DTT) (50 µl for cells, 70 µl for capsules), capsules were mechanically destroyed by a 
pestle, and incubated for 15 minutes at room temperature. Capsules were centrifuged for 5 
min at 1000 rpm and supernatant of capsule or cell lysate was used for luciferase activity 
measurement in a LUMAT LB 9705 luminometer.  
Firefly luciferase assay: 
For firefly luciferase activity determination 50 µl cell lysate was provided, 100 µl D-luciferin 
solution (0.2 mM D-luciferin, 20 mM Tris pH 7.5) and ATP solution (5 mM ATP, 25 mM Tris 
pH 7.5, 15 mM MgCl2) were injected by the luminometer and relative light units (RLU) were 
determined for 10 sec. 
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Dual luciferase assay: 
For detecting firefly and Gaussia luciferase, 40 µl of the cell lysate was used for firefly 
luciferase assay and 10 µl of the cell lysate was used for Gaussia luciferase assay. Within 
this assay the luminometer injected 100 µl substrate solution (2.5 mM EDTA, 6.25 mM Tris 
pH 7.5, 3 µM Coelentrazine) and determined RLU production for 10 sec. 
Top assay the background levels of both measurements RLU of the lysis buffer was detected 
and subtracted from the sample values. 
 
4.4. OTHER METHODS 
 
4.4.1. MAGNETIC FIELD GENERATOR 
The magnetic field generator was designed and built by Christian Halter, Group of Johann 
Walzer, University of Applied Sciences, FH Campus Wien, Department for Engineering using 
a frequency generator, an oscilloscope and a induction coil (Figure 4-6 A-D) to establish an 
alternating magnetic field of ~ 30 kA/m using a frequency of 60 kHz and 27 A input current. 
The induction coil was manufactured from highly conductive brass tubes (Figure 4-6 C). 
During operation, the induction coil itself heats because of the high current and was therefore 
permanently cooled using deionised water (20°C) (Figure 4-6 E). For the experiments without 
capsules an additional cooled water jacket was used to ensure a temperature of 37°C for the 
cells.  
A) power supply B) oscilloscope 
C) 
Induction coil 
         
D) frequency generator and  
power amplifier 
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E) The magnetic field generator including the water cooling system 
FIGURE 4-6 THE MAGNETIC FIELD GENERATOR. The homemade magnetic field generator contains a power supply, an 
oscilloscope, a frequence generator and a water cooled induction coil. 
 
4.4.2. INDUCTION IN THE MAGNETIC FIELD 
For the induction experiments in the alternating magnetic field (AMF), 105 cells o 140 
capsules per 200 µl culture medium were transferred to a reaction tube, pre-incubated at 
37°C and put into the coil for defined durations of 30 minutes. Directly after the induction, the 
temperature of the suspension was determined using a digital fine tune thermometer and 
cells or capsules were supplied with 2 ml medium and transferred to 37°C for recovery. 
Luciferase activity was determined 6 h after induction. 
For the determination of nanoparticle mediated heat production, the particles were 
suspended in 200 µl culture medium, transferred to a reaction tube, pre-incubated at 37°C 
and put into the coil for defined durations of 5 - 30 minutes. Directly after the induction, the 
temperature of the suspension was determined using a digital fine tune thermometer. 
 
4.4.3 ENCAPSULATION 
All cell encapsulations were performed by Cornelius Kaspar at the Department for 
Pathobiology, Institute of Virology, University of Veterinary Medicine, as described in Ortner 
et al. Materials and Methods. 
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5. RESULTS 
 
5.1. CONCEPT 
Gene and cell therapy approaches have shown the tremendous potential of the in vivo 
production of therapeutic proteins in the treatment of diseases (see also 3.1.1-3.1.2). 
Nevertheless, some problems still limit the clinical use of these therapies. Firstly, the 
production of therapeutic substances needs to be regulated to ensure optimal 
pharmacodynamics, but in most cases the production is constitutive and may lead to side 
effects due to drug overdose. Secondly, when cells are used for treatment they are either 
affected by the immune system if they are of heterologous origin or they can only be used in 
individual patients when autologous cells are used. In addition, modified cells always 
comprise the risk of unwanted reactions within the tissue, even when autologous cells are 
used (see 3.1.1 and 3.1.2.). Thirdly, also when inducible expression systems are used, the 
inducer has to be introduced into the whole system first and has to reach the side of action, 
which drastically increases the time until the system can be turned on (see 3.2.). In recent 
years, many different strategies were invented to solve one or more of the discussed 
problems. Within this thesis, an additional strategy for regulated in vivo production of 
therapeutical proteins was established and elaborated. This new approach uses an artificial 
heat inducible promoter (Bajoghli et al. 2004) stably integrated into a human cell line. The 
cells are encapsulated with cellulose sulphate to generate a barrier against the host immune 
system, but the membrane still allows the transport of macromolecules to the surrounding 
tissue. To induce the expression system by heat, magnetic iron oxide nanoparticles are 
coencapsulated. When an alternating magnetic field is applied to the capsules, the 
nanoparticles start to produce heat and in turn activate the artificial heat shock expression 
system. This activation strategy can also be applied to capsules within a patient, as the 
magnetic field is able to activate the nanoparticles even at a distance of several centimetres 
(Figure 5-1). 
 
FIGURE 5-1 CONCEPT OF HEAT INDUCED GENE EXPRESSION IN ENCAPSULATED CELLS. A stable cell line 
harbouring an artificial heat shock promoter is encapsulated together with magnetic nanoparticles using cellulose sulphate. 
These capsules can then be implanted into tissues and modified cells are protected from the host immune system by the 
capsule membrane. When an alternating magnetic field is applied from the outside, the magnetic nanoparticles start to 
produce heat which in turn activates the artificial heat shock promoter leading to the expression of therapeutic proteins.  
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This approach combines previously well established clinical methods like hyperthermia 
treatment (see 3.4) with promising pre-clinical strategies like heat shock activated gene 
expression (see 3.2.2) and encapsulation (3.1.2.3.). Taken together a promising new method 
to activate gene expression in encapsulated cells with an external stimulus was established: 
In addition, problems with the host response were avoided by encapsulation and this method 
might also reduce the amount of necessary drug by a local and regulated production. 
 
5.2. STABLE CELL LINE 
The first step of the project was to generate a stable cell line, harbouring an artificial heat 
inducible promoter. This stable cell line has the benefit of constant levels of promoter 
construct integrated and therefore consistent activation behaviour, whereas transient 
transfections would always vary because of different transfection efficiencies. 
 
5.2.1. PROMOTER 
The artificial heat inducible promoter was previously established as an inducible expression 
system for medaka (Bajoghli et al. 2004). The promoter is built of eight idealised heat shock 
elements with a sequence of A GAA CG TTC TA GAA C compared to the general consensus 
sequence n GAA nn TTC nn GAA n. The eight idealised HSEs are flanked on both sites by a 
CMV minimal promoter driving the expression of two different genes in a bidirectional 
manner. For the application in mammalian cells and for the selection of stable cell clones, the 
promoter was integrated into an expression vector harbouring a puromycin resistance gene 
under the control of a constitutive actin promoter. To analyse the induction of the promoter 
and the expression of the genes of interest, on one side a firefly luciferase reporter gene and 
on the other side of the bidirectional promoter a gene encoding green fluorescent protein 
(GFP) was placed. The ampicillin resistance gene in the expression vector is used for 
selection during the cloning procedure and BGH or SV40 late poly adenylation signals (pA) 
are located at the end of the two reporter genes (Figure 5-2). 
 
 
  
 
FIGURE 5-2 THE ARTIFICIAL HEAT 
SHOCK PROMOTER. Vector map of 
pSGH2 luc puro. The promoter is build of 
a core of eight idealised HSEs flanked by 
two minimal CMV promoters. These CMV 
promoters drive the expression of the two 
reporter genes firefly luciferase and GFP 
in a bidirectional manner. An ampicillin 
resistance gene is integrated into the 
plasmid for selection during the cloning 
procedure and a puromycin resistance 
gene under the control of an actin 
promoter is used for selection of stable cell 
clones. 
7520 bp 
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5.2.2. COMPARISON OF DIFFERENT HS PROMOTERS 
Heat shock promoters have previously been used for the generation of inducible expression 
systems but they often had problems with high background activation and low induction 
levels (see 3.2.2.2.). To verify the high inducibility of the artificial HSE promoter and to 
compare our system to established heat shock promoters, the different promoter constructs 
driving the expression of firefly luciferase were analysed after heat treatment. HEK 293 cells 
were transfected with the different promoter-luciferase constructs and incubated at 43°C for 
30 min or 1 hr. Luciferase activity was determined 6 hrs after heat treatment using a 
luciferase assay. 
 
FIGURE 5-3 LUCIFERASE EXPRESSION 
CAPACITY OF DIFFERENT HEAT SHOCK 
PROMOTERS. HEK 293 cells were transfected with 
different heat shock promoters driving the 
expression of firefly luciferase, incubated for 24 hrs 
at 37°C and heat shock treatment was performed for 
30 min or 1 hr at 43°C. Luciferase activity was 
measured 6 hrs later. The luciferase activities were 
normalised to the expression levels at 37°C. This 
diagram shows one representative experiment. 
const. Luc: human CMV promoter, zfHsp70: 
zebrafish homolog of Hsp72 promoter, HSE prom.: 
artificial heat shock promoter, hHsp70B´ part: 400 
bp promoter of human HSPA6 (Hsp70B´).  
The artificial HSE promoter showed high inducibility of more than 100 fold in response to 
heat treatment for 1 hr similar to the hHsp70B´part promoter (Figure 5-3), which is known to 
be the highest inducible heat shock promoter for expression systems. In comparison, the 
zebrafish Hsp70 promoter could induce luciferase expression at 1 hr heat treatment around 
10 fold which is similar to the levels of a 30 min heat treatment of the HSE promoter. This 
experiment clearly showed the potential of the artificial HSE promoter as a tool for inducible 
expression systems. 
 
5.2.3. EXPRESSION IN DIFFERENT CELL LINES 
In addition to high background activation of heat shock promoters or designed heat inducible 
promoters, most of them also showed tissue or cell type specific activation differences 
(3.2.2.2.). To analyse the potential cell type specific behaviour of the artificial HSE promoter, 
several different human cell lines were transfected with the HSE promoter construct and 
luciferase activity was determined after standard heat shock and at 37°C. 
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FIGURE 5-4 PROMOTER ACTIVITY IN 
DIFFERENT CELL LINES. HEK 293, HeLa, 
MCF-7, U2OS, PANC-1 or SW480 cells 
were transfected with the HSE promoter 
construct (pSGH2luc puro) in a 24 well 
scale (0.3x10
5
cells/well, 10 ng pSGH2 luc 
puro) and incubated at 37°C for 1 day. After 
standard heat treatment (HS) (1hr, 43°C) 
cells were incubated for 4 hrs at 37°C and 
afterwards luciferase activity was 
determined in heat treated cells and 
transiently transfected cells without heat 
treatment as a negative control. This 
diagram shows one representative 
experiment. RLU: relative light units HS: 
heat shock 
Tumour cell lines of different origin like cervix (HeLa) (Figure 5-4light blue), mammary gland 
(MCF-7) (Figure 5-4green) or colorectum (SW480) (Figure 5-4 red), the osteosarcoma cell 
line U2OS (Figure 5-4 orange) and a pancreas epitheloid carcinoma cell line (PANC-1) 
(Figure 5-4 dark blue) were transfected with the artificial HSE promoter driving the 
expression of firefly (10 ng pSGH2luc puro). The inducibility of the promoter in the different 
cell lines was compared to the induction in the non-cancer cell line HEK 293 (Figure 5-4 
yellow). In general most tumours cell lines showed higher luciferase activity 6 hrs after heat 
treatment (1 hr, 43°C) (above 100 000 relative light units (RLU)) compared to a 2-5 fold lower 
luciferase activity in the adenovirus transduced HEK 293 (around 60 000 RLU). The 
transfected mammary gland carcinoma cell line MCF-7 showed similar luciferase activity 
after heat treatment like HEK293, but for all tumour cell lines the basal activation of the HSE 
promoter driven luciferase expression was 2-8 fold higher (500 RLU for HEK 293, 1000-4000 
RLU for SW480 – PANC-1) than in HEK 293. Although basal luciferase expression and the 
maximum luciferase activity after heat treatment differ in the tested cell lines, all of them 
showed at least a 100 fold induction of luciferase expression after heat treatment, which 
clearly shows no cell type specific limitations of our HSE promoter. Nevertheless, for the 
application in cell therapy a cell line with extreme low background activity is crucial to avoid 
leaky expression of therapeutic substances. In addition, the cell line should be well 
characterised. As HEK 293 cells showed the lowest basal activation of the HSE promoter 
and the cells are not of tumourigenic origin, these cells were used to generate a stable cell 
line harbouring the artificial promoter. 
 
5.2.4. GENERATION OF A STABLE CELL LINE 
After testing different cell lines, the adenovirus transduced human embryonic kidney cell line 
(HEK 293) was chosen as suitable for our inducible expression system because of the low 
basal activity of the promoter and the application of the cell line in approved medical 
treatments (Hacker et al. 2009).  
For the generation of the stable cell line, the HSE promoter construct pSGH2 luc puro 
(Figure 5-2), which includes the two reporter genes firefly luciferase and GFP, was 
introduced into the HEK 293 cells by transfection with polyethylenimine (PEI). Cells were 
cultivated for 2-3 days and then stably transfected cells were selected with puromycin 
(1 µg/ml). After one to two weeks, colonies were picked. The selected cell clones were 
cultivated with puromycin and first tests were performed using 1 h heat shock (HS) at 43°C 
with ensuing GFP detection and luciferase reporter gene assay. Cell lines with GFP 
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expression and/or high luciferase inducibility were selected and used for further experiments 
(Figure 5-5 A+B).  
A 
 
B 
 
FIGURE 5-5 STABLE CELL LINES: HEK 293 stably transfected with pSGH2 luc puro were incubated at 43°c for 1 hr (HS) 
and luciferase induction was measured 4 h after HS. Therefore 2x10
5
 cells were seeded in 3.5 cm dish and 3 days later cells 
were incubated at 43°C in an incubator (+CO2) for 1 h. Cells were lysed 4 h after heat shock and a luciferase reporter gene 
assay was performed. All luciferase expression levels were normalised to cells incubated at 37°C. A) shows a representative 
experiment of the screening procedure, the highest inducible cell clone is marked with an arrow, other highly inducible clones 
are marked with an arrowhead. B) A representative experiment of the best four cell clones (A: arrow + arrowheads) that were 
tested again to verify the results. 
In total, two different batches of single cell clones were generated within the project. The first 
batch resulted in the selection of one highly inducible cell clone, C5. In the second batch, 
different cell clones (48 clones in total) were analysed in respect to GFP and luciferase 
expression after heat treatment and compared to the highest inducible cell line, C5, derived 
from the first round of stable transfection (Figure 5-5 A). The tests resulted in the selection of 
three additional cell clones, #7, #22 and #31 (Figure 5-5 arrowhead). All of them were used 
in further heat induction experiments to compare their inducibility to those of the C5 cell line 
(Figure 5-5 B). In the end, the stable cell line C5 showed the highest induction levels (Figure 
5-5 arrow) and therefore was used for all further experiments. 
 
5.3. PROMOTER ANALYSIS 
As a first step of the project, a stable cell line harbouring the artificial heat shock promoter 
was generated. With this stable cell line, the behaviour of the artificial HSE promoter now 
could be analysed in detail. Natural heat shock promoters do not exclusively react to one 
kind of stress, but they induce the stress response through a variety of different triggers like, 
heat, hypoxia, heavy metals or some pharmacological components (3.2.2.2.). Hence, the 
application of heat shock promoters as inducible expression systems always have to deal 
with this co-activation by different triggers. An optimal promoter would respond only to one or 
few stimuli, like heat, whereas not responding to other stress triggers, like hypoxia. The 
restriction to one or at least a limited number of externally applied induction signals increases 
the safety of the induction system for clinical application as the promoter would not be 
activated by background stress signals like hypoxia, low/higher pH or depletion of nutrition, 
all naturally occurring in the patient. 
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5.3.1. HEAT INDUCIBILITY 
The first kind of stress that was analysed was heat, as this was also the trigger planned for 
induced expression within the capsules. In the literature, different temperatures ranging from 
41°C to 45°C were used to induce the different heat shock promoters. For our artificial HSE 
promoter a temperature range of 41-44°C was tested (Figure 5-6). 
A 
 
FIGURE 5-6 TEMPERATURE 
DEPENDENT PROMOTER 
ACTIVATION AND PROTEIN 
DENATURATION. A) This figure was 
recently published in Ortner et al. 2012  
(see appendix Fig.2a) and adopted here. 
2x10
5
 C5 cells per well of a 6-well plate 
were incubated at 41-44°C for 1 hr and 
recovered for 6 hrs at 37°C. The 
expression of luciferase was determined 
using a luciferase assay. Luciferase 
activity was normalised to the expression 
levels at 37°C. The experiment was 
performed in sextuplicates. Error bars: 
+/- SEM n=6. B) Protein denaturation 
assay. HeLa cells were transiently 
transfected with constitutively expressing 
firefly luciferase (CMV Luc) and Gaussia 
luciferase (CMV GLuc) constructs and 
incubated for 2 days at 37°C. Cells were 
trypsinised and resuspended in 200 µl 
medium in a PCR tube. Cells and 
medium were incubated for 15 min at 
different temperatures in a PCR gradient 
cycler (30, 31.9, 36, 39.1, 42.8 
and47.2°C) and lysed afterwards to 
analyse firefly luciferase and Gaussia 
luciferase activity.  
B 
 
The induction of the stable cell line C5 at different temperatures showed highest activation of 
the promoter at 44°C (~7000 fold). At 43°C the stable cell line showed a ~ 3000 fold 
induction which decreased to ~30 fold when the temperature was reduced by 1°C. A further 
reduction to 41°C resulted in ~2 fold induction of the promoter which is close to the basal 
levels (Figure 5-6 A). Although 44°C showed the highest expression levels of luciferase, 
43°C were chosen as standard heat treatment temperature. The exclusion of 44°C is based 
on the severe stress at this temperature which results in increased cell death (see also 
5.5.1.). In addition, this high temperature stress might also influence the cell survival when 
repeated heat treatments are performed. The increase in temperature resulted in an 
exponential activation of the artificial HSE promoter when 41°C were compared to 42 or 
43°C. In contrast the increase to 44°C resulted only in a 2.5 fold higher expression of the 
reporter gene. Nevertheless, with this experiment the heat-dependent induction of the 
promoter could be shown, as the promoter activity increased with rising temperatures. In 
addition, an assay to determine the degradation of proteins was established. Therefore, 
HeLa cells were transiently transfected with two different constitutively expressing luciferase 
constructs. One construct harbours firefly luciferase, which is known to be sensitive to 
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temperature changes and the other luciferase, derived from Gaussia, has previously been 
shown to be highly stable (Wiles et al. 2005). The cells were incubated for 15 min at 
temperatures between 30 and 47°C and luciferase activity was determined directly 
afterwards. Firefly luciferase showed decreased activity at temperatures above 39°C down to 
around 1.2 % of the initial activity at 47°C (Figure 5-6B, yellow line). In contrast, the activity of 
Gaussia luciferase was not influenced by increasing temperatures (Figure 5-6 B, red line). A 
similar approach to test stress-dependent denaturation of proteins by determining the activity 
of firefly luciferase has previously been used (Nguyen et al. 1994; Torok et al. 2003). Here 
highly stable Gaussia luciferase was added as a reference. 
5.3.2.  INDUCTION WITH HYPOXIA 
In addition to heat, also other stress triggers are able to induce natural heat shock promoters. 
The stress factors are divided into external signals, activator components and environmental 
conditions. External signals are all kinds of radiation but also temperature. Additionally, in the 
tissue there are different situations initiating the stress response like depletion of nutrition, 
changes in pH or too low levels of oxygen. As our stable cell line harbouring the artificial heat 
shock promoter should be used for encapsulation and these capsules have a diameter of 
700 µm up to 1 mm, the problem of oxygen diffusion has to be kept in mind. Therefore it was 
analysed, if hypoxic conditions within the capsules might induce the artificial promoter 
consisting of heat shock elements (HSE), although hypoxia is thought to be induced through 
different recognition sites in the natural heat shock promoters. To test the induction of the 
artificial promoter in response to hypoxic conditions, cells were incubated in a hypoxic 
chamber for several hours and luciferase expression was measured at several time points 
after hypoxia treatment. 
 
FIGURE 5-7 6 H OF HYPOXIA TREATMENT. 
Cells of the cell line C5 were incubated at 
hypoxic conditions and luciferase expression 
was measured at different time points after 
hypoxia. Therefore, 2x10
5
 cells were seeded 
and 3 days later cells were incubated for 6 h 
under hypoxic conditions (10 %CO2, 90 % N2) 
at 37°C in an incubator (+CO2). Cells were 
lysed directly, 4 h and 16 h after hypoxia 
treatment and a luciferase reporter gene 
assay was performed. As a positive control, 
cells were incubated for 1 h at 43°C and lysed 
6 h later. The luciferase expression levels 
were normalised to cells incubated at 37°C 
(negative control). This figure shows one 
representative experiment. 
This experiment using hypoxic conditions for 6 h showed no induction of luciferase 
expression after 0-16 h (Fig.10, yellow bars). When cells were incubated at for 1 hr at 43°C 
for and 6 h at 37°C, luciferase expression increased around 2000-fold (Figure 5-7 red bar) 
compared to cells incubated at 37°C ((Figure 5-7, green bar) as a control. As in the literature 
different periods of hypoxia treatment from 6 h - 20 h were reported the experiment was 
repeated using 20 h of hypoxia treatment. In addition, also hypoxia treated cells were 
incubated at 43°C for 1 h directly after hypoxia treatment and lysed 6 h later to verify the 
inducibility of the promoter even after hypoxia.  
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FIGURE 5-8 20 h OF HYPOXIA 
TREATMENT. Cells of the cell line C5 were 
incubated at hypoxic conditions and 
luciferase expression was measured at 
different time points after hypoxia. Therefore, 
2x10
5
 cells were seeded and 3 days later 
cells were incubated for 20 h under hypoxic 
conditions (10 %CO2, 90 % N2) at 37°C in an 
incubator (+CO2). Cells were lysed directly, 6 
h and 16 h after hypoxia treatment and a 
luciferase reporter gene assay was 
performed. As positive controls, cells were 
incubated for 1 h at 43°C and lysed 6 h later 
and cells incubated for 20 h under hypoxic 
conditions were incubated for 1 h at 43°C 
and lysed after 6 h. The luciferase 
expression levels were normalised to cells 
incubated at 37°C (negative control). This 
figure shows one representative experiment. 
Like in the previous experiment with 6 h of hypoxia treatment ((Figure 5-7), an induction of 
the artificial promoter and the resulting luciferase expression in cells, which were treated for 
20 h under hypoxic conditions, could not be detected (Figure 5-8, yellow bars). To ensure, 
that the stable cell line was still inducible after hypoxia treatment, cells were incubated for 1 h 
at 43°C in addition to the incubation under hypoxic conditions which resulted in ~ 600 fold 
luciferase expression (Figure 5-8, blue bar) compared to ~850-fold induction when cells were 
incubated for 1 h at 43°C without previous hypoxia treatment (Figure 5-8, red bar). As a 
result we could show that the stable cell line is inducible by heat treatment, with or without 
previous hypoxia treatment. However, 20 h of hypoxia treatment alone were not sufficient to 
induce the artificial promoter.  
The different durations of hypoxia treatment did not result in an induction of the artificial 
promoter, but in all control cells incubated at 43°C the expected increase of luciferase levels 
could be shown indicating that the cells were alive and functional. In order to exclude 
problems with the experimental settings we introduced a positive control for hypoxia, which in 
our case was a natural Hsp70-promoter of Danio rerio fused to luciferase as a marker gene.  
 
FIGURE 5-9 20 h OF HYPOXIA TREATMENT 
WITH TRANSIENTLY TRANSFECTED HELA 
CELLS. The HeLa cells were transiently 
transfected with a natural heat shock promoter-
luciferase construct or the artificial heat shock 
promoter construct and induced by hypoxia 
treatment. Luciferase expression was 
measured at different time points after hypoxia. 
One day in advance, 1,5x10
5
 cells were 
seeded, transfected with 50 ng natural 
zebrafish Hsp70 promoter construct 
(zfHsp70luc) or the artificial heat shock 
promoter construct (HSE prom. luc) and 1 day 
later cells were incubated for 20 h under 
hypoxic conditions (10 %CO2, 90 % N2) at 
37°C. Cells were lysed directly, 6 h or 24 h 
after hypoxia treatment and a luciferase 
reporter gene assay was performed. As 
positive controls, cells were incubated for 1 h at 
43°C and lysed 6 h later and cells incubated for 
20 h under hypoxic conditions were incubated 
for 1 h at 43°C and lysed after 6 h. The 
luciferase expression levels were normalised to 
cells incubated at 37°C (negative control). This 
figure shows one representative experiment. 
0.1 
1.0 
10.0 
100.0 
1000.0 
37°C   0 h   6 h   16 h    43°C    hypoxia + 
43°C 
x
-f
o
ld
 l
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 
time after hypoxia treatment for 20 hrs 
0.001 
0.010 
0.100 
1.000 
10.000 
100.000 
37°C 0 hrs 6 hrs 24 hrs hypoxia + 
43°C 
43°C 
x
-f
o
ld
 l
u
c
if
e
ra
s
e
 e
x
p
re
s
s
io
n
 
time after 20 hrs hypoxia 
zfHsp70 luc 
HSE prom. luc 
72 
When compared to the literature, the highest expression of reporter protein in HeLa cells was 
observed 6-10 h after 20 h hypoxia treatment so the late induction in this experiment might 
include other stress factors. Like shown for the HSE promoter cell line, also in HeLa cells the 
artificial heat shock promoter did not respond to hypoxia at all time points (Figure 5-9, yellow 
bars) verifying the previous observations.  
Although the natural heat shock promoter of zebrafish was induced to some extent after 
hypoxia treatment, the induction levels were relatively low, which might be due to the 
transient transfection, but might also result from problems with the experimental settings of 
the hypoxic chamber. To exclude the possibility, that the artificial promoter could be induced 
to some extent by hypoxia not detectable with the transient transfection and to exclude 
problems with the experimental settings of the hypoxia an additional test of hypoxia induced 
activation was performed. In the literature, cobalt chloride was shown to mimic hypoxic 
conditions (An et al. 1998). Hence, the next step was to incubate the stable cell line 
harbouring the artificial HSE promoter with different concentrations of cobalt chloride. Within 
this experiment, the induction of the stably integrated artificial promoter could be directly 
compared to the expression of an endogenous heat shock protein (Hsp72) without the 
fluctuations and lower expression rate resulting from transient expression. 
A
 
B
 
FIGURE 5-10 HYPOXIA MIMICKED BY COBALT 
CHLORIDE. The stable cell line C5 was incubated with 
different concentrations of cobalt chloride in medium for 
1 hr at 37°C. Afterwards the medium was removed and 
the cells were incubated at 37°C with fresh medium. A) 
Luciferase assay. 0.3x10
5
 C5 cell per well of a 24-well 
plate were seeded 3 days before incubation with 
different concentrations of CoCl for 1 hr. Afterwards the 
cells were incubated for 6 hrs at 37°C. The expression 
of luciferase was determined using a luciferase assay. 
Luciferase activity was normalised to the expression 
levels at 37°C. B) 2x10
5
 C5 cells were seeded in 6 well 
plates, incubated 3 days at 37°C, treated for 1 hr with 
different concentrations of CoCl (1 mM, 10 mM, 30 
mM), medium was changed and after 2 hrs at 37°C total 
RNA was isolated, transcribed into cDNA and qPCR 
was performed for luciferase, Hsp72 and Hsp70RY. All 
RNA levels were normalised to the internal reference 
GAPDH and to the RNA levels at 37°C. The 
measurements were performed in triplicates and for all 
experiments a summary of three separate experiments 
is shown. Error bars: +/- SEM n=3. 
Mimicking hypoxic condition by the incubation with cobalt chloride showed weak induction of 
the artificial promoter up to 3 fold at 25 mM CoCl2 (Figure 5-10 A), which is negligible in 
comparison to the more than thousand fold induction in response to heat treatment (Figure 
5-6). Incubation of the stable cell line at higher concentrations of CoCl2 resulted in a 
decrease of luciferase activity below basal levels which is due to increased cell death (50 – 
100 mM, Figure 5-10 A). In contrast to luciferase driven by the artificial promoter (Figure 5-10 
B, red bars) and the Hsp70RY (Figure 5-10 B, green bars), the endogenous Hsp72 was 
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shown to be up-regulated in response to cobalt induction in a concentration dependent 
manner at least two fold (Figure 5-10 B, blue bars).  
These experiments showed that the artificial promoter cannot be properly induced by either 
hypoxia (Figure 5-7-Figure 5-9) or by mimicking hypoxic conditions with cobalt chloride 
(Figure 5-10), whereas the endogenous Hsp72 promoter is activated Figure 5-10 B) as well 
as a zebrafish Hsp70 promoter driven luciferase expression construct (Figure 5-9, red bars). 
In some of the experiments, a slight activation of the artificial promoter could be observed but 
rather seemed to be a result of fluctuations of the basal levels than a real induction of the 
promoter. 
 
5.3.3. INDUCTION WITH HEAVY METALS 
Beside this natural stress conditions, a variety of chemical substances are known to induce 
the heat shock response. Most prominent are the heavy metals which mainly activate the 
promoter via HSF1 but also pharmacological inducers modulating the pathway are known. 
To test the ability of our artificial promoter to be activated after heavy metal induction two well 
established heavy metal inducers, cadmium and zinc were analysed. Promoter activation 
was determined by measurement of luciferase activity (Figure 5-11 A-B) but also of mRNA 
levels (Figure 5-11 E-F) and compared to the activation on the natural highly inducible Hsp72 
(HSPA1A) promoter. As a control for a non-inducible heat shock protein, Hsp70RY was used 
and all mRNA levels were normalised to the internal reference GAPDH. Both assays analyse 
the promoter activity but not the initiating pathway. As the key event of the heat shock 
response is the denaturation of proteins, it was also analysed if the heavy metals are able to 
generate protein denaturation. Therefore, two different luciferases were constitutively 
expressed in cells and incubated with the heavy metals (Figure 5-11 C-D). Firefly luciferase 
was previously shown to be sensitive for denaturation whereas Gaussia luciferase is highly 
stable (Figure 5-6 B). This feature is used in the degradation assay to determine on the one 
hand the denaturation capacity of the heavy metals by firefly luciferase and Gaussia 
luciferase was used as an internal reference for expression and cell number. The induction of 
the stable cell line C5 with heavy metals for 1 hr showed a concentration dependent 
expression of luciferase from 3 fold at 100 µM CdSO4 up to 200 fold luciferase activity at 
1600 µM CdSO4. At 3200 µM the luciferase activity dropped down to levels below the basal 
activation, which is most probably due to the loss of cells and cell death at this high 
concentration (Figure 5-11 A). The high inducibility of the artificial promoter could also be 
verified by analysing mRNA expression levels after Cd2+ induction. Within this assay, a peak 
of 15 fold induction of luciferase mRNA could be assayed at 1600 µM CdSO4 (Figure 5-11 E 
red). When compared to the expression of the highly inducible endogenous Hsp72, Cd2+ was 
shown to increase mRNA levels up to 16 fold at 400 µM CdSO4, which is a shift to lower 
concentrations compared to the artificial luciferase. At higher concentrations the mRNA 
levels started to decrease again (Figure 5-11 E, blue). The expression of Hsp70RY was not 
influenced by the incubation with cadmium (Figure 5-11 E, green). In case of protein 
denaturation the incubation of cells with cadmium resulted in a 25 % decreased firefly 
luciferase activity at high concentrations of CdSO4 (1600 µM) but still high expression of 
Gaussia luciferase (2 fold at 1600 µM compared to 2.3 fold at 100 µM) suggesting a protein 
denaturation effect of cadmium on the firefly luciferase without significant changes in 
Gaussia luciferase activity. 
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FIGURE 5-11 INDUCTION OF THE STABLE CELL LINE WITH HEAVY METALS. The stable cell line C5 was incubated with 
different concentrations of cadmium sulphate (A, C, E) or zinc chloride (B, D, F) in medium for 1 hr at 37°C. Afterwards medium 
was removed and cells were incubated at 37°C with fresh medium. A+B).Luciferase assay. 0.3x10
5
 C5 cells per well of a 24-
well plate were seeded 3 days before incubation with different concentrations of CdSO4 or ZnCl2 for 1 hr. Afterwards the cells 
were incubated for 6 hrs at 37°C. The expression of luciferase was determined using a luciferase assay. Luciferase activity was 
normalised to the expression levels at 37°C. B+C) Degradation assay: 0.2x10
5
 HeLa cells per well of a 24-well plate were 
incubated for 1 day at 37°C, transiently transfected with plasmids encoding constitutively expressed firefly luciferase and 
Gaussia luciferase. After 2 days cells were incubated for 1 hr with different concentrations of CdSO4 (100, 400, 1600 µM) or 
ZnCl2 (200, 400, 1600 µM) and the activity of firefly as well as Gaussia luciferase were determined directly afterwards. E+F) 
2x10
5
 C5 cells were seeded in 6 well plates, incubated 3 days at 37°C, treated for 1 hr with different concentrations of CdSO4 
(10, 40, 100, 400, 1600 and 3200 µM) or ZnCl2 (40, 200, 400, 1600 and 3200 µM), medium was changed and after 2 hrs at 
37°C total RNA was isolated, transcribed into cDNA and qPCR was performed for luciferase, Hsp72 and Hsp70RY. All RNA 
levels were normalised to the internal reference GAPDH and to the RNA levels at 37°C. The experiments A-D were performed 
in triplicates and a summary of three separate experiments is shown. Error bars: +/- SEM n=3. 
For the induction of the stable cell line C5 with zinc, no activation of the artificial promoter 
could be observed neither on protein levels (Figure 5-11 B) nor at mRNA levels (Figure 5-11 
F, red). In contrast, the mRNA levels of the endogenous Hsp72 increased up to 9 fold at 
1600 µM ZnCl2 in a concentration dependent manner (Figure 5-11 E, blue). At a higher 
concentration of 3200 µM the Hsp72 mRNA levels started to decrease again like shown for 
the induction with CdSO4. The levels of Hsp70RY were not affected by zinc incubation 
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(Figure 5-11 F, green), similar to Cd2+. Analysing the protein denaturating capacity of zinc, a 
30 % reduction of firefly luciferase activity was observed without changes in Gaussia 
luciferase activity (Figure 5-11 D). Therefore, zinc seems to act on protein stability at high 
concentrations of 1600 µM without activation of the artificial HSE promoter.  
To conclude, the artificial HSE promoter was shown to be robustly activated by incubation 
with cadmium but not zinc although both heavy metals were able to induce the expression of 
the endogenous Hsp72 (Figure 5-11 E-F, blue).  
 
5.3.4. INDUCTION WITH PHARMACEUTICAL COMPONENTS 
In the last decades, heat shock proteins and the heat shock response in general became a 
promising research area to treat several diseases like neurodegenerative diseases but also 
cancer (see also 3.5.4.). Therefore, a lot of effort was put into the development and analysis 
of substances, which are able to modulate the heat shock response or the expression of heat 
shock proteins. The artificial promoter was designed for the use in cell therapy applications. 
Hence, the interference of some of this stress response modulating components with our 
artificial promoter was analysed. For this propose the activation of the promoter was tested 
on protein levels, mRNA levels and compared to the endogenous activation of Hsp72. To 
analyse also the indirect activation of the promoter via protein denaturation, a degradation 
assay was performed. In total three heat shock promoter inducing components, the Hsp90 
inhibiting antibiotic geldanamycin, the anti-inflammatory drug carbenoxolone and the 
protease inhibitor tosyl phenylalanyl chloromethyl ketone (TPCK) and one HSF inhibiting 
substance, the flavonoid quercetin, were tested. Testing the stable cell line harbouring the 
artificial HSE promoter for the induction with different pharmacological inducers showed only 
partial initiation of protein expression (Figure 5-12 A-D). In case of TPCK a concentration 
dependent activation of luciferase expression could be observed with a maximum of 50 fold 
at 80 µM. At higher concentrations the luciferase activity dropped down to levels below basal 
activity suggesting increased cell death (Figure 5-12 B). Nevertheless, the activation is not 
linked to protein denaturation, as TPCK showed no effect in the denaturation assay, but 
seemed to increase cell death at higher concentration of TPCK (Figure 5-12 F). In contrast 
carbenoxolone only showed induction at the highest concentration of 1500 µM (Figure 5-12 
C) which is linked to the high degradation capacity of the substance (Figure 5-12 G). The 
activator geldanamycin (Figure 5-12 A) as well as the inhibitor quercetin (Figure 5-12 D) 
were not able to induce the expression of luciferase and did not show any effects on protein 
denaturation (Figure 5-12 E and H). At mRNA levels, all three inducers showed increased 
levels of Hsp72 mRNA. Geldanamycin showed a robust Hsp72 expression of ~80 fold at 
9 µM (Figure 5-12 I, blue) but like the experiments at protein levels no increase in luciferase 
mRNA (Figure 5-12 I, red). For the induction with TPCK the mRNA levels of the endogenous 
Hsp72 increased up to 60 fold at 75 µM (Figure 5-12 J, blue) but in contrast to the protein 
activity assay (Figure 5-12 B) no increase of luciferase mRNA levels could be observed 
(Figure 5-12 J, red). Incubation of the C5 cells with carbenoxolone resulted in an increase of 
both, Hsp72 (up to 50 fold, Figure 5-12 K, blue) and luciferase (~ 9 fold) mRNA levels (Figure 
5-12 K, red) corresponding well to the strong protein denaturation (Figure 5-12 G). 
Interestingly, also the HSF inhibitor quercetin was able to induce the endogenous Hsp72 
gene to some extent (up to 4.5 fold, Figure 5-12 L, blue), but no increase in luciferase mRNA 
levels were observed (Figure 5-12 L, red). 
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FIGURE 5-12 INDUCTION WITH DIFFERENT PHARMACOLOGICAL HEAT SHOCK MODULATORS. The stable cell line C5 was incubated with different 
concentrations of geldanamycin (A, E, I), TPCK (B, F, J), carbenoxolone (C, G, K) or quercetin (D, H, L) in medium for 1 hr at 37°C. Afterwards medium was 
removed and the cells were incubated at 37°C with fresh medium. A-D) Luciferase assay. 0.3x10
5
 C5 cells per well of a 24-well plate were seeded 3 days 
before incubation with different concentrations of the different pharmacological components A) geldanamycin (0.5, 1, 3, 5, 9, 10 and 50 µM), B) TPCK ( 5, 
10, 25, 50, 80 and 100 µM), C) carbenoxolone ( 50, 100, 150, 300, 500, 900, 1000 and 1500 µM) or D) quercetin (1, 3, 9, 25, 30, 50, 90, 100, 200 and 270 
µM) for 1 hr. Afterwards cells were incubated for 6 hrs at 37°C. The expression of luciferase was determined using a luciferase assay. Luciferase activity 
was normalised to the expression levels at 37°C. E-H) Degradation assay: 0.2x10
5
 HeLa cells per well of a 24-well plate were incubated for 1 day at 37°C, 
transiently transfected with plasmids encoding constitutive expressed firefly luciferase and Gaussia luciferase. After 2 days cells were incubated for 1 hr with 
different concentrations of E) geldanamycin (5, 10 and 20 µM), F) TPCK (10, 25, 50 and 75 µM), G) carbenoxolone (1000, 1500, 2000 and 2500 µM) or H) 
quercetin (30, 90 and 270 µM) and the activity of firefly as well as Gaussia luciferase were determined directly afterwards. I-L) 2x10
5
 C5 cells were seed in 6 
well plates, incubated 3 days at 37°C, treated for 1 hr with different concentrations of I) geldanamycin (1, 3 and 9 µM), J) TPCK (10, 25 and 50 µM), K) 
carbenoxolone (300, 900 and 1500 µM) or L) quercetin (30, 90 and 270 µM), medium was changed and after 2 hrs at 37°C total RNA was isolated, 
transcribed into cDNA and qPCR was performed for luciferase, Hsp72 and Hsp70RY. All RNA levels were normalised to the internal reference GAPDH and 
to the RNA levels at 37°C. All measurements were performed in triplicates and for all graphs a summary of three separate experiments is shown. Error bars: 
+/- SEM n=3. 
For all tested components, the NEF Hsp70RY mRNA levels were constant, independent of 
concentration or substance type (Figure 5-12 I-L, green). In conclusion, only one tested 
pharmacological inducer, the serine proteinase inhibitor TPCK, was able to induce the 
artificial promoter, at least at protein levels, whereas geldanamycin and carbenoxolone could 
not induce luciferase expression except at highly denaturating concentrations of 
carbenoxolone. As shown in the literature, the tested components could induce the 
endogenous Hsp72 gene and had no effect of the constitutively expressed Hsp70RY. 
 
The artificial HSE promoter was designed for applications in regulated gene expression in 
cell therapy. Therefore, it was important to analyse, if additional triggers can activate the 
promoter beside heat. In this section, it could be shown, that the artificial HSE promoter does 
not respond to naturally occurring additional stress triggers such as hypoxia as well as two 
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important pharmacological components, the anti-cancer drug geldanamycin and the anti-
inflammatory drug carbenoxolone. TPCK, a serine protease inhibitor was the only component 
tested that was able to induce luciferase expression. These results verify the application of 
the artificial HSE promoter in cell therapy as it is strictly regulated by heat, but hardly any 
other stress factors or treatments. In our experiments only TPCK could induce the promoter. 
 
5.4. CHARACTERISATION OF PROMOTER KINETICS 
Regulated gene expression systems have been previously used in medical approaches (see 
also 3.2.). Although these inducible systems showed high expression after activation, at least 
for the two component systems the expression kinetics is very static and a short time 
regulation is not possible (see 3.2.1.). For other one component systems the induction 
worked faster but the resulting amounts of product most of the time are very low (see 3.2.2.). 
The artificial promoter was shown to be highly inducible producing high amounts of protein 
without the problem of high basal activity (5.2.) known for other inducible systems. In 
addition, the promoter was shown to be strictly heat dependent without activation by most 
other stress conditions tested. The next step was to analyse the kinetics of the artificial HSE 
promoter after induction to prove the postulated use as a tightly regulated expression system 
in gene and cell therapy approaches.  
 
5.4.1. PROTEIN KINETICS 
The first step was to determine the kinetics of protein expression after heat treatment. 
Hence, the stable cell line C5 was incubated for 1 hr at 43°C and luciferase activity was 
determined at different time points afterwards. To ensure, that the expression kinetic is due 
to the activation of the artificial HSE promoter and not based on specific integration events in 
the stable cell line C5 a second HEK 292 based cell line harbouring the artificial HSE 
promoter was analysed the same way. 
 
FIGURE 5-13 COMPARISON OF 
EXPRESSION KINETICS IN DIFFERENT 
SINGLE CELL CLONES. Two different 
HEK 293 based stable cell lines (C5 and 
D4) harbouring the artificial HSE promoter 
driving the expression of luciferase (pSGH2 
luc) were seeded in 6 well plates 
(2x10
5
cells/well) and after 3 days at 37°C 
incubated at 43°C for 1 h. Cells were lysed 
directly, 1, 2, 4, 6, 8, 10 and 24 hrs after 
heat treatment and a luciferase assay was 
performed. Luciferase activity was 
compared to cells incubated at 37°c. This 
figure shows one representative 
experiment. 
Treating the two different stable cell lines for 1 hr at 43°C resulted in increasing luciferase 
activity up to 4-6 hrs after heat treatment (~3000 fold) and a decrease down to almost basal 
levels (~20-50 fold) 24 hrs later (Figure 5-13). Both cell lines showed the same kinetics 
although in general the stable cell line C5 (Figure 5-13, yellow bars) showed higher 
luciferase expression than stable cell line D4 (Figure 5-13, blue bars). This experiment 
therefore verifies that the observed kinetics of protein expression is not an artefact of the 
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stable cell line C5 but represents the kinetics of the HSE promoter as also a second 
independent cell clone showed the same expression kinetics.  
 
5.4.2. MRNA KINETICS 
The artificial heat shock promoter consists of a core structure of 8 idealised heat shock 
elements flanked by two minimal CMV promoters. If the promoter is activated, two reporter 
genes, GFP and luciferase are expressed by bidirectional promoter activation. To assay 
promoter activation kinetics in detail a series of different heat shock experiments was 
performed by activating the promoter through different incubation times at 43°C and assaying 
the induction at different time points afterwards. So far the measurement of luciferase protein 
levels was used to get a first idea about the promoter kinetics. However, to get more detailed 
data independent of the protein stability the respective mRNA was quantified and compared 
to the endogenous situation by detecting the mRNA levels of the major inducible heat shock 
protein Hsp72. In addition, GFP mRNA levels were analysed to determine the bidirectional 
expression behaviour of the artificial HSE promoter. 
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FIGURE 5-14 PROTEIN AND MRNA EXPRESSION KINETICS AFTER HEAT TREATMENT. This figure was recently 
published in (Ortner et al. 2012) as Fig.3 and adopted here (see also appendix). The stable cell line C5 was seeded in 6 well 
plates (2x10
5
cell/well), after 3 days at 37°C cells were incubated for 30 min to 2 hrs at 43°C and lysed 0.5, 1, 2, 4, 6, 8, 10, 12, 
24 or 48 hrs afterwards. A) Luciferase assay after different durations of heat treatment for 30 min (light yellow), 1 hr (dark 
yellow) or 2 hrs (orange). Luciferase activity was determined at 0.5 – 48 hrs afterwards. B-D) Stable cell line C5 was incubated 
for 30 min (light), 1 hrs (normal) or 2 hrs (dark) at 43°C and total RNA was isolated 0.5 – 48 hrs afterwards, transcribed into 
cDNA and qPCR was performed for luciferase (B), Hsp72 (C) and Hsp70RY (D). All RNA levels were normalised to the 
internal reference GAPDH and to the RNA levels at 37°C. The experiments A-D were performed in triplicates and for all 
graphs a summary of three separate experiments is shown. Error bars: +/- SEM n=3 
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The stable cell line C5 was incubated for 30 min up to 2 hrs at 43°C and either luciferase 
protein expression (Figure 5-14 A) or the corresponding mRNA levels (Figure 5-14 B) were 
analysed up to 48 hrs afterwards. Similar to the previous experiment, the luciferase protein 
showed peak activity of ~6000 fold at 6 hrs after 1hr incubation at 43°C (Figure 5-14 A, 
yellow bars) and a reduction to basal levels 24-48 hrs afterwards, whereas the reduction of 
heat treatment to 30 min resulted in a shift in peak activity to 4 hrs and ~ 2000 fold 
expression levels (Figure 5-14 A, light yellow bars). Extension of heat treatment led again to 
a shifted and also wider peak of protein activity but at later time points (6-10 hrs, ~5000 fold) 
(Figure 5-14 A, orange bars). On mRNA levels, the same kinetics was observed with peaks 
at 2 hrs for 30 min (Figure 5-14 B, orange bars), 4 hrs for 1 hr incubation (Figure 5-14 B, red 
bars) and 4 - 6 hrs peak levels when cells were incubated for 2 hrs at 43°C (Figure 5-14 B, 
dark red bars). In general, the mRNA levels showed the similar kinetics but the maxima were 
reached 2 hrs earlier compared to the protein levels. For the expression of the endogenous 
Hsp72, the kinetics was again similar to that of luciferase but the maxima of mRNA levels 
were reached at 2 hrs for 30 min (Figure 5-14 C, light blue bars) and 1 hr heat treatment 
(Figure 5-14 C, blue bars) and at 4hrs for the 2 hrs incubation at 43°C (Figure 5-14 B, dark 
blue bars). The levels of Hsp72 started to increase again after 12 - 24 hrs, which might be 
due to prolonged incubation of the cells without refreshing medium. This resulted in a kind of 
nutrition depletion which is also known to induce the natural heat shock promoters.  
Analysing the expression of GFP confirmed the bidirectional design of the promoter, as GFP 
mRNA levels showed the same kinetics, but a slower decrease independent of heat 
treatment duration (Figure 5-14 D). The maximum levels of mRNA were reached at 2 hrs 
after heat treatment for the 30 min incubation (Figure 5-14 D, light green bars), at 4 hrs for 
the 1 hr incubation (Figure 5-14 D, green bars) or at 4 - 6 hrs after 2 hrs incubation at 43°C 
(Figure 5-14 D, dark green bars). In principle, the mRNA levels of GFP were around 10 fold 
higher than the corresponding luciferase mRNA levels which again were around 10 fold 
higher than the endogenous mRNA levels. For all tested mRNAs, as for the protein a shift of 
maximum expression was observed when the duration of heat treatment was extended, but 
in general the expression was high around 2 - 6 hrs after heat treatment and dropped down 
to basal levels at 24 - 48 hrs. In addition, the bidirectional expression potential of the 
promoter was verified and similar kinetics of the natural and artificial promoter were 
observed.  
The previous experiment showed that the artificial promoter is highly inducible with distinct 
kinetics. Different durations of heat treatment resulted in a time variation of the maximum 
expression levels. For a detailed analysis of this shift in peak levels to later time points, the 
stable cell line was induced for 30 min to 6 hrs at 43°C and mRNA levels of luciferase and 
Hsp72 were analysed. 
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FIGURE 5-15 PROMOTOR mRNA 
KINETICS FOR DIFFERENT 
INDUCTION TIMES. The stable cell 
line C5 was seeded in 6 well plates 
(2x10
5
cells/well) and kept at 37°C for 3 
days. Afterwards the cells were 
incubated for 30 min to 6 hrs at 43°C 
and then again at 37°C, and total RNA 
was isolated 0.5 – 48 hrs after start 
(time of total incubation: heat 
treatment + recovery at 37°C), 
transcribed into cDNA and qPCR was 
performed for luciferase (A) or Hsp72 
(B) All mRNA levels were normalised 
to the internal reference GAPDH and 
to the mRNA levels at 37°C. The 
measurements were performed in 
triplicates and for all graphs a 
summary of three independent 
experiments is shown. Error bars: +/- 
SEM n=3 
B 
 
Like in the previous experiment, incubation for 30 min at 43°C resulted in peak mRNA levels 
at 2 hrs for both the activation of the artificial HSE promoter (Figure 5-15 A, light yellow bars) 
and the endogenous promoter (Figure 5-15 B, light blue bars). Extending heat shock duration 
again resulted in peak luciferase mRNA levels at later time points (2 hrs for 1 hr heat 
treatment, 4 hrs for 2 hrs heat treatment and 6 hrs for 4 hr incubation at 43°C) to maximum 
levels at 8 hrs for 6 hr incubation at 43°C (Figure 5-15 A, dark red bars). The levels of 
endogenous Hsp72 again had their peak levels 2 hrs earlier than luciferase, but they 
decreased to basal levels after 8 hrs independent on the heat shock duration. As observed 
before, the levels increased again 24 - 48 hrs later (Figure 5-15 B). 
 
To conclude, the artificial HSE promoter shows the same expression kinetics but higher total 
levels as the natural Hsp72 promoter, except the late induction observed for the natural 
Hsp72 after 24 - 48 hrs. In addition, it could be shown, that the artificial promoter reaches its 
maximum activity 2-6 hrs after heat treatment and returns to basal levels after 24 hrs, which 
is important for a tight regulation compared to several days of promoter activity, when for 
example the tetracycline based induction system is used. Another important observation was 
the shift in maximum expression levels when prolonged heat shock durations were 
performed. This heat shock duration dependent expression adds an additional level of 
regulation as the amount of expressed protein can be regulated by the duration of heat 
treatment. 
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5.5. SURVIVAL 
Exposing cells to stress factors like high temperatures, results in the activation of an 
emergency program to survive. The activation of the heat shock response therefore is a 
defence against stress induced cell death. Therefore, the application of heat induced gene 
expression always bears the risk of increased cell death. 
 
5.5.1. SURVIVAL AFTER HEAT TREATMENT AT DIFFERENT TEMPERATURES 
In the beginning of the project, the stable cell line C5 was tested for its expression capacity at 
different heat shock temperatures. The result showed highest induction levels at 44°C and 
slightly lower induction at 43°C. Nevertheless 43°C was chosen as the heat shock standard 
temperature to avoid to high stress. Now the survival of the cells after treatment at different 
temperatures was analysed to substantiate the selected heat shock conditions. 
 
FIGURE 5-16 SURIVAL AFTER DIFFERENT HEAT 
SHOCK TEMPERATURES. This figure was recently 
published in (Ortner et al. 2012) as Fig.2b and 
adopted here (see also appendix). 2x10
5
 C5 cell per 
well of a 6-well plate were incubated at 41 - 44°C for 
1 hr and recovered for 24 hrs at 37°C. The viability of 
the cells was determined by Trypan blue assay. The 
experiment was performed in sextuplicates. Error 
bars: +/- SEM n=6. 
Analysing the survival of the cells after heat shock at different temperatures showed no 
decreased viability when cells were incubated at 41°C or 42°C, but a decrease of almost 3 % 
when incubated at 43°C. At the highest temperature tested, the viability dropped down to ~90 
% which is still high (Figure 5-16). Nevertheless, if each heat treatment would result in ~10 % 
death rate, this would lead to a significantly reduced amount of cells over the time of 
application. Therefore, the selected condition of 43°C are more suitable for cell therapy 
application as the viability is still comparable to untreated cells combined with a more than 
thousand fold induction of protein expression. 
 
5.5.2. REPEATED HEAT TREATMENT 
A critical point of the whole project is the survival of cells upon repeated heat shock as for 
later applications in cell therapy the cells in the capsules would have to tolerate multiple heat 
shock treatments over several weeks. Therefore it is necessary to assay the survival of the 
cells first in a cell culture system. In order to achieve a time window of 2 weeks (10 heat 
shock treatments) for the experiments, the cells were incubated at reduced FCS 
concentrations (0.5 % after 4 days at 10 % FCS standard condition) to reduce proliferation to 
a minimum level. In parallel to the viability also luciferase expression was analysed to 
demonstrate the inducibility of the artificial HSE promoter at repeated heat shock treatments. 
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FIGURE 5-17 SURVIVAL AND PROTEIN EXPRESSION AFTER REPEATED HEAT TREATMENT. The stable cell line C5 
was incubated every day (1HS/day) or once (1xHS) at 43°C for 1h or incubated at 37°C with reduced concentration of FCS 
(0.5 %). After one and two weeks the cells were washed twice with PBS, trypsinised, cells were collected and resuspended in 
medium. One half of the cells were analysed for their viability (A) the other half was subjected to a luciferase activity assay 
(B). A) Viability of the cells incubated for one week (light green) or two weeks (dark green) was determined using the Trypan 
blue assay. B) The remaining cells were lysed and a luciferase reporter gene assay was performed. The luciferase activity 
was normalised to basal activity in cells incubated at 37°C for one (yellow) of two (orange) weeks. The experiment was 
performed in triplicates. SEM, n=3 
Compared to the viability of the cells at standard conditions (37°C, 10 % serum), the 
reduction of serum to 0.5 % and the prolonged incubation alone resulted in a decreased 
survival of ~90 % for 1 week at 37°C (Figure 5-17 A, light green bars) or ~87 % for a 2 weeks 
incubation at 37°C (Figure 5-17 A, dark green bars). This reduced viability is most probably 
due to the highly artificial incubation conditions at low serum. The incubation of these cells 
once at 43°C resulted in a decreased survival of 88 % after 1 week of culture and 82 % for 
the 2 weeks of culture. Interestingly, with the repeated heat treatment of cells the protein 
expression in response to heat treatment could still be strongly induced either by a single 
heat treatment or repeated heat shock (Figure 5-17 B). The induction levels of cells 
incubated for 1 week with reduced levels of serum reached ~ 50 fold (Figure 5-17 B, yellow 
bars) independent of the number of heat treatments, whereas the cells incubated for 2 weeks 
at reduced serum showed even higher induction rates of ~ 1000 fold for one heat treatment 
and 600 fold for repeated incubation at 43°C (Figure 5-17 B, orange bars). This increasing 
induction might be due to a general upregulation of the stress response pathway at these 
highly artificial conditions and a resulting amplification of heat shock pathway activation. 
Although the cultivation conditions within this experiment were highly artificial, it could be 
demonstrated that cells easily survive repeated heat treatment and that the artificial HSE 
promoter can still be induced repeatedly to high levels.  
 
5.6. THE MAGNETIC FIELD GENERATOR 
Beside the stable cell line harbouring the heat inducible expression system, the magnetic 
field generator for generation of magnetic nanoparticle induced heat had to be established. 
The magnetic field generator for production of the oscillating magnetic field was built by the 
Department of Applied Electronics and Information Technology, University of Applied 
Sciences, FH-Campus Wien. The construction includes a wave generator, power amplifier 
and a coil. Wave generator and power amplifier are commercially available pre-made units 
and the coil was constructed according to the required dimensions and field strength of the 
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magnetic field. In a first series of experiments the optimal frequency could be narrowed down 
between 40 and 80 kHz, as there was an optimum in temperature increase around 40 kHz. 
Nevertheless, only short time activation (up to 1 min) could be tested as the coil heated up 
fast. Another output of the first experiments was the switch from a sinus curve to a rectangle 
of the current input for the coil, as even better results could be obtained with this version (the 
rectangle input allows dramatically cheaper versions for the power amplifier). For the next 
version of the magnetic field generator the power was strongly increased, the generator and 
the amplifier were combined into one element and the coil was replaced by a new version. 
To avoid previous observed heating of the coil a water cooling system was introduced by 
using a brass tube instead of a normal wire to run cooling water directly through the coil. With 
the improvement of the water cooling system it was for the first time possible to activate the 
magnetic nanoparticles at higher power (up to 80 kHz and 20 A) and for durations up to 30 
min. To avoid strong temperature increase of the amplifier cooling block, the amplifier and 
the frequency generator were combined and an air cooling system was introduced. With 
these improvements we could minimise heating of the amplifier-frequence generator. All data 
shown below were obtained with this last version of the magnetic field generator in order to 
establish conditions for the activation of the encapsulated cells with magnetic nanoparticles. 
 
5.6.1. DETERMINATION OF CONDITIONS FOR HEAT ACTIVATION 
To activate encapsulated cells with magnetic nanoparticles in the magnetic field a 
temperature of at least 43°C in the capsules has to be reached. For this purpose, first a 
suspension of 1 % magnetic nanoparticles in standard cell culture medium was used to test 
different settings with varying frequencies or current to find conditions for induction of the 
artificial HSE promoter. A suspension of 1 % magnetic nanoparticles (SIGMA) in medium 
was sonicated for 1 min at 50 % power with a sonificator. 100 µl of the suspension were 
transferred to a 2 ml reaction tube and put into the middle of the coil. Activation was 
performed by using different settings of current and the following frequencies: 40 kHz (light 
blue), 50 kHz (green), 60 kHz (petrol), 70 kHz (blue) and 80 kHz (dark blue). Temperature 
was measured before starting the magnetic field generator and immediately after 5min 
(Figure 5-18 A) or 30 min (Figure 5-18 B) activation.  
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FIGURE 5-18 HEAT GENERATION OF 1 % NANOPARTICLES IN AN ALTERNATING MAGNETIC FIELD. A 1 % 
suspension of magnetic nanoparticles (Sigma) in cell culture medium without serum (DMEM) was sonicated at 50 % power 
and incubated for 5 min (A) or 30 min (B) in the alternating magnetic field. The magnetic field was established using different 
frequencies of 40 kHz (light blue), 50 kHz (green), 60 kHz (petrol), 70 kHz (blue) or 80 kHz (dark blue). In addition to the 
different frequencies also increasing current was used (15, 20, 23, 25, 26, 27 and 30 A) for the incubation of 5 min (A) or 15, 
20, 25, 26, 27 and 30A for the 30 min incubation (B). Temperature increase was determined by measuring the starting 
temperature and the temperature directly after the end of incubation time using a temperature sensor. 
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The incubation of the 1 % magnetic nanoparticles for 5 min showed a frequency dependent 
increase in temperature with highest heat generation (12°C) at 80 kHz and 23 A (Figure 5-18 
A, dark blue) but due to technical limitations of the system, neither the current could be 
increased nor the incubation time could be extended. Similar to the situation at 80 kHz also 
incubation at 70 kHz showed a temperature increase of ~10°C but again was limited in 
duration and applied current (Figure 5-18 A, blue). For the alternating magnetic field 
generated at 60 kHz, the current could be increased up to 30 A and this led to a robust heat 
generation of the magnetic nanoparticles up to 12.7°C at 60 kHz and 30 A (Figure 5-18 A, 
petrol). Induction using 50 kHz (Figure 5-18 A, green) or 40 kHz (Figure 5-18 A, light blue) 
resulted in lower heat generation of 10.6°C for 50 kHz and 6°C for 40 kHz. The induction for 
5 min at different frequencies and increasing current clearly showed that higher frequencies 
and high current up to 30 A resulted in best heat generation. As the incubation time of 5 min 
is clearly too short for the induction of the artificial HSE promoter, the incubation time was 
extended to 30 min. At this experimental design, best conditions for heat shock activation 
were shown to be at 60 kHz and 25-27 A (Figure 5-18 B, petrol). With these adjustments, a 
temperature increase of 12°C could be reached in the supernatant of the magnetic 
nanoparticle suspension and also the required duration of 30 min was possible. There were 
also other conditions with a high increase of temperature (50 kHz and 30 A, Figure 5-18 B, 
green), but with these settings the duration of activation was limited due to heating of the coil 
although a cooling system was used. Magnetic fields using frequencies above 60 kHz could 
not be tested at currents above 20 A as here the same technical limitation as for 50 kHz and 
30 A were seen. Testing of different current and frequence combinations for the generation 
on an alternating magnetic field showed highest temperature increase at 60 kHz and 27A in 
a 30 min incubation of 1 % magnetic nanoparticles. So these conditions were used as a 
standard for the induction of the artificial HSE promoter in all following experiments. 
 
5.7. INDUCTION OF CELLS AND NANOPARTICLES IN THE MAGNETIC FIELD 
The aim of the project was the induction of gene expression in encapsulated cells harbouring 
the artificial HSE promoter. In the previously described experiments, the magnetic field 
generator settings were determined to produce the necessary amount of heat. The next step 
now was to analyse, if these settings would generate appropriate heat to induce the 
expression of luciferase in the stable cell line. Therefore C5 cells were incubated in the 
magnetic field together with magnetic nanoparticles but without encapsulation. In the 
previous experiments, a concentration of 1 % magnetic nanoparticles was used and resulted 
in a temperature increase of 12.7°C. As the amount of magnetic nanoparticles is directly 
linked to their heat generation (see Ortner, Kaspar et al. 2012, Supplementary Figure S1, 
appendix) first different nanoparticle concentrations were tested for their ability to induce the 
artificial promoter when incubated together with the stable cell line in the magnetic field 
generator for 30 min at 60 kHz and 27A. In addition, different currents and induction times 
were tested to find optimal conditions for the activation of protein expression in encapsulated 
cells. 
85 
A 
 
FIGURE 5-19 ACTIVATION OF THE 
ARTIFICIAL HSE PROMOTER USING 
DIFFERENT SETTINGS. This figure was 
recently published in (Ortner et al. 2012) 
as Fig.4 and adopted here (see also 
appendix). A) 1x10
5
cells were incubated 
without or with 0.3 %, 0.5 %, 0.8 % or 1 % 
magnetic nanoparticles at 37°C (green 
bars), for 45 min at 43°C (red bars) or for 
30 min in the magnetic field generator at 
60 kHz and 27A (yellow bars). After 
treatment cells were incubated for 6 hrs at 
37°C and luciferase expression was 
determined in a luciferase assay. The 
luciferase expression levels of cells + 
0.5 % nanoparticles incubated at 43°C for 
45 min were set as 100 % and all other 
luciferase activities were normalised to 
these levels. The figure shows one 
representative experiment. B) 1x10
5
cells 
were incubated with 0.5 % magnetic 
nanoparticles for 45 min at 43°C (red bar) 
or for 30 min in the magnetic field 
generator at 60 kHz and 17-27A (yellow 
bars). After treatment cells were incubated 
for 6 hrs at 37°C and luciferase expression 
was determined in a luciferase assay. The 
luciferase activity of cells incubated for 45 
min at 43°C was set to 100 % (positive 
control) and all other luciferase levels were 
normalised to this levels. This figure 
shows a summary of five independent 
experiments. SEM n=5. C) 1x10
5
cells 
were incubated with 0.5 % magnetic 
nanoparticles at 37°C (green bars), for 45 
min at 43°C (red bars) or for 1.8 -60 min in 
the magnetic field generator at 60 kHz and 
23 A (yellow bars). After treatment cells 
were incubated for 6 hrs at 37°C and 
luciferase expression was determined in a 
luciferase assay. The luciferase activity of 
cells incubated for 45 min at 43°C was set 
to 100 % (positive control) and all other 
luciferase levels were normalised to this 
levels. This figure shows a summary of 
five independent experiments. SEM n=5. 
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When cells were incubated in the magnetic field generator at 60 kHz and 27 A without 
nanoparticles they showed no increase in luciferase expression (Figure 5-19 A, green bars) 
and also the inducibility of the heat shock promoter was verified with heat treatment at 43 °C 
for all tested nanoparticles (Figure 5-19 A, red bars). For heat treatment an incubation time of 
45 min at 43°C was used as temperature kinetics of the incubator showed that it takes ~15 
min to establish 43°C within the reaction tube. Nanoparticle concentrations of 0.3 – 1 % were 
used for induction of luciferase expression in the magnetic field at 60 kHz and 27 A. When 
cells were induced with different amounts of nanoparticles luciferase expression showed 
peak levels at 0.5 % nanoparticles and decreased with higher nanoparticle concentrations of 
0.8 % and 1 % but also with lower nanoparticle concentrations of 0.3 % (Figure 5-19 A, 
yellow bars). Higher amounts of nanoparticles seemed to generate temperatures above 43 - 
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44°C, which resulted in increasing cell death and therefore reduced luciferase expression. 
Lower amounts were not able to generate enough heat for induction of the promoter. As 0.5 
% magnetic nanoparticles showed best induction levels at 60 kHz and 27 A, these settings 
were used for the following experiment, inducing the stable cell line C5 together with 
magnetic nanoparticles in the alternating magnetic field. Additionally, cells were incubated in 
the magnetic field generator with increasing current to generate an alternating magnetic field 
with increasing strength. When cells were induced with 0.5 % magnetic nanoparticles at 60 
kHz and increasing current (17-27 A) expression levels of luciferase also increased (Figure 
5-19 B, yellow bars) up to levels similar to the positive control cells (45 min 43°C) (Figure 
5-19 B, red bar). As a third parameter, the incubation time was varied when cells together 
with 0.5 % magnetic nanoparticles were incubated in the magnetic field generator at 60 kHz 
and 23 A. The lower current was used to avoid extended heat production when the 
incubation time was increased up to 60 min. Nevertheless, the experiment showed an 
incubation time dependent increase in luciferase expression (Figure 5-19 C, yellow bars) up 
to levels of the heat treatment control (Figure 5-19 C, red bar). 
In summary, the experiments testing different parameters of alternating magnetic field 
induction resulted in a new possibility to regulate the expression of proteins either by varying 
the nanoparticle concentration, the magnetic field strength or the induction time. This 
regulation was shown to act over several orders of magnitude and is therefore an important 
tool for the accurate dosage of therapeutical substances in future medical approaches of the 
system.  
 
5.8. KINETICS AFTER MAGNETIC FIELD TREATMENT 
After determining the optimal conditions for the induction of the artificial HSE promoter of 0.5 
% magnetic nanoparticles induced in the alternating magnetic field at 60 kHz and 27 A the 
kinetics of protein expression was analysed. This kinetics will give important hints how the 
future therapeutical substance will be expressed in the encapsulated cells. Therefore, cells 
were induced together with 0.5 % magnetic nanoparticles (SIGMA) for 30 min in the 
alternating magnetic field at 60 kHz and 27 A, aliquoted afterwards to 1x105 cells in 1 ml 
medium and incubated for different durations at 37°C. Luciferase protein expression was 
determined at different time points after induction using a luciferase activity assay. As a 
positive control for the inducibility of the artificial promoter, the cells with or without magnetic 
nanoparticles were incubated for 45 min at 43°C and luciferase activity was determined 6 hrs 
later. To analyse, if there is any effect of the magnetic field treatment on the promoter not 
involving the particles, also cells without magnetic nanoparticles were induced at 60 kHz and 
27A in the alternating magnetic field. 
87 
 
FIGURE 5-20 PROTEIN EXPRESSION KINETICS 
AFTER INDUCTION IN THE ALTERNATING 
MAGNETIC FIELD. 1x10
6
 cells of the stable cell 
line C5 in 200 µl medium were incubated without 
(light yellow bars) or with 0.5 % magnetic 
nanoparticles (dotted yellow bars) for 30 min at 60 
kHz and 27A. Cells were resuspended with 800 µl 
medium and aliquoted to 100 µl. The aliquots 
containing 1x10
5
cell were incubated with 1 ml of 
medium for 0-24 hrs at 37°C and luciferase activity 
was determined directly after AMF treatment, 1, 2, 
4, 6, 8, 10, 12 or 24 hrs afterwards. Luciferase 
expression was normalised to expression levels of 
cells incubated at 37°C either without magnetic 
nanoparticles or with 0.5 % nanoparticles. As a 
positive control for promoter induction, cells were 
treated for 45 min at 43°C and luciferase 
expression was determined 6 hrs later. This figure 
shows a summary of 2 independent experiments. 
SEM n=2, AMF: alternating magnetic field. 
Analysing the expression kinetics of luciferase after treatment in the magnetic field showed 
slight background activation of the promoter of ~4 fold 4-12 hrs after induction, when just 
cells without magnetic nanoparticles were exposed to the alternating magnetic field (Figure 
5-20, light yellow bars). In contrast, heat treatment resulted in a more than 1000 fold 
induction. When cells were induced together with 0.5 % magnetic nanoparticles in the 
alternating magnetic field, the expression of luciferase increased in the first 8 hrs to 
maximum levels of 10000 fold and high activity was determined up to 24 hrs later (Figure 
5-20, yellow dotted bars). The increase up to a maximum of 8 hrs corresponds to the 
expression kinetics of cells incubated for 2 hrs at 43°C (Figure 5-15A) whereas the prolonged 
high activity was not shown for the 2 hrs induction at 43°C. Therefore it seems that induction 
in the magnetic field resulted in similar activation kinetics of protein expression but after 
reaching maximum levels, the high protein expression is somehow prolonged up to 24 hrs. 
To analyse, if the prolonged maximum activation of luciferase expression, is due to extended 
promoter activation or an effect of protein stability, the experiment was repeated and the 
corresponding mRNA levels of luciferase were analysed and compared to the expression of 
the natural Hsp72. Similar to protein levels, the mRNA kinetics is comparable to an induction 
of cells for 2 hrs at 43°C (Figure 5-15 B-C) for both, the artificial HSE promoter (Figure 5-21 
A, dark red dotted bars) as well as the natural Hsp72 promoter (Fig. 24 B, dark blue dotted 
bars). When mRNA levels were analysed 6-24 hrs after induction of the cells with magnetic 
nanoparticles in the alternating magnetic field, the previously observed plateau of high 
luciferase activity could not be confirmed at mRNA levels as here the levels start to decrease 
again after 4 hrs back to basal levels at 24 hrs (Figure 5-21 A, dark red dotted bars). The 
same kinetics was observed for Hsp72 mRNA levels (Figure 5-21 B, dark blue dotted bars) 
although for Hsp72 the kinetics showed slower decrease of mRNA levels down to basal 
values compared to a fast reduction and levels below that at 37°C for the 2 hrs incubation at 
43°C (Figure 5-15 C). The magnetic field treatment of cells without magnetic nanoparticles 
showed no increase of luciferase levels except at 8 hrs where an increase of 1.8 fold was 
observed (Figure 5-21 A, light red bars) and a slight increase of Hsp72 levels up to 4 fold 1-
12 hrs after magnetic field induction (Figure 5-21 B, light blue bars). The analysis of mRNA 
kinetics after alternating magnetic field induction at 60 kHz and 27 A resulted in only 
background activation of the artificial promoter but slight activation of the natural promoter 
when cells were incubated without magnetic nanoparticles. 
0.1 
1.0 
10.0 
100.0 
1000.0 
10000.0 
100000.0 
37°C  0 hr 1 hr 2 hrs 4 hrs 6hrs 8hrs 10 hrs 12 hrs  24 hrs  43°C 
x
-f
o
ld
 l
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 
time after AMF 
C5 C5 + NP 
88 
A 
  
FIGURE 5-21 mRNA KINETICS 
AFTER INDUCTION IN THE 
ALTERNATING MAGNETIC FIELD. 
1x10
6
 cells of the stable cell line C5 in 
200 µl medium were incubated without 
(light bars) or with 0.5 % magnetic 
nanoparticles (dotted dark bars) for 30 
min at 60 kHz and 27A. Cells were 
resuspended with 800 µl medium and 
aliquoted to 100 µl. The aliquots 
containing 1x10
5
cell were incubated 
with 1 ml of medium for 0-24 hrs at 
37°C and RNA was isolated directly 
after AMF treatment, 1, 2, 4, 6, 8, 10, 
12 or 24 hrs afterwards, transcribed 
into cDNA and A) luciferase specific or 
B) Hsp72 specific quantitative PCR 
was performed using GAPDH as an 
internal reference. All expression 
levels were normalised to GAPDH 
levels and to the expression levels at 
37°C. As a positive control for 
promoter induction, cells were treated 
for 45 min at 43°C and luciferase 
expression was determined 6 hrs later. 
This figure shows a summary of 2 
independent experiments. SEM n=2, 
AMF: alternating magnetic field. 
B 
  
In contrast to the prolonged high activity of luciferase protein after induction of the cells with 
magnetic nanoparticles in the alternating magnetic field, the mRNA levels of luciferase as 
well as Hsp72 showed a peak at 4 hrs after treatment and decreased then down to basal 
levels at 24 hrs afterwards. Therefore, the extended maximum protein activity is not the 
result of higher mRNA levels. One possible explanation would be that the protein is 
somehow stabilised after magnetic field treatment and as a consequence shows high 
expression up to 24 hrs after the incubation.  
 
5.9. ESTABLISHMENT OF LUCIFERASE MEASUREMENT IN CAPSULES 
The concept of a heat inducible gene expression system using encapsulated cells and 
activation through heat generation by magnetic nanoparticles exposed to an alternating 
magnetic field should be established within this work. First, a stable cell line harbouring the 
artificial HSE promoter was generated and characterised (5.2-5.5). Next, the stable cell line 
together with magnetic nanoparticles was exposed to an alternating magnetic field to 
optimise the induction conditions (5.6-5.8) for the following proof-of-principle experiments. 
Another major factor of the concept was the encapsulation of cells using sodium cellulose 
sulphate as a polymer and pDADMAC as a polylinker. All encapsulations as well as the 
establishment of con-encapsulation of cells with magnetic nanoparticles were performed by 
Cornelius Kaspar at the Department of Pathology, Institute of Virology, University of 
Veterinary Medicine, Vienna. The generated capsules had a size of approximately 700 µM 
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and contained initially 10 000 cells. The membrane of the capsules is semipermeable and 
allows diffusion of nutrients and O2 into the capsules, but prevents the interaction of the 
encapsulated cells with cells of the immune system. In addition, the membrane to some 
extent mechanically shields the cells. As the transport into the capsule as well as the export 
of substances is based on diffusion, a standard luciferase assay using the addition of the 
substrate D-luciferin and the co-factors ATP and Mg2+ as a starting point for the detection of 
luciferase driven light production by the conversion of the substrate, this slow diffusion of the 
co-factors into the capsule might not be suitable for the detection of luciferase activity of 
encapsulated cells. Hence, a new protocol to determine luciferase activity of encapsulated 
cells had to be established. First, the assay kinetics was determined in intact capsules. For 
the establishment a stable cell line constitutively expressing luciferase was used to reduce 
possible fluctuations of luciferase expression due to heat induction. The stable cell line A6 
like the stable cell line C5 harbours the artificial heat shock promoter, but accidently is not 
inducible by heat treatment and expresses luciferase in a constitutive manner. Sequencing of 
the promoter region of A6 cells showed that the promoter sequence is identical to the initially 
transfected construct so the constitutive expression behaviour of the cell line might be due to 
an integration of the promoter near a constitutive endogenous promoter. Nevertheless, this 
stable cell line emerged as a perfect tool to establish a luciferase assay in encapsulated 
cells. The first step was to analyse the effect of diffusion of D-luciferin and ATP into the 
capsule and the resulting delay in light production in the luciferase activity assay. Therefore, 
intact capsules were incubated in luciferase lysis buffer as in a standard luciferase assay and 
transferred to the luminometer. After starting the measurement, the substrate and the co-
factors were injected automatically to the capsules in lysis buffer and after 10 seconds the 
detector started to measure the relative light production per second. When plotted against 
the total measure time, the kinetics of light production could be observed (Figure 5-22 A). 30 
seconds after starting the measurement, the light production reached a plateau of maximum 
light production for more than 200 seconds. In the standard luciferase assay the detection 
time is limited to 10 seconds. Therefore, the extended production of light over long periods 
would result in false results as only the first 10 sec were used for the calculation of luciferase 
activity. In addition, the kinetics showed almost no difference in RLU/sec when 3 capsules 
were compared to 6 capsules (Figure 5-22 A). The measurement of 9 capsules in contrast 
showed higher RLU/sec. Nevertheless, the slow kinetics due to diffusion of the substrate into 
the capsules showed, that capsules have to be opened to determine luciferase activity 
properly. To compare, if luciferase activity of the released cells from the capsules would 
correspond to the levels of free cells, one capsule containing approximately 10000 cells was 
lysed according to the protocol in Ortner et al. 2012 and luciferase assay kinetics was 
compared to different amounts of cells of the stable cell line A6 without encapsulation. The 
experiment shown in Figure 5-22 B could proof that cells released from the capsule have the 
same assay kinetics as free cells and the RLU levels for all tested cells dropped down to 
almost basal levels 20 seconds after starting the measurement. In addition, the 
approximately 10000 encapsulated cells (Figure 5-22 B, blue) showed similar levels of RLU 
compared to their corresponding standard of 10000 cells (Figure 5-22 B, dark red). Reducing 
the amount of cells stepwise from 10000 cells down to 625 cells also showed that the 
detected RLU are directly proportional to the amount of luciferase producing cells. As the 
released cells from the capsules showed the same assay kinetics as the free cells, a 
standard luciferase assay could be performed for capsules were the membrane was either 
dissolved by special reagents (see Material and Methods of Ortner et al. 2012) or somehow 
disrupted to release the encapsulated cells. Lysis of the capsule membrane needs incubation 
of 1 hr. Therefore, a faster way to release the cells was established by disruption of the 
capsule membrane mechanically with a pistil. 
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FIGURE 5-22 LUCIFERASE KINETICS 
IN CAPSULES. Approximately 10000 
cells of a stable cell line expressing 
luciferase in a constitutive manner 
(stable cell line A6) per capsule were 
encapsulated by Cornelius Kaspar. A) 3 
capsules (light blue), 6 capsules (blue) 
or 9 capsules (dark blue) were washed 
with PBS and incubated for 15 min in 
luciferase lyse buffer. Afterwards, the 
capsules were transferred to the 
luminometer and relative luciferase 
activity was determined in a time course 
by measuring the relative light units 
(RLU) for 10-200 seconds after the 
addition of the substrate D-luciferin and 
the required co-factors ATP and Mg
2+
. 
Luciferase activity per second was 
plotted against detection time to show 
the kinetics of the luciferase 
measurement. B) One capsule of the 
stable cell line A6 was lysed (blue) (see 
Materials and Methods (Ortner et al. 
2012)) and luciferase measurement 
kinetics was compared to that of 10000 
cells(dark red), 5000 cells (brown), 2500 
cells (red), 1250 cells (orange) or 625 
cells (yellow) of the stable cell line A6. 
Relative luciferase activity was 
determined in a time course by 
measuring the relative light units (RLU) 
for 10-200 seconds after the addition of 
the substrate co-factors. Luciferase 
activity per second was plotted against 
detection time to show the kinetics of the 
luciferase measurement. C) 10 capsules 
or 1 capsule containing approximately 
10000 cells of the stable cell line A6 
were either lysed (see Material and 
Methods (Ortner, Kaspar et. al. 2012) for 
detailed information) (green bars) or 
mechanically disrupted in luciferase lysis 
buffer using a pistil (blue bars). Aliquots 
corresponding to the cell amount of 1 
capsule (1/10), 2 capsules (2/10), 4 
capsules (4/10) of 9 capsules (9/10) 
were compared to 1 disrupted capsule in 
a standard luciferase assay. As a control 
one intact capsule was measures (red 
bar). All figures show representative 
experiments. 
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Comparison of luciferase activity of A6 cells released by lysis (Figure 5-22 C, green bars) or 
after disruption of the membrane (Figure 5-22 C, blue bars) by a pistil showed no difference 
in luciferase activity using the standard luciferase assay except one sample, where an aliquot 
of 9 capsules (out of 10 capsules lysed or disrupted) showed lower luciferase activity when 
capsules were disrupted compared to capsule lysis. This decreased value might be due to 
experimental problems as all other aliquots showed the same levels of luciferase expression. 
When the luciferase activity of two capsules was compared to the activity of four capsules a 
2 fold increase was observed compared to a 3 fold increase when one capsule or 2 capsules 
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were used (Figure 5-22 C). Testing one intact capsule resulted in a 10 fold decreased 
luciferase activity using the standard luciferase assay (Figure 5-22 C, red bar). In summary, 
a new protocol of luciferase activity determination using the standard luciferase assay could 
be established. To detect the total activity of luciferase within the capsules the membrane 
has to be opened to release the cells. The release is achieved in the new established 
protocol by mechanical disruption of the capsule membrane with a pistil, which in turn is 
much faster than the established lysis of the capsule membrane. The new protocol for 
determination of luciferase of encapsulated cells was shown to be equally efficient as the 
lysis of capsules and the measurement was shown to be directly dependent on the amount 
of luciferase producing cells.  
 
5.10. PROOF-OF-PRINCIPLE 
The experiments so far resulted in suitable conditions for heat shock activation, where the 
necessary temperature increase could be reached within 30 min and robust protein 
expression could be observed and a protocol for luciferase activity measurement was 
established for the capsules. Therefore, first tests with the stable cell line C5 co-
encapsulated with magnetic nanoparticles could be performed. In contrast to the results of 
the stable cell line without encapsulation, in this experiment 1 % magnetic nanoparticles 
were used to ensure a proper heating even if the cells and particles are possibly more 
loosely arranged in the capsule and the temperature distribution within the capsule is not 
known. The experiments using encapsulated cells were performed together with Cornelius 
Kaspar. 
80 capsules of the stable cell line C5 encapsulated together with 1 % magnetic nanoparticles 
(SIGMA) (capsules ~50 % confluent) in 200 µl DMEM were transferred to a 2 ml reaction 
tube and put into the middle of the coil. The temperature of the supernatant was measured 
with a temperature sensor and the capsules were activated via the magnetic field generator 
at 60 kHz 25 A, 25.5 A, 26 A and 27 A for 30 min. Immediately after activation the 
temperature of the supernatant was measured again and then the capsules were transferred 
to a 6-well plate and cultivated for 24 h in a cell culture incubator at 37°C. After 24 h the 
capsules were assayed for GFP expression with the UV microscope to determine if an 
activation of the heat shock response could be obtained with the magnetic field generator. As 
it was observed that some but not all capsules showed GFP expression these GFP positive 
capsules were collected to analyse the expression of luciferase. The capsules which showed 
no GFP expression were also analysed for expression of luciferase to see if in these 
capsules a week heat shock response could be detected. As different settings for the 
induction of heat shock with the magnetic field generator were used, for each setting 20 
capsules of the batch of capsules which showed or did not show GFP expression were 
analysed with a luciferase reporter gene assay.  
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conditions  total caps GFP+ % GFP + 
60 kHz 27 A 143 86 60,1 % 
60 kHz 26 A 85 55 64,7 % 
60 kHz 25.5 A 103 46 44,7 % 
60 kHz 25 A 122 12 9,8 % 
FIGURE 5-23 PROOF-OF-PRINCIPLE: The stable cell line C5 was encapsulated by Cornelius Kaspar together with 1 % 
magnetic nanoparticles (SIGMA). Cells were grown in the capsules to 50 % confluence. 80 capsules per 200µl DMEM were 
treated in the magnetic field generator for 30 min at the following conditions: Frequency: 60 kHz, Current 25 A, 26 A, 25.5 A 
and 27 A. Capsules were afterwards cultivated again at 37°C for 24 h. GFP expression was assayed via UV microscopy and 
capsules showing GFP expression were separated. 20 capsules of the batch of the GFP expressing capsules and 20 
capsules of the batch of capsules showing no GFP expression were crushed in 50 µl Lysis buffer with a pestle and a 
luciferase reporter gene assay was performed. A) Results of the luciferase reporter gene assay. X-fold luciferase expression 
was calculated relative to the expression in capsules incubated at 37°C (negative control). B) Fluorescence microscopy of 
capsules treated with magnetic field in different conditions. magnification = 10x C) Table of number of capsules expressing 
GFP within the different conditions of activation via a magnetic field. 
With all four settings used for the magnetic field generator, expression of luciferase in 
response to heat shock activation could be observed, ranging from 500-fold for 25 A (Figure 
5-23 A, light green bars) up to 1500-fold for 26-27 A (Figure 5-23 A, petrol and blue bars) 
and also ~ 60 % of the capsules activated at 26-27 A showed GFP expression and even with 
25 A, 10 % of the capsules showed GFP expression (Figure 5-23 C). These results showed 
that induction of the heat shock response within the capsules could be performed with the 
magnetic field generator and that the resulting luciferase and GFP expression was 
proportional to the current input into the magnetic field generator. Interestingly also in the 
capsules which showed no GFP signal luciferase expression (Figure 5-23 B) up to 200-fold 
could be observed (Figure 5-23 A). This expression of luciferase in capsules without GFP 
could be the result of a basal activation of the heat shock promoter and therefore basal 
luciferase expression. Another explanation could be that the capsules were just slightly 
activated in the magnetic field, due to unknown reasons, and because of this slight activation 
the expression of GFP could not be detected using fluorescence microscopy. Nevertheless 
luciferase expression could be detected under these settings and this activation seems to be 
specific for the nanoparticles as the temperature of the surrounding medium of the capsules 
never exceeded 41°C which is not enough to induce the heat shock response. This 
experiment showed the first proof-of-principle for our concept of regulated gene expression in 
encapsulated cells by incubation in an alternating magnetic field. 
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6. DISCUSSION 
 
6.1. CONCEPT 
The concept of regulated gene expression in encapsulated cells provides a new approach for 
the treatment of many diseases. It combines different established strategies like 
heterologous cell therapy, heat induced gene expression, hyperthermia and encapsulation 
technology. In contrast to gene therapy, where genetic information is introduced directly into 
the host system, in cell therapy genetically engineered cells are introduced into the patient. 
This method avoids the problem of transfer and integration of the genetic material into host 
cells often resulting in non-successful production of therapeutic proteins (Hacein-Bey-Abina 
et al. 2003). In cell therapy the cells are pre-selected for correct integration and production of 
therapeutic substances. In addition, potential side effects caused by non-viral or viral delivery 
pathways (Raper et al. 2003) are eliminated due to the preselection. Nevertheless, cell 
therapy has to deal with certain problems like evoking an immune response, survival of the 
transplanted cells or delivery to the site of action (Nelson et al. 2002; Subramanian et al. 
2002; Tatake et al. 2007; Morgan et al. 2010b). To protect heterologous cells from the 
immune response, encapsulation can be applied. This technology is well established for 
certain cell therapies (Bachoud-Levi et al. 2000; Lindvall et al. 2008), as it shields the cells by 
surrounding them with a semipermeable membrane. This barrier allows the transport of 
nutrition and proteins into and out of the capsule, but excludes the interaction with the host 
immune system (Chang 1964; Hauser et al. 2004; Orive et al. 2010).  
A major advantage of encapsulation is the localisation of the heterologous cells in a capsule 
directly in, or next to the target tissue. In our approach this concentration of the cells in the 
capsule bears the additional advantage, that all cells can be induced by magnetic 
nanoparticle mediated heat generation in an equal manner. For hyperthermia treatment of 
tumours nanoparticles are directly injected into the tissue, which is then heated by 
application of an external magnetic field. Depending on their properties, like specific coating 
the distribution of the nanoparticles is a significant problem. This is not the case when they 
are encapsulated. In addition, this strategy allows the removal of the nanoparticles from the 
patient after the therapy. Furthermore, when magnetic nanoparticles are encapsulated 
together with cells, a lower amount of particles can be used as a sufficient concentration is 
reached within the small region of the capsules.  
The application of heat generation by magnetic nanoparticles together with a heat inducible 
expression system can ideally be combined with encapsulation technology. In general, 
inducible expression systems were shown to be more efficient for therapeutic applications 
than a constant production of pharmacologic substances. In the treatment of most diseases 
the defined spatial and temporal production of the encoded proteins is essential. Examples 
are the production of BMP-2 to induce bone formation (Smoljanovic et al. 2009) or the 
expression of cytotoxic enzymes in cancer treatment (Brade et al. 2003). Without a distinct 
regulation these treatments would result in malformation of tissues or too high concentrations 
of a toxic agent. In addition, a regulated expression can be turned on at the most beneficial 
time point within the therapy and therefore the overall dose of the therapeutic substance can 
be reduced, without loss of the required effect. Heat inducible expression systems have been 
already established for the activation of suicide genes together with hyperthermia for cancer 
treatment. In this case, gene therapy and hyperthermia are used to express suicide genes 
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like HSVtk (herpes simplex virus thymidine kinase), which together with ganciclovir lead to 
enhanced killing of tumour cells (Freeman et al. 1996). The advantage of a heat inducible 
system is the induction from the outside by different heating techniques like focused 
ultrasound or magnetic nanoparticle mediated heat generation by an alternating magnetic 
field. In contrast, other inducible expression systems need the help of an inducer substance 
to start expression, like for example doxycycline in the TetR system. This inducer first has to 
reach the site of action in the body, resulting in a delayed activation of the system (Gossen et 
al. 1992). In addition, the inducers as well as the expression system itself often are of non-
human origin (Gossen et al. 1995; Abruzzese et al. 2000). This might lead to stimulation of 
an immune response or even a toxic reaction in the patient (Wang et al. 1994; Witzgall et al. 
1994a; Deuschle et al. 1995). By using the highly conserved heat shock response as basis 
for an expression system the above mentioned problems are avoided. Using natural heat 
shock promoters the induction system shows high expression levels due to elevated 
temperatures, but is also activated by other stress factors like depletion of nutrition or oxygen 
or toxic components. Therefore, primarily artificial heat shock promoters lacking most 
regulatory elements are used for application in gene and cell therapy (Rome et al. 2005). 
These modified promoters reduce the response to other stress factors like hypoxia and were 
shown to be highly inducible (Vekris et al. 2000; Borrelli et al. 2001; Rohmer et al. 2008). In 
one approach, magnetic nanoparticles were coated with plasmid DNA harbouring a heat 
inducible expression system based on a minimal Hsp70B´ promoter, injected into mouse 
tissue and an alternating magnetic field was applied. Induction in the magnetic field resulted 
in high reporter activity (Tang et al. 2008). Truncated heat shock promoters were also used 
in an adeno-virus based gene therapy approach, where high intensity ultrasound was applied 
to induce the promoter resulting in ~100 fold induction of marker gene expression (Liu et al. 
2006). Another attempt combines a truncated Hsp promoter with a TetR induction system 
leading to highly enhanced induction but also a to slower expression kinetics (Yamaguchi et 
al. 2012). In this experimental procedure the cells are transiently transfected with the 
construct, which leads to a transient but efficient production of protein, although the 
respective cells first have to be reached within the tissue. With the introduction of the stable 
cell line in our system the heat inducible promoter is already integrated within the cells. 
Together with the co-encapsulation of cells and magnetic nanoparticles our approach 
combines all advantages of the individual methods. In addition problems concerning the 
immune response, distribution of cells and nanoparticles, as well as fluctuations in 
transfection efficiency are avoided. Within this thesis the novel concept of regulated gene 
expression in encapsulated cells could be established and verified by a first proof-of-principle 
experiment.  
 
6.2. THE HEAT INDUCIBLE CELL LINE 
One of the key components of our concept is the heat inducible expression system. For the 
experimental design of such a system natural promoters of the highly inducible heat shock 
protein family Hsp70 are used. In previous attempts either natural Hsp72 (Dreano et al. 
1986; O'Connell-Rodwell et al. 2004) or Hsp70B promoters were used (Brade et al. 2000; 
Huang et al. 2000; Guilhon et al. 2003a). These promoters showed high inducibility with 
weak basal expression for the Hsp70B promoter. In case of the Hsp72 promoter, the basal 
expression was higher due to the involvement of the chaperone Hsp72 in normal cellular 
homeostasis. In addition, both natural promoters did not exclusively respond to heat but also 
to other stressful conditions like hypoxia, depletion of nutritions or exposure to toxic 
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components. This basal expression might therefore result in problems of such systems in 
gene or cell therapy when they are enhanced by stressful conditions within the patient as for 
example observed in tumour tissue. To minimise the background activation a reduction of 
natural promoter sequences down to a minimal version containing only 400 bp of the 
promoter including the HSEs (Vekris et al. 2000; Borrelli et al. 2001; Smith et al. 2002) or the 
insertion of additional HSEs (Brade et al. 2000) were established. These modified promoters 
resulted in even higher induction rates with lower basal activation. Nevertheless, these 
promoters still contain additional regulatory elements beside the HSEs and therefore at least 
partially respond to other inducers (Voellmy et al. 1985; Schiller et al. 1988; Borrelli et al. 
2001). In contrast the promoter used in this project is not based on a natural promoter, but is 
a completely artificial sequence of eight idealised HSEs (Bajoghli et al. 2004). The 
uncoupling of the HSEs from natural promoters resulted in high expression levels in 
response to heat treatment similar to the minimal Hsp70B promoter. Both promoters showed 
around 10 fold higher induction levels than the natural Hsp70 promoter (Figure 5-3) in 
transient transfection experiments. Compared to untreated cells the basal expression was 
higher when the natural promoter was used than with the Hsp70B minimal promoter or the 
newly established artificial HSE promoter. When the artificial HSE promoter is stably 
integrated into HEK 293 cells, the basal expression levels were close to the detection limit of 
luciferase, but expression levels after heat treatment increased up to 3000 fold (Figure 5-5 
and Figure 5-6). Natural heat shock promoters often are regulated in a tissue specific 
manner and all natural promoters showed cell type dependent differences in induction levels 
(Rohmer et al. 2008). To analyse this for the artificial HSE promoter, different cell lines were 
tested for their ability to express the reporter protein in response to heat treatment when 
transiently transfected. After induction a robust expression of luciferase was observed in all 
five cell lines tested. The basal expression levels increased when carcinoma cell lines were 
used instead of the HEK 293 cell line (Figure 5-4). For the application in encapsulated cells, 
HEK 293 cells were selected as here the basal levels without heat induction were lowest and 
a high inducibility of the promoter could be observed. But other cell lines also gave 
reasonable results which underlines the broad applicability of the artificial promoter. In 
addition, this promoter was also successfully applied in other species under different 
conditions (Bajoghli et al. 2004), further demonstrating the potential of this artificial 
expression system. 
 
6.3. PROMOTER KINETICS 
For the application in cell or gene therapy, the kinetics of the expression system has to be 
defined. In case of the most prominent version, the TetR system, the regulation of target 
gene expression within mouse tissue is in the range of days (Sommer et al. 2002). This slow 
response to induction is due to the fact that the inducer first has to diffuse to the site of 
action. Also other established inducer dependent systems show similar kinetics. Therefore, a 
system, which can be activated by an external trigger, has important advantages for medical 
application. Previous research of heat responsive gene expression systems showed high 
expression levels up to 24 hrs after heat induction and a reduction to basal levels after 48-72 
hrs depending on the initial heat shock temperature (Braiden et al. 2000; Vekris et al. 2000; 
Smith et al. 2002; Brade et al. 2003). The here described artificial HSE promoter exhibits 
even tighter kinetics. The highest induction levels were observed 4-6 hrs after heat treatment 
and basal levels were reached within 24-48 hrs (Figure 5-14). In addition it could be 
demonstrated, that expression levels and maximum induction could be regulated by the 
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duration of heat treatment. The resulting shift of maximum expression to later time points by 
increased heat shock duration allows an additional level of regulation for the expression 
system. When mRNA kinetics of the artificial promoter construct was compared to the 
expression of the endogenous Hsp72 gene, maximum reporter gene mRNA levels were 
reached 2 hrs earlier than the endogenous Hsp72 mRNA levels. This shift of mRNA peak 
levels to earlier time points is most likely the result of the isolated HSEs in the artificial 
promoter. Within this experiment a decrease in Hsp72 levels below basal levels was 
observed 8-12 hrs after treatment, returning to basal levels at later time points, which was 
not observed for the artificial promoter. This temporal decrease of Hsp72 might be the result 
of a feedback regulation system (Baler et al. 1996; Balakrishnan et al. 2006; Gomez et al. 
2008). The analysis of promoter kinetics was also used to examine the bidirectional design of 
the artificial promoter. Indeed, it could be demonstrated that both reporter genes, luciferase 
as well as GFP, showed the same mRNA kinetics in response to heat treatment. This 
bidirectional design might be used to express different components of therapeutic 
substances in later medical applications. 
 
6.4. INADVERTENT ACTIVATION BY OTHER STRESS FACTORS  
Although heat responsive gene expression is a fast and easy way to produce all kinds of 
peptides or proteins in a regulated manner, this system is underrepresented in cell and gene 
therapy approaches. One reason for this is the possible background activation by other 
stressful conditions including hypoxia, depletion of nutrition or interference with 
pharmacological substances. It has previously been described that natural heat shock 
promoter systems respond to most of these triggers (Pirkkala et al. 2001; Siddiqui et al. 
2008). When exposing the artificial HSE promoter to different stress factors we could 
demonstrate that only two out of seven known factors (cadmium sulphate and a serine 
protease inhibitor) were able to induce expression, whereas all other tested stress conditions 
resulted in no increase of luciferase activity (but activated the natural promoter). For hypoxic 
conditions even extended exposure did not show any expression fromthe artificial HSE 
promoter (Figure 5-7 and Figure 5-8), although it was still inducible by heat afterwards. 
Mimicking hypoxia by cobalt chloride resulted in 2-3 fold higher expression levels but only at 
the highest tolerated cobalt chloride concentrations (Figure 5-10). In contrast the natural 
Hsp72 promoter showed induction levels up to 25 fold when exposed to hypoxic conditions 
(Figure 5-9). The discrepancy between the two promoters may be explained by the additional 
regulatory elements located in the natural promoters. Hypoxia was previously shown to 
activate specialised elements, the so-called hypoxia responsive elements (HREs) (Arany et 
al. 1996; Gray et al. 2005), via the key regulator hypoxia-inducible factor 1 (HIF-1). These 
HREs are also located in heat shock promoters (Huang et al. 2009). However it was shown 
that HSF-1 can be activated in response to hypoxia and acts via HSE (Benjamin et al. 1990). 
Additionally, HIF-1 leads to transcriptional upregulation of HSF-1 by direct binding to HRE in 
the Hsf1 promoter (Baird et al. 2006). Due to this cross talk between the two pathways it was 
not clear whether the HSE promoter would react to hypoxia. 
Similar to the exposure to hypoxic conditions also the incubation of the stable cell line with 
zinc chloride was not able to induce the artificial promoter. Nevertheless, Zinc2+ showed 
robust expression of endogenous Hsp72 (Figure 5-11), suggesting an activation pathway 
independent of HSE. Zn2+ was previously described as one of the major inducers for the 
metal response pathway via MRE-binding transcription factor 1 (MTF-1) (Heuchel et al. 1994; 
Palmiter 1994). The Hsp72 promoter as well as other heat shock promoters contain also 
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metal response elements (MRE) (Wu et al. 1986) beside the HSE and the metal response 
pathway is highly sensitive to Zn2+ (Murata et al. 1999). Therefore the observed Hsp72 
activation can be explained by MRE induction, whereas HSEs do not seem to be activated 
by Zn2+. In contrast to induction with zinc chloride, Cd2+ was able to induce both, the natural 
Hsp72 promoter and the artificial HSE promoter. On the protein level as well as on the 
mRNA level a robust concentration dependent activation of the reporter gene was observed. 
Similar to the situation in heat treatment the endogenous Hsp72 promoter showed peak 
levels of induction at lower concentrations compared to the artificial promoter (Figure 5-11). 
This activation of heat shock promoters was also previously observed in different mammalian 
cells (Wagner et al. 1999; Lee et al. 2002; Valbonesi et al. 2008). 
The exposure of the heat inducible expression system to heavy metals is mainly of interest 
for the analysis of heat shock pathway regulation. For the proposed application in cell 
therapy, this response to heavy metals is less important, as here other stress factors might 
be more important. Among them, also pharmacological substances used for the treatment of 
diseases have previously been shown to interfere with the heat shock pathway (Morimoto 
2008; Akerfelt et al. 2010). The anti-cancer drug geldanamycin, an established activator of 
the heat shock response was shown to be a specific inhibitor of Hsp90 (Whitesell et al. 1994) 
by blocking the interaction with client proteins. This process leads to the activation of HSF1. 
Exposure of cells to geldanamycin further results in phosphorylation of HSF1 and enhanced 
binding to the HSE (Kim et al. 1999) resulting in increased expression of heat shock proteins. 
Similar to these results the stable cell line showed high levels of Hsp72 mRNA (up to 100 
fold induction), when exposed to increasing concentrations of geldanamycin. Interestingly, 
the drug failed to induce the artificial HSE promoter (Figure 5-12 A and I). To ensure that the 
concentrations used are sufficient for induction also higher concentrations of geldanamycin 
were used. However, high amounts of the drug did not induce the artificial promoter, but 
resulted in increased cell death (Figure 5-12 A).  
In contrast, the serine proteinase inhibitor TPCK was able to induce luciferase protein 
expression (Figure 5-12 B). In line with the literature (Rossi et al. 1998), also endogenous 
Hsp72 expression was induced by TPCK (Figure 5-12 J). Interestingly, the mRNA levels of 
the reporter gene luciferase did not increase upon exposure to the serine protease inhibitor 
(Figure 5-12 J), whereas protein expression increased in a concentration dependent manner 
(Figure 5-12 B). Protein expression was determined 6 hrs after induction (60 fold increase), 
whereas mRNA levels were analysed 2 hrs after induction. These time points were chosen 
as standard settings after a detailed analysis of the promoter kinetics in response to heat 
treatment (Figure 5-14). Induction of the heat shock response by TPCK might however result 
in a delayed expression starting after 2 hours. 
The anti-inflammatory drug carbenoxolone has also previously been shown to induce the 
heat shock response and the expression of heat shock proteins (Nagayama et al. 2001; 
Kawashima et al. 2009). This could be verified by an increase in Hsp72 mRNA levels (Figure 
5-12 K). Induction of the artificial HSE promoter could be observed only at higher 
concentrations (1000-15000 µM) at the mRNA level (Figure 5-12 K) and also at the protein 
level (Figure 5-12 C). Nevertheless, this activation of the promoter did not seem to be a 
specific effect of the anti-inflammatory drug rather than an effect of high amounts of 
denaturated proteins. When carbenoxolone was analysed for its capacity to denature 
proteins using the degradation assay, high amounts of inactive luciferase could be observed 
together with an increase in cell death indicated by the decrease in both proteins, the 
denaturation sensitive firefly luciferase as well as the highly stable Gaussia luciferase (Figure 
5-12 G). In addition to heat shock inducers, also one inhibitor was tested for its influence on 
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the artificial promoter. Quercetin, a flavonoid, was previously shown to decrease HSF1 
expression levels (Nagai et al. 1995) leading to a reduced expression of heat shock proteins 
(Hosokawa et al. 1992). When the stable cell line was exposed to increasing concentrations 
of quercetin, slightly increased Hsp72 mRNA levels could be observed (2-3 fold Figure 5-12 
L), which was independent of the concentration. However, this increase seems to be an 
unspecific effect. In addition, no activation of the artificial promoter could be observed on the 
mRNA level (Figure 5-12 K), as well as on the protein level (Figure 5-12 D), but also no 
signal reduction could be observed for exposure to quercetin. 
 
6.5. REPEATED ACTIVATION OF THE INDUCIBLE CELLS 
The general idea of this project was to establish a new approach for heat induced gene 
expression of therapeutical substances in encapsulated cells. The capsules containing a 
producer cell line would be transplanted into a patient and gene expression would then be 
regulated from the outside. Beside the parameters for a single release cycle, it is however 
equally important how the system would behave upon repeated delivery of the therapeutic 
substances. Since repeated release rounds also require repeated application of stress to the 
cells, the viability of the cells under these conditions might play a critical role. The induction 
of gene expression by heat has some advantages as discussed above, but this activation 
route also bears the potential to be harmful for the cells. The heat shock response is one of 
the major cellular defence mechanisms to resist environmental stress, but strong or extended 
stress will nevertheless kill the cells. When exposed to temperatures above 41°C the cells 
activate the heat shock response, but in parallel also the viability starts to decrease. 
Temperatures in the range of peak heat shock activation (43-44°C) at the same time resulted 
in a reduction of cell survival down to 94 % (43°C) or 90 % (for 44°C) (Figure 5-16). Although 
this decreased cell viability is still in a tolerable range it has to be considered that repeated 
heat treatments at 44°C might continuously reduce the cell population. To reduce the 
problem of cell death after heat induction, a temperature of 43°C was chosen although this 
does not result in the highest induction levels. Nevertheless the cell viability is high at 43°C 
(Figure 5-16) and the expression levels are induced more than 1000 fold (Figure 5-6 A). 
When the viability of the cells after repeated heat treatment was analysed, no difference in 
cell survival could be detected, whether the cells were exposed once or every day to heat 
during a period of two weeks (Figure 5-17). The survival of the cells incubated for two weeks 
was generally reduced by ~ 6-7 % compared to cells incubated for one week, but this was 
independent of the number of heat exposures. This reduction is most likely due to the 
artificial culture conditions used in this experiment as reduced serum concentrations of 0.5 % 
were necessary to cultivate cells over a period of two weeks without propagation. 
Nevertheless, even with these highly artificial cultivation conditions it could be shown that 
repeated heat treatment does not result in increased cell death and the system is still 
inducible to the same levels as for a single heat treatment (Figure 5-17 B). Furthermore 
these experiments were performed under the assumption that each release cycle in the 
patient would be performed under maximum expression levels. The main advantage of the 
presented system is however a fine tuned adoption of the expression to the needs of the 
patient. This in turn means reduced stress levels during induction. Activation of the system 
by heat is therefore suitable for repeated application. 
The artificial HSE promoter and the corresponding stable cell line have been shown to fulfil 
all criteria necessary for a cell therapy application. The promoter is highly inducible by heat 
treatment with a well defined expression maximum in the range of 4-8 hrs. In contrast to 
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previously published attempts, the artificial HSE promoter does not respond to environmental 
stress conditions like hypoxia or most tested pharmacological inducers. The system only 
showed activation when exposed to Cd2+ or the serine protease inhibitor TPCK. In addition it 
was shown that repeated induction did not influence cell viability making this system perfectly 
suitable for therapeutic applications.  
 
6.6. HEAT GENERATION BY MAGNETIC NANOPARTICLES 
To induce the heat responsive gene expression system in the encapsulated cells, in this 
approach magnetic nanoparticles were employed. These particles are in the size range of 
10-100 nm and composed of magnetic material. When magnetic nanoparticles are exposed 
to an alternating magnetic field they absorb energy and convert it to heat depending on the 
magnetic field strength, frequency and kind of particles. Particles of a size between 40-100 
nm convert the applied energy directly to heat by the mechanism of hysteresis heating, when 
high frequencies are used (Pankhurst 2003). Similar to the size of the particles also their 
chemical composition regulates the amount of heat production. This regulation is due to the 
Curie point (TC), a material dependent property of the nanoparticles. The TC represents the 
maximal heat production which can be performed by the particle independent of the applied 
energy. Iron oxide nanoparticles, as used in the here described approach have a TC of 
~600°C whereas other magnetic materials like Mn-Zn-ferrite have a TC slightly above heat 
shock temperature (44°C) (Meijer et al. 1995; Kotte et al. 1998). A lower Curie point has the 
advantage that potential overheating of the tissue or cells can be avoided. In the concept of 
regulated gene expression in encapsulated cells iron oxide nanoparticles were used, but 
heat generation could be properly regulated by different concentrations of nanoparticles and 
by different frequencies (Figure 5-18). However, for applications in medicine particles with a 
lower Curie point would increase the level of safety for the method. Another aspect for 
clinical application is the applied magnetic field and the frequency, as too high magnetic field 
strengths and frequencies would cause tissue damage in the patient. 60 kHz, applied in this 
project perfectly fit into the range of 50 kHz – 10 MHz used for medical applications, although 
the magnetic field strength (~ 36 kA/m) is relatively high. In previously published clinical trials 
a magnetic field strength of 10-20 kA/m showed no harmful effects on patients, but fields up 
to 55 kA/m are still tolerated (Ivkov et al. 2005). For the here described approach it could be 
shown that the application of the high magnetic field strength, together with the iron oxide 
nanoparticles did not cause any cytotoxic effects in the encapsulated cells (Ortner et al. 
2012). The applied magnetic field strength is regulated by the settings of the magnetic field 
generator. Here a homemade generator consisting of commercially available pre-units was 
employed. The induction coil was built form brass-tubes forming an inner diameter of ~ 
1.5 cm, which is sufficient for small reaction tubes. Therefore, experiments with larger 
vessels or even animals could not be performed. Depending on the type of coil, the power 
supply and the windings, the power of the magnetic field is determined. For the applied 
magnetic field generator there was a technical limitation to 45-48 kA/m due to the power 
supply and the generation of heat within the induction coil. To reduce the self-heating of the 
coil, the brass tubes were permanently cooled with water. In addition, a water jacket was 
inserted between the coil and the reaction tube to balance the temperature of the induction 
coil. Despite these limitations the magnetic field system was sufficient to generate the field 
strength needed for the proof-of-principle experiments. The clinical application of 
hyperthermia (see below) however demonstrated that sufficiently powerful magnetic field 
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generators can be built even for patient applications and that the problems of heat production 
in the coil can be solved even in large scale. 
Another way to improve the method would be the coating of magnetic nanoparticles. As 
magnetic nanoparticles are co-encapsulated with cells a possible harmful effect on cell 
survival has to be kept in mind. In general iron oxide particles are mostly coated to decrease 
their aggregation tendency and to improve their biocompatibility (Soenen et al. 2010; 
Mahmoudi et al. 2011). In the first proof-of-principle experiments presented within this thesis, 
commercially available uncoated iron oxide particles were used. No severe effects of the 
particles on cell viability could be observed. Nevertheless, for further encapsulation 
experiments particles with polyethylenimine coating were used to improve biocompatibility 
(Ortner et al. 2012).  
 
6.7. INDUCTION WITH MAGNETIC NANOPARTICLES 
The data discussed so far showed that the established expression system is highly inducible 
after heat exposure with well defined kinetics. The time for activation is in the range of hours, 
compared to expression kinetics in the range of days for the well established TetR induction 
system in animal experiments (Gossen et al. 1992; Sommer et al. 2002). These differences 
in activation time result from the different inducers used. In the TetR system a small molecule 
which has to first reach the site of action activates the expression. On the other hand heat 
inducible systems directly respond to elevated temperatures, a condition that can be reached 
in the tissue within minutes. This technology is also applied in hyperthermia treatment, where 
tissue temperature is increased to treat diseases, but primarily cancer (Johannsen et al. 
2005; Rewcastle 2006). For the necessary heat generation different strategies can be 
applied like radio waves (Issels et al. 2010), laser (Vogl et al. 2001), high focused ultrasound 
(Rewcastle 2006) or magnetic nanoparticles combined with an alternating magnetic field 
(Jordan et al. 2001; Johannsen et al. 2005). In 2010, the German company MagForce 
received the first clinical approval for their nanoparticle based hyperthermia treatment of 
brain tumours (Gneveckow et al. 2004).  
For the system presented here magnetic nanoparticles were used to generate the required 
heat. Testing different frequencies and magnetic field strengths, suitable conditions for HSE 
promoter activation by magnetic nanoparticles could be defined for our system at 60 kHz and 
36 kA/m (27 A current). As nanoparticle concentration influences the heat generation (Ortner 
et. al, Supplementary data S1, see also appendix), cells without encapsulation were first 
tested for the amount of magnetic nanoparticles needed to activate gene expression. It could 
be demonstrated that increasing concentrations of particles resulted in increased expression 
of marker proteins up to a maximum for 0.5 % nanoparticles (at the settings used for this 
experiment). When higher particle concentrations were used, the expression levels 
decreased (Figure 5-19 A) most probably due to too high temperatures. This decrease can 
be explained by a higher cell death rate at these temperatures, as even the increase of heat 
shock temperature form 43°C to 44°C resulted in reduced viability (Figure 5-16). Below its 
peak levels the artificial HSE promoter showed increased inducibility, when either the 
temperature was raised or heat treatment duration was prolonged (Figure 5-6 and Figure 
5-14). Hence, regulation of expression levels was analysed by applying different current and 
therefore different magnetic field strength or by variation of the induction time (Figure 5-19 B 
and C). These experiments demonstrated the possibility to regulate the expression levels 
over several orders of magnitude by variation of nanoparticle concentration, magnetic field 
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strength or induction time. The possibility to vary the amount of produced protein is of high 
importance for the application in medicine as for most diseases a dose dependent therapy is 
needed. Most treatments used today are based on constitutive expression and even if an 
inducible system is used, a fine-regulation of the system cannot be facilitated. This fact 
highlights the potential of the system for application in cell therapy approaches.  
The expression kinetics after alternating magnetic field treatment showed a similar behaviour 
as observed for heat treatment up to 8 hrs after induction (Figure 5-14 A). At later time points 
the protein levels were still at a maximum when the cells were induced in the magnetic field, 
whereas they dropped down to basal levels when exposed to standard heat treatment 
(Figure 5-20). This prolonged expression seems to be the result of a stabilisation effect of the 
protein as the mRNA levels did not show this behaviour. Kinetics of both, the artificial HSE 
promoter (Figure 5-21 A) as well as the endogenous Hsp72 promoter (Figure 5-21 B) 
showed a decrease in mRNA levels after 4-6 hrs, which was again similar to the kinetics 
observed for heat treatment (Figure 5-14 B and C). It is not clear if the effect of prolonged 
protein activation after magnetic field treatment is limited to the expression of the marker 
protein luciferase, or represents a general phenomenon. However, this has to be kept in 
mind for the production of therapeutic substances. 
 
6.8. PROOF-OF-PRINCIPLE 
All induction experiments discussed so far were performed with a combination of cells and 
magnetic nanoparticles but without encapsulation. They were however critical to define 
settings for the optimised induction conditions and kinetics. As these experiments resulted in 
conditions where robust expression was induced within the cells, the final proof-of-principle 
experiment could be performed with encapsulated cells. For this experiment cells were co-
encapsulated with 1 % nanoparticles, which is higher that the previously used 0.5 %. This 
increase of particle concentration was used to ensure that enough heat is generated to 
induce the expression system, as in the capsule cells and nanoparticles might not be equally 
distributed. To avoid too high temperatures different magnetic field strengths were applied to 
the capsules. A first observation of the treated capsules revealed the presence of GFP 
expression. However, not all capsules within one setting were GFP positive, indicating 
variations among the capsules. The amount of capsules expressing GFP increased with 
higher magnetic field strength. This observation might be due to the lower heat generation 
capacity of the nanoparticles at reduced field strength, which was not sufficient to induce all 
capsules within the tested batch. Therefore only capsules expressing GFP were used for the 
luciferase activity assay to analyse the induction levels. With the applied settings, induction 
rates up to 1500 fold could be measured. As a control the activation of the promoter in 
capsules without a detectable GFP expression level was analysed and even here a 200 fold 
induction of the promoter could be determined. The performed proof-of-principle experiment 
therefore clearly showed that the artificial HSE promoter based expression system could be 
induced in cells co-encapsulated with magnetic nanoparticles when an alternating magnetic 
field is applied. Although around 40 % of the induced capsules showed no expression of the 
marker protein GFP, even in these capsules the heat inducible expression system was 
activated to some extent. For future therapeutical applications it would be possible to 
preselect the capsules depending on their expression rates and thus avoid variability among 
the transplanted capsules. Coexpression of GFP with the bidirectional promoter would 
present one simple way to achieve such a preselection. In summary the proof-of-principle for 
the here described new approach could be demonstrated. 
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6.9. OUTLOOK 
 
FIGURE 6-1 OUTLOOK. The externally induced expression of biologicals in encapsulated cells provides several advantages for 
application in medicine. A heat inducible expression system is stably introduced into a cell line which is then carefully 
characterised. The cells are then encapsulated together with magnetic nanoparticles to protect them from the immune response. 
Afterwards the capsules can be injected into the patient near to the affected tissue. When an external alternating magnetic f ield 
is applied, the nanoparticles within the capsule will produce heat which in turn activates expression of the encoded therapeutic 
protein. This regulation can be applied for the treatment of diseases where a dose dependent release of a therapeutic substance 
is critical. 
The newly established method to induce the production of therapeutic substances in 
encapsulated cells regulated by an external trigger can be applied for the treatment of many 
diseases. The system is perfectly suitable for a dose regulated therapy by expressing 
therapeutic proteins, but also viral delivery systems. One potential application area is the 
field of cancer treatment. Here the main propose is to kill tumour cells by applying cytotoxic 
agents. In the last years several different substances were employed to act on cancer and 
most of them were applied via viral delivery systems. Among them are different cytokines 
such as TNF-(Gossen et al. 1992) or IL-12 (Huang et al. 2000), suicide genes like HSV-tk 
(Barzon et al. 2009) or enzymes like iNOS (Bian et al. 2012). All these substances result in 
unspecific killing of the tumour cells and are therefore also harmful for normal cells. 
Regulating the expression of these therapeutic substances from the outside allows the 
adoption to the patients needs. In addition, the temporal regulation results in a more efficient 
cell killing as the most beneficial time point for action of the different proteins can be chosen. 
The treatment can be stopped once the required toxicity is reached or repeated multiple 
times if necessary. Inducible expression systems are already employed in cancer treatment 
(Gossen et al. 1992; Huang et al. 2000). By applying encapsulated cells, the previously 
described substances, but also viral delivery systems can be placed near to the affected 
tissue leading to reduced impact on the surrounding tissue. 
Another area of application is regenerative medicine. Here tissues or cells are stimulated by 
different growth factors or morphogenic proteins to recover after severe damage. The 
success of these therapies is often linked to a controlled release of the stimulating proteins 
as overexpression might result in severe problems. One example is the regeneration of 
bones where BMP2 is released to initiate bone formation in vivo. BMP2 is already 
established as a protein therapy, but was shown to result in massive bone formation if the 
dose of the protein is too high (Smoljanovic et al. 2009). Another application for inducible 
expression in encapsulated cells would be the treatment of cardiovascular diseases, where 
VEGF is used for regeneration of vascularising tissue (Yang et al. 2010) or the regeneration 
after stroke by a regulated expression of EFG (Cooke et al. 2011) or glucagon-like peptide 1 
(Heile et al. 2009). 
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The application of regulated protein production by encapsulated cells might also be beneficial 
when hormonal dysfunctions are treated. Here a regulation of expression in the range of 
hours is beneficial for the therapy and accumulation after constitutive or slow expression 
kinetics would result in too high amounts of the hormone. The treatment of dwarfism by 
expression of growth hormone in encapsulated cells has already been tried (al-Hendy et al. 
1995) and the addition of a regulated expression system would substantially improve this 
approach. In addition, hormones are also used for the treatment of neural damage (Devesa 
et al. 2012). Similar to the hormone therapies also for the treatment of pain a fast responding 
expression system is of major importance. Within this area, a fast and fine-tuned regulation 
of expression is necessary to adopt the production to the needs of the patient (Milligan et al. 
2012).  
In the last years several approaches for the treatment of diseases based on cell or gene 
therapy have been established. In addition, the pharmacokinetics of therapeutic substances 
becomes more and more important. The here established approach of a heat inducible 
expression system combined with external induction and encapsulation is therefore of high 
relevance for the improvement of already existing therapies. With this method, high levels of 
proteins can be expressed by the encapsulated cell line within short time without any basal 
activation or problems with the host immune response. In addition the expression system can 
be regulated in a dose-dependent manner from the outside via magnetic field strength or the 
induction time. To summarise, this approach is a new way to express therapeutic substances 
in a defined, well regulated manner and can be controlled from the outside of the patient.  
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8.3. ABBREVIATIONS 
AAV - adenovirus-associated virus 
ABD - ATP-binding domain 
AD -  activation domain 
ADA – adenosine deaminase 
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ALS – amyotrophic lateral sclerosis  
AMF - alternating magnetic field  
Ask-1 - apoptosis signal-regulating kinase 1 
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CHIP - carboxyl terminus of Hsp70-interacting protein 
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DBD - DNA binding domain 
DNA – deoxyribonucleic acid 
DOPE - dioleoylphosphatidylethanolamine 
Dox - doxycycline 
ds – double-stranded 
E.coli - Escherichia coli 
EcR - ecdysone receptor  
eEF1A - elongation factor 1a 
EMA – European Medical Agency 
ER - endoplasmic reticulum  
ESC - embryonic stem cell 
FKBP - FK506-binding protein 
FRAP - FKBP-rapamycin-associated protein  
FRB - FKBP rapamycin binding  
FU-  focused ultrasound  
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase  
GDNF – glia-cell line derived neurotrophic factor  
GFP - green fluorescent protein 
HEK – human embryonic kidney 
HEMA-MAA – hydroxyethyl methaacrylate-
metaacrylic acid 
HIF-1 - hypoxia inducible factor-1  
HIP - HSC70-interacting protein 
HIV – human immunodeficiency virus 
HO-1 - haemoxygenase-1 
HOP - Hsp-organising protein 
HR - hepta repeats  
HRE - hypoxia response elements  
HSBP1 - heat shock factor binding protein 1  
HSC – hematopoietic stem cell 
HSE- heat shock element 
HSF1 - heat shock factor 1 
HspBP1 - heat shock protein binding protein 1 
HSPs -  heat shock proteins 
 
 
HSR1 - heat shock RNA1 
HSV – herpes simplex virus 
HSV-tk - HSV-1 thymidine kinase  
HSVtk- herpes simplex virus thymidine kinase 
HtpG -  high-temperature protein G  
hTRT - human telomerase reverse transcriptase  
IL-2 – interleukin 2 
IL-2R – interleukin-2 receptor 
IL-6 – interleukin 6 
iNOS - inducible nitrogen oxide synthase  
iPSC – induced pluripotent stem cells 
IRES - internal ribosomal entry site  
JNK - c-Jun NH2-terminal kinase  
JNK - c-Jun N-terminal kinase  
KRAB - Krüppel-associated box  
LTR – long terminal repeats 
MAP/ERK - mitogen-activated protein kinase/ 
extracellular signal-regulated kinase 
MCL - magnetic cationic liposomes 
MCS – mesenchymal stem cells  
MHC - major histocompatibility  
MK2 - MAPK- activating protein kinase 2 
MPF/RU486 - mifepristone 
MRI - magnetic resonance imaging 
mTor - mammalian target of rapamycin  
MTS - mitochondrial targeting sequence 
MWCO – molecular weight cut-off 
NBD - nucleotide binding domain 
NEF - nucleotide exchange factor 
NK – natural killer cells 
NLS - nuclear localisation signal 
NSB - nuclear stress bodies  
OTC – ornithine transcarbamylase 
PARP-1 - poly(ADP)-ribose polymerase 1  
PBMC - peripheral blood mononuclear cells  
PBS - peptide binding domain 
pDADMAC – poly-diallyl-dimethyl-ammonium 
chloride 
PDSM - phosphorylation dependent sumoylation 
motif  
PEG - polyethylene glycol 
PEI – polyethylenimine 
PGK - phosphoglycerate kinase 1-gene  
PKB - protein kinase B  
PKC - protein kinase C  
PLK1 - Polo-like kinase 1 
PLL – poly-L-lysine 
PMT - post-translational modification  
PSS – poly styrene sulfonate 
P-TEFb- positive transcription elongation factor b 
PVA- polyvinylalcohol 
RD - regulatory domain 
RF - radiofrequency 
RGD - Arg-Gly-Asp 
RLU – relative light units 
RNA – ribonucleic acid 
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ROS - reactive oxygen species  
RSV - Rous sarcoma virus long terminal repeats  
rTS - TetR-KRAB system  
rtTA - reverse tetracycline dependent transcriptional 
activator 
rtTetR - reverse Tet repressor 
RXR - retinoid X receptor  
SAR - specific adsorption rate 
SBD - substrate binding domain 
SCID – severe combined immunodeficiency 
SCS – sodium cellulose sulphate 
Ser - serine 
SIN - self-inactivating 
SIRT1 - sirtuin 1  
ss – single stranded 
Strap - Stress-responsive activator of p300 
TAD - transactivation domain  
TBP - TATA box binding protein  
Tc- Curie point 
TCR – T-cell receptors 
Tet - tetracycline 
TetR – tetracycline repressor 
TGF –ß1 –transforming growth factor ß1  
TNF – tumor necrosis factor 
TPCK - tosyl phenylalanyl chloromethyl ketone  
TPR - tetratricopeptide repeat 
TRAP1 - tumor necrosis factor receptor-associated 
protein 1  
TRE - Tet response element 
tTA - tetracycline dependent transcriptional activator 
UTR - untranslated region  
VEGF – vascular endothelial growth factor 
VP16 - herpes simplex virion protein 16 
WPRE – woodchuck post-transcriptional regulatory 
element 
ZFHD-1 - zinc finger homeodomain 1 
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